The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Lobeline results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
CHRNA7 protein mutant form affects the susceptibility to Lobeline Lobeline binds to and results in decreased activity of CHRNA7 protein; Lobeline binds to and results in increased activity of CHRNA7 protein mutant form
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Lobeline results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]
Thiamethoxam results in increased activity of ALPL protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of ALPL protein]
Thiamethoxam results in increased expression of CAT mRNA Thiamethoxam results in decreased expression of CAT mRNA Thiamethoxam results in decreased activity of CAT protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of CAT mRNA]
Thiamethoxam results in decreased expression of CYP11A1 mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in decreased expression of CYP11A1 mRNA]
Thiamethoxam results in decreased expression of CYP17A1 mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in decreased expression of CYP17A1 mRNA]
Thiamethoxam results in increased expression of CYP19A1 mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in increased expression of CYP19A1 mRNA] Thiamethoxam results in increased activity of CYP19A1 protein
Thiamethoxam results in increased activity of GOT1 protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of GOT1 protein]
Thiamethoxam results in increased expression of GPX1 mRNA Thiamethoxam results in decreased expression of GPX1 mRNA Thiamethoxam results in decreased activity of GPX1 protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of GPX1 protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of GPX1 mRNA]
Silymarin inhibits the reaction [Thiamethoxam results in increased expression of IL1B protein] Thiamethoxam results in increased expression of IL1B mRNA; Thiamethoxam results in increased expression of IL1B protein
Thiamethoxam results in increased activity of LDHA protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of LDHA protein]
Thiamethoxam results in decreased expression of LHCGR protein Plant Extracts inhibits the reaction [Thiamethoxam results in increased expression of LHCGR mRNA]
Thiamethoxam metabolite results in decreased activity of NOS2 protein Silymarin inhibits the reaction [Thiamethoxam results in increased expression of NOS2 mRNA] [Thiamethoxam metabolite results in decreased activity of NOS2 protein] which results in increased chemical synthesis of Formaldehyde
Thiamethoxam results in decreased activity of SOD1 protein Thiamethoxam results in decreased expression of SOD1 mRNA [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of SOD1 protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of SOD1 mRNA]
Thiamethoxam results in decreased expression of STAR mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in decreased expression of STAR mRNA]
Silymarin inhibits the reaction [Thiamethoxam results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Thiamethoxam results in increased expression of TNF protein] Thiamethoxam results in increased expression of TNF mRNA; Thiamethoxam results in increased expression of TNF protein
Thiamethoxam results in increased secretion of TNNT2 protein fenugreek seed meal inhibits the reaction [Thiamethoxam results in increased secretion of TNNT2 protein]; Polysaccharides inhibits the reaction [Thiamethoxam results in increased secretion of TNNT2 protein]
GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCA1 mRNA]; GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCA1 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 protein] Nicotine results in decreased expression of ABCA1 mRNA; Nicotine results in decreased expression of ABCA1 protein
GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCG1 mRNA]; GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCG1 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 protein] Nicotine results in increased expression of ABCG1 protein Nicotine results in decreased expression of ABCG1 mRNA; Nicotine results in decreased expression of ABCG1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ACAA2 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACAA2 mRNA]
Nicotine results in decreased expression of ACAN mRNA; Nicotine results in decreased expression of ACAN protein NLRP3 protein affects the reaction [Nicotine results in decreased expression of ACAN mRNA]
Nicotine results in decreased activity of ACHE protein Nicotine results in increased activity of ACHE protein Nicotine inhibits the reaction [Chlorpyrifos results in decreased activity of ACHE protein]
Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; Nicotine promotes the reaction [Quartz results in increased expression of ACTA2 protein] Nicotine results in increased expression of ACTA2 protein Bungarotoxins inhibits the reaction [Nicotine results in increased expression of ACTA2 protein]; Nicotine promotes the reaction [Arginine results in increased expression of ACTA2 protein] Nicotine results in increased expression of ACTA2 mRNA; Nicotine results in increased expression of ACTA2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ACTR1A mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ADCY7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADGRL1 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADNP mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADNP mRNA]
[Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased susceptibility to Nicotine Nicotine results in increased expression of ADRB1 mRNA
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased susceptibility to Nicotine Nicotine results in increased expression of ADRB2 mRNA
Nicotine results in decreased expression of AGTR2 mRNA; Nicotine results in decreased expression of AGTR2 protein Nicotine affects the expression of AGTR2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of AKR1A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein]; [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of FOXO1 protein; [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of GSK3A protein; [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of GSK3B protein; CDK1 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; CDK2 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; CHRNA7 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; CSNK2A1 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; Curcumin inhibits the reaction [Nicotine results in increased expression of AKT1 protein modified form]; CYP1A1 protein affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein]; Nicotine affects the reaction [Camptothecin affects the phosphorylation of AKT1 protein]; Nicotine affects the reaction [Fluorouracil affects the phosphorylation of AKT1 protein]; Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein Nicotine results in decreased phosphorylation of AKT1 protein Nicotine results in increased expression of AKT1 mRNA
Nicotine results in increased activity of ALDH1A1 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ALDH1A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA]
[RTKI cpd co-treated with AG 1879] inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; AG 1879 inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; MK-886 inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; RTKI cpd inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; U 0126 inhibits the reaction [Nicotine results in increased expression of ALOX5 mRNA] Nicotine results in increased expression of ALOX5 mRNA; Nicotine results in increased expression of ALOX5 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of APEX1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of APEX1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of API5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of API5 mRNA]
[Nicotine results in increased metabolism of APP protein] which results in increased secretion of APP protein modified form; Bungarotoxins inhibits the reaction [Nicotine inhibits the reaction [Copper results in increased expression of APP protein]]; Mecamylamine inhibits the reaction [Nicotine inhibits the reaction [Copper results in increased expression of APP protein]]; Nicotine inhibits the reaction [Copper promotes the reaction [APP protein binds to APP protein]]; Nicotine inhibits the reaction [Copper results in increased expression of APP mRNA]; Nicotine inhibits the reaction [Copper results in increased expression of APP protein]; Tubocurarine inhibits the reaction [[Nicotine results in increased metabolism of APP protein] which results in increased secretion of APP protein modified form]; Tubocurarine inhibits the reaction [Nicotine results in increased metabolism of APP protein] APP protein modified form inhibits the reaction [Nicotine results in increased secretion of Acetylcholine]; spiro(imidazo-(1,2-a)pyridine-3,2-indan)-2(3H)-one inhibits the reaction [APP protein modified form inhibits the reaction [Nicotine results in increased secretion of Acetylcholine]] Nicotine results in decreased expression of APP protein alternative form Nicotine results in decreased expression of APP mRNA; Nicotine results in decreased expression of APP protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ARF1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ARF3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF3 mRNA]
ARRB1 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; ARRB1 protein affects the reaction [Nicotine results in increased phosphorylation of and results in increased activity of SRC protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ASPM mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ASPM mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ATP6V0A4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0A4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ATP9A mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP9A mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATRN mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BAP1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAP1 mRNA]
Nicotine results in increased phosphorylation of BAX protein Nicotine results in decreased expression of BAX protein Nicotine results in increased expression of BAX protein dexpanthenol inhibits the reaction [Nicotine results in increased expression of BAX protein]; Folic Acid inhibits the reaction [Nicotine results in increased expression of BAX protein] Nicotine results in increased expression of BAX mRNA; Nicotine results in increased expression of BAX protein Nicotine affects the localization of BAX protein Nicotine results in decreased expression of BAX mRNA; Nicotine results in decreased expression of BAX protein 3-methyladenine inhibits the reaction [Nicotine results in increased expression of BAX protein]; [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in decreased expression of BAX protein; MK-886 inhibits the reaction [Nicotine results in decreased expression of BAX protein]; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] affects the localization of BAX protein]; PRKCZ protein affects the reaction [Nicotine results in increased phosphorylation of BAX protein]
3-methyladenine inhibits the reaction [Nicotine results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [Nicotine results in increased expression of BCL2 protein]; edelfosine inhibits the reaction [Nicotine results in increased phosphorylation of BCL2 protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of BCL2 protein]; MK-886 inhibits the reaction [Nicotine results in increased expression of BCL2 protein]; Nicotine inhibits the reaction [Aflatoxin B1 results in decreased expression of BCL2 protein] royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA] Folic Acid inhibits the reaction [Nicotine results in decreased expression of BCL2 protein] Nicotine results in decreased expression of BCL2 mRNA; Nicotine results in decreased expression of BCL2 protein Nicotine results in increased expression of BCL2 mRNA; Nicotine results in increased expression of BCL2 protein; Nicotine results in increased expression of BCL2 protein modified form
Nicotine results in decreased expression of BCL2L1 mRNA Nicotine results in decreased expression of BCL2L1 protein resveratrol inhibits the reaction [Nicotine results in decreased expression of BCL2L1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2L10 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2L10 mRNA]
BDNF gene polymorphism affects the susceptibility to Nicotine [Nicotine co-treated with Quartz] results in increased expression of BDNF protein Nicotine results in increased expression of BDNF mRNA Nicotine affects the expression of BDNF mRNA Nicotine results in increased secretion of BDNF protein methyllycaconitine inhibits the reaction [Nicotine results in increased secretion of BDNF protein]
Nicotine results in increased expression of BECN1 mRNA Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein] dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]
Nicotine results in increased expression of BGLAP Nicotine results in decreased expression of BGLAP mRNA Tubocurarine inhibits the reaction [Nicotine results in increased expression of BGLAP]
Curcumin inhibits the reaction [Nicotine results in increased expression of BIRC5 protein]; Hexamethonium affects the reaction [Nicotine results in increased expression of BIRC5 protein]; Nicotine inhibits the reaction [RB1 protein binds to BIRC5 promoter]; Nicotine promotes the reaction [E2F1 protein binds to BIRC5 promoter] Nicotine results in increased expression of BIRC5 mRNA; Nicotine results in increased expression of BIRC5 protein
Nicotine results in increased expression of BMI1 mRNA; Nicotine results in increased expression of BMI1 protein SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of BMI1 mRNA]
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BNIP3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA]
Nicotine results in decreased expression of BRCA1 mRNA Nicotine inhibits the reaction [aflatoxin G1 results in increased expression of BRCA1 protein modified form]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of C1R mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA]
alpha-cobratoxin inhibits the reaction [Nicotine results in increased expression of C7 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of C7 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of C7 mRNA]
Nicotine results in increased expression of CALB1 protein Mecamylamine inhibits the reaction [Nicotine results in increased expression of CALB1 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CALM1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA]
CHRNA5 protein affects the reaction [Nicotine results in increased expression of and results in increased cleavage of CASP1 protein]; Nicotine affects the reaction [Staurosporine affects the localization of CASP1 protein]; Nicotine inhibits the reaction [Staurosporine results in increased activity of CASP1 protein]; Nicotine results in increased expression of and results in increased cleavage of CASP1 protein Nicotine results in increased expression of CASP1 mRNA Nicotine results in increased expression of CASP1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP12 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP12 mRNA] Nicotine inhibits the reaction [Tunicamycin results in increased activity of CASP12 protein]
geldanamycin inhibits the reaction [Nicotine results in increased activity of CASP3 protein]; MK-886 inhibits the reaction [Nicotine results in decreased expression of CASP3 protein]; Nicotine inhibits the reaction [Aflatoxin B1 results in increased cleavage of CASP3 protein]; Nicotine inhibits the reaction [aflatoxin G1 results in increased expression of CASP3 protein modified form]; Nicotine inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein] Nicotine results in increased cleavage of CASP3 protein Nicotine results in increased activity of CASP3 protein; Nicotine results in increased activity of CASP3 protein alternative form Nicotine results in increased expression of CASP3 mRNA; Nicotine results in increased expression of CASP3 protein Nicotine affects the expression of CASP3 mRNA [Ethanol co-treated with Nicotine] results in increased expression of CASP3 protein; Nicotine inhibits the reaction [Ethanol results in increased activity of CASP3 protein] Nicotine results in increased expression of CASP3 mRNA; Nicotine results in increased expression of CASP3 protein modified form Nicotine results in increased expression of CASP3; Nicotine results in increased expression of CASP3 mRNA; Nicotine results in increased expression of CASP3 protein; Nicotine results in increased expression of CASP3 protein modified form Nicotine results in decreased expression of CASP3 mRNA; Nicotine results in decreased expression of CASP3 protein [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein]; Resveratrol inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA]; royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA] Nicotine results in decreased activity of CASP3 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CASP9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA] Nicotine results in increased expression of CASP9 protein dexpanthenol inhibits the reaction [Nicotine results in increased expression of CASP9 protein]; Folic Acid inhibits the reaction [Nicotine results in increased expression of CASP9 protein] Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein] Nicotine results in decreased expression of CASP9 mRNA
[acephate co-treated with methamidophos co-treated with Nicotine] results in increased activity of CAT protein; [Ethanol co-treated with Nicotine] results in decreased activity of CAT protein; [Ethanol co-treated with Nicotine] results in increased activity of CAT protein; Folic Acid inhibits the reaction [Nicotine results in decreased activity of CAT protein] royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein] Nicotine results in increased activity of CAT protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CBX5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CBX5 mRNA]
Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; ZFP36 mutant form inhibits the reaction [Nicotine results in decreased expression of CCL2 mRNA] Nicotine results in decreased expression of CCL2 mRNA; Nicotine results in decreased expression of CCL2 protein Nicotine results in decreased secretion of CCL2 protein Mecamylamine inhibits the reaction [Nicotine results in decreased expression of CCL2 mRNA]
Nicotine results in increased expression of CCNB1 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNB1 mRNA]
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Nicotine results in increased expression of CCND1 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine results in increased expression of CCND1 protein]; Curcumin inhibits the reaction [Nicotine results in increased expression of CCND1 protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of CCND1 protein]; MK-886 inhibits the reaction [Nicotine results in increased expression of CCND1 mRNA]; MK-886 inhibits the reaction [Nicotine results in increased expression of CCND1 protein]; Nicotine promotes the reaction [CDK4 protein binds to CCND1 protein]; Nicotine promotes the reaction [CDK6 protein binds to CCND1 protein]; U 0126 inhibits the reaction [Nicotine results in increased expression of CCND1 protein] Nicotine results in decreased expression of CCND1 mRNA; Nicotine results in decreased expression of CCND1 protein Nicotine results in increased activity of CCND1 promoter Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of CCND1 mRNA] Nicotine results in increased expression of CCND1 mRNA; Nicotine results in increased expression of CCND1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCND2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCND2 mRNA] Nicotine results in decreased expression of CCND2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNL2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNL2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CD151 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CD151 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CD44 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD44 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CD9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD9 mRNA]
Nicotine inhibits the reaction [E2F4 protein binds to CDC25A promoter]; Nicotine inhibits the reaction [E2F5 protein binds to CDC25A promoter]; Nicotine inhibits the reaction [RB1 protein binds to CDC25A promoter]; Nicotine inhibits the reaction [RBL1 protein binds to CDC25A promoter]; Nicotine inhibits the reaction [RBL2 protein binds to CDC25A promoter]; Nicotine promotes the reaction [E2F1 protein binds to CDC25A promoter]; Nicotine promotes the reaction [E2F2 protein binds to CDC25A promoter]; Nicotine promotes the reaction [E2F3 protein binds to CDC25A promoter]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CDC42 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CDC42 mRNA]
Nicotine inhibits the reaction [E2F4 protein binds to CDC6 promoter]; Nicotine inhibits the reaction [E2F5 protein binds to CDC6 promoter]; Nicotine inhibits the reaction [RB1 protein binds to CDC6 promoter]; Nicotine inhibits the reaction [RBL1 protein binds to CDC6 promoter]; Nicotine inhibits the reaction [RBL2 protein binds to CDC6 promoter]; Nicotine promotes the reaction [E2F1 protein binds to CDC6 promoter]; Nicotine promotes the reaction [E2F2 protein binds to CDC6 promoter]; Nicotine promotes the reaction [E2F3 protein binds to CDC6 promoter]
MK-886 inhibits the reaction [Nicotine results in decreased expression of CDH1 mRNA]; U 0126 inhibits the reaction [Nicotine results in decreased expression of CDH1 mRNA] [Nicotine co-treated with Quartz] results in increased expression of CDH1 protein Nicotine results in decreased expression of CDH1 mRNA; Nicotine results in decreased expression of CDH1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CDH11 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CDH11 mRNA]
[Nicotine co-treated with Quartz] results in increased expression of CDH2 protein; staurosporine aglycone inhibits the reaction [[Nicotine co-treated with Quartz] results in increased expression of CDH2 protein]
Nicotine results in increased expression of CDK1 protein CDK1 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; CHRNA7 affects the reaction [Nicotine results in increased expression of CDK1 protein]
Bungarotoxins inhibits the reaction [Nicotine results in decreased expression of CDK4 protein]; Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of CDK4 protein]; Hexamethonium inhibits the reaction [Nicotine results in decreased expression of CDK4 protein]; Nicotine promotes the reaction [CDK4 protein binds to CCND1 protein]; Nicotine promotes the reaction [NFATC2 protein results in decreased expression of CDK4 protein]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of CDK4 protein] Nicotine results in decreased expression of CDK4 mRNA; Nicotine results in decreased expression of CDK4 protein
Nicotine results in decreased expression of CDKN1A protein Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CDKN1A mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CDKN1A protein]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN1A mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN1A protein] Nicotine results in increased expression of CDKN1A mRNA; Nicotine results in increased expression of CDKN1A protein 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Nicotine results in decreased expression of CDKN1A protein]; Nicotine inhibits the reaction [Cisplatin results in increased expression of CDKN1A protein]; Nicotine inhibits the reaction [Gemcitabine results in increased expression of CDKN1A protein]; Nicotine inhibits the reaction [Paclitaxel results in increased expression of CDKN1A protein]
Nicotine results in decreased expression of CDKN1B protein 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Nicotine results in decreased expression of CDKN1B protein]; Nicotine results in increased expression of and results in increased stability of CDKN1B protein
Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CDKN2A mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CDKN2A protein]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN2A mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN2A protein] Nicotine results in increased expression of CDKN2A mRNA; Nicotine results in increased expression of CDKN2A protein
[Nicotine results in increased abundance of Cotinine] which results in increased expression of CEBPA protein Nicotine affects the expression of CEBPA mRNA Nicotine results in increased expression of CEBPA mRNA
Nicotine results in increased expression of CEBPB mRNA [Nicotine results in increased abundance of Cotinine] which results in increased expression of CEBPB mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CETN3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA]
Nicotine inhibits the reaction [Vanadium results in decreased expression of CHAT protein]; Nicotine promotes the reaction [Bucladesine results in increased expression of CHAT protein] Nicotine results in increased activity of CHAT protein Nicotine results in decreased activity of CHAT protein
CHGA protein alternative form inhibits the reaction [Nicotine results in increased activity of CHGA promoter]; Chlorisondamine inhibits the reaction [Nicotine results in increased activity of CHGA promoter] Nicotine results in increased expression of CHGA mRNA
Nicotine results in decreased expression of CHRNA3 mRNA Nicotine results in increased activity of CHRNA3 protein Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Nicotine analog binds to and results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine binds to and results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein] Nicotine results in increased expression of CHRNA3 mRNA CHRNA3 protein affects the susceptibility to Nicotine CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA5 protein]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA7 protein]; Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]
Nicotine binds to [CHRNA4 protein binds to CHRNB2 protein] Nicotine results in increased expression of CHRNA4 mRNA; Nicotine results in increased expression of CHRNA4 protein Nicotine results in decreased expression of CHRNA4 mRNA Nicotine analog binds to [CHRNA4 protein binds to CHRNB2 protein]; Nicotine binds to [CHRNA4 protein binds to CHRNB2 protein] 1-(5-azido-6-chloropyridin-3-ylmethyl)-2-nitroiminoimidazolidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; [Nicotine co-treated with Benzo(a)pyrene] results in decreased expression of [CHRNA4 protein binds to CHRNB2 protein]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of CHRNA4 mRNA]; imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; N-(5-azido-6-chloropyridin-3-ylmethyl)-N'-methyl-N''-nitroguanidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased expression of [CHRNA4 protein binds to CHRNB2 protein] [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with Nicotine] inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CHRNA4 protein]; cytisine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Nicotine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CHRNA4 protein]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] CHRNA4 protein mutant form results in increased susceptibility to Nicotine CHRNA4 gene polymorphism affects the susceptibility to Nicotine; CHRNA4 protein affects the susceptibility to Nicotine; CHRNA4 protein mutant form affects the susceptibility to Nicotine [CHRNA4 protein binds to CHRNB2 protein] which results in increased susceptibility to Nicotine; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]
CHRNA5 gene polymorphism results in increased susceptibility to Nicotine Nicotine results in increased expression of CHRNA5 mRNA CHRNA5 gene polymorphism affects the susceptibility to Nicotine Nicotine results in increased expression of CHRNA5 mRNA; Nicotine results in increased expression of CHRNA5 protein Nicotine results in decreased expression of CHRNA5 mRNA 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; 5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; 5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; alpha-conotoxin MII inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; alpha-conotoxin MII inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA5 protein]; CHRNA5 mutant form inhibits the reaction [Nicotine results in increased expression of HIF1A protein]; CHRNA5 mutant form inhibits the reaction [Nicotine results in increased expression of VEGFA protein]; CHRNA5 protein affects the reaction [Nicotine results in increased expression of and results in increased cleavage of CASP1 protein]; CHRNA5 protein affects the reaction [Nicotine results in increased expression of NLRP3 protein]; CHRNA5 protein affects the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; CHRNA5 protein affects the reaction [Nicotine results in increased secretion of IL18 protein]; CHRNA5 protein affects the reaction [Nicotine results in increased secretion of IL1B protein]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of CHRNA5 protein]; Go 6976 inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; Go 6976 inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; KN 62 inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; KN 62 inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; manumycin inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; manumycin inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]
Nicotine results in decreased expression of CHRNA6 mRNA Nicotine results in increased expression of CHRNA6 mRNA Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine]; Nicotine inhibits the reaction [Paraquat results in decreased expression of [CHRNA6 protein binds to CHRNB2 protein]] CHRNA6 gene polymorphism affects the susceptibility to Nicotine
CHRNA7 protein mutant form results in increased susceptibility to Nicotine Nicotine results in increased expression of CHRNA7 mRNA; Nicotine results in increased expression of CHRNA7 protein Nicotine affects the activity of CHRNA7 protein Nicotine results in increased activity of CHRNA7 protein Nicotine results in decreased expression of CHRNA7 mRNA; Nicotine results in decreased expression of CHRNA7 protein [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] which affects the susceptibility to Nicotine; [Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of CHRNA7 protein; [Nicotine results in increased activity of CHRNA7 protein] which results in increased transport of Calcium; Nicotine inhibits the reaction [iodo-alpha-bungarotoxin binds to CHRNA7 protein]; Nicotine inhibits the reaction [methyllycaconitine binds to CHRNA7 protein]; Nicotine results in increased expression of and results in increased phosphorylation of CHRNA7 protein [Bungarotoxins results in decreased activity of CHRNA7 protein] which results in decreased susceptibility to Nicotine; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] which results in decreased susceptibility to Nicotine; [triethyl-(beta-4-stilbenoxyethyl)ammonium results in decreased activity of CHRNA7 protein] which results in decreased susceptibility to Nicotine CHRNA7 gene polymorphism affects the susceptibility to Nicotine; CHRNA7 protein affects the susceptibility to Nicotine Nicotine results in increased expression of CHRNA7; Nicotine results in increased expression of CHRNA7 mRNA; Nicotine results in increased expression of CHRNA7 protein Nicotine results in increased activity of CHRNA7 protein; Nicotine results in increased activity of CHRNA7 protein mutant form 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased expression of CHRNA7 protein]; 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea promotes the reaction [Nicotine affects the activity of CHRNA7 protein]; 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea promotes the reaction [Nicotine results in increased activity of CHRNA7 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Nicotine results in increased expression of CHRNA7 protein]; [GATA4 co-treated with GATA6] affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased abundance of Epinephrine]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased expression of DBH mRNA]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased expression of TH mRNA]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; [Nicotine results in increased activity of CHRNA7 protein] which results in increased transport of Calcium; Bungarotoxins inhibits the reaction [Nicotine binds to and results in increased activity of CHRNA7 protein]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of CHRNA7 protein]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA7 protein]; CHRNA7 affects the reaction [Nicotine results in decreased expression of SLBP protein]; CHRNA7 affects the reaction [Nicotine results in increased expression of CDK1 protein]; CHRNA7 affects the reaction [Nicotine results in increased expression of CSNK2A1 protein]; CHRNA7 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; CHRNA7 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of CHRNA5 protein]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of GATA2 mRNA]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of GATA2 protein]; GATA2 protein affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; GATA2 protein affects the reaction [Nicotine results in increased expression of CHRNA7 protein]; KN 62 inhibits the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; KN 62 inhibits the reaction [Nicotine results in increased expression of CHRNA7 protein]; MB327 analog promotes the reaction [Nicotine affects the activity of CHRNA7 protein]; MB327 promotes the reaction [Nicotine affects the activity of CHRNA7 protein]; MB327 promotes the reaction [Nicotine results in increased activity of CHRNA7 protein]; methyllycaconitine inhibits the reaction [Nicotine binds to and results in increased activity of CHRNA7 protein]; methyllycaconitine promotes the reaction [[Nicotine results in increased activity of CHRNA7 protein] which results in increased transport of Calcium]; Nicotine binds to and results in increased activity of CHRNA7 protein; Nicotine inhibits the reaction [Bungarotoxins binds to CHRNA7 protein]; Nicotine promotes the reaction [[GATA4 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [[GATA6 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [GATA6 protein binds to GATA4 protein binds to SP1 protein binds to CHRNA7 promoter]; Nicotine results in increased expression of and results in increased phosphorylation of CHRNA7 protein; Pyridinium Compounds analog promotes the reaction [Nicotine results in increased activity of CHRNA7 protein]
Nicotine results in increased expression of CHRNA9 mRNA [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased expression of CHRNA9 protein
[CHRNA4 protein binds to CHRNB2 protein] which results in increased susceptibility to Nicotine; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] Nicotine results in increased expression of CHRNB2 mRNA 1-(5-azido-6-chloropyridin-3-ylmethyl)-2-nitroiminoimidazolidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; [Nicotine co-treated with Benzo(a)pyrene] results in decreased expression of [CHRNA4 protein binds to CHRNB2 protein]; Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; N-(5-azido-6-chloropyridin-3-ylmethyl)-N'-methyl-N''-nitroguanidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]; Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein]; Nicotine results in increased expression of [CHRNA4 protein binds to CHRNB2 protein] Nicotine results in decreased expression of CHRNB2 mRNA Nicotine analog binds to [CHRNA4 protein binds to CHRNB2 protein]; Nicotine binds to [CHRNA4 protein binds to CHRNB2 protein] Nicotine results in increased expression of CHRNB2 mRNA; Nicotine results in increased expression of CHRNB2 protein CHRNB2 protein affects the susceptibility to Nicotine CHRNB2 promotes the reaction [Nicotine results in increased expression of RYR2 mRNA]; cytisine inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein]; Nicotine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine]; Nicotine inhibits the reaction [Paraquat results in decreased expression of [CHRNA6 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein]
Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] Nicotine results in increased expression of CHRNB4 mRNA Nicotine results in increased activity of CHRNB4 protein Nicotine analog binds to and results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine binds to and results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein] CHRNB4 protein affects the susceptibility to Nicotine
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CIB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CIB1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CKMT1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CKMT1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CLCA2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLCA2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CLSTN1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLSTN1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CNN2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA]
CNR1 protein affects the susceptibility to Nicotine Nicotine results in increased expression of CNR1 mRNA [rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to Nicotine
Nicotine results in decreased expression of CNTN1 mRNA Nicotine results in increased expression of CNTN1 mRNA alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of CNTN1 mRNA]; alpha-cobratoxin inhibits the reaction [Nicotine results in increased expression of CNTN1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of CNTN1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CNTN1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of CNTN1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CNTN1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL1A1 mRNA; NGF protein affects the reaction [Nicotine results in increased expression of COL1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL1A1 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of COL1A1 protein]; Nicotine promotes the reaction [Thioacetamide results in increased expression of COL1A1] Nicotine results in increased expression of COL1A1 mRNA; Nicotine results in increased expression of COL1A1 protein
Nicotine promotes the reaction [Arginine results in increased expression of COL1A2 protein] Nicotine promotes the reaction [Quartz results in increased expression of COL1A2 protein]
Nicotine results in decreased expression of COL2A1 mRNA; Nicotine results in decreased expression of COL2A1 protein NLRP3 protein affects the reaction [Nicotine results in decreased expression of COL2A1 mRNA]
Nicotine results in increased expression of COL3A1 mRNA Nicotine results in increased expression of COL3A1 mRNA; Nicotine results in increased expression of COL3A1 protein Nicotine promotes the reaction [Arginine results in increased expression of COL3A1 protein] NGF protein affects the reaction [Nicotine results in increased expression of COL3A1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL6A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL6A1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of COX7A2L mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA]
CREB1 protein promotes the reaction [Nicotine results in increased expression of MMP7 mRNA] Nicotine results in increased expression of CREB1 mRNA Nicotine results in increased phosphorylation of CREB1 protein CREB1 protein promotes the reaction [Nicotine results in increased expression of RYR2 mRNA]; Excitatory Amino Acid Antagonists inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein]; KN 93 inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein]; Mecamylamine inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein]; Nicotine promotes the reaction [CREB1 protein modified form binds to RYR2 promoter]; Nifedipine inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein]; Ryanodine inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein] Nicotine results in decreased expression of CREB1 mRNA
Nicotine results in decreased expression of CRH mRNA; Nicotine results in decreased expression of CRH protein Nicotine results in increased expression of CRH protein
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA
Nicotine results in increased expression of and results in increased secretion of CSF2 protein; Tubocurarine inhibits the reaction [Nicotine results in increased secretion of CSF2 protein]
Nicotine results in increased expression of CSNK2A1 protein CHRNA7 affects the reaction [Nicotine results in increased expression of CSNK2A1 protein]; CSNK2A1 affects the reaction [Nicotine results in decreased expression of SLBP protein]; CSNK2A1 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CST3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA]
Carbon Tetrachloride inhibits the reaction [Nicotine results in decreased expression of CTNNB1 mRNA]; Nicotine inhibits the reaction [Carbon Tetrachloride results in decreased expression of CTNNB1 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of CTNNB1 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of CTNNB1 protein] Nicotine results in increased expression of CTNNB1 mRNA; Nicotine results in increased expression of CTNNB1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CTSL mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA]
Nicotine results in decreased expression of CXCL1 mRNA Nicotine results in decreased secretion of CXCL1 protein Nicotine results in increased expression of CXCL1 protein
[Mecamylamine co-treated with Dihydro-beta-Erythroidine co-treated with Bungarotoxins] inhibits the reaction [Nicotine results in increased expression of CXCR4 protein] Nicotine results in increased expression of CXCR4 mRNA; Nicotine results in increased expression of CXCR4 protein
Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium affects the localization of CYCS protein] Nicotine results in increased expression of CYCS protein Nicotine results in increased secretion of CYCS protein Folic Acid inhibits the reaction [Nicotine results in increased expression of CYCS protein]; Nicotine inhibits the reaction [[Calcium co-treated with Phosphates] affects the localization of CYCS protein] Nicotine affects the localization of CYCS protein Nicotine results in decreased secretion of CYCS protein
Nicotine results in decreased expression of CYP11A1 mRNA; Nicotine results in decreased expression of CYP11A1 protein Nicotine results in decreased activity of CYP11A1 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYP11A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP11A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 protein]
Nicotine results in decreased expression of CYP17A1 mRNA Nicotine results in decreased expression of CYP17A1 mRNA; Nicotine results in decreased expression of CYP17A1 protein
Nicotine results in decreased expression of CYP19A1 mRNA; Nicotine results in decreased expression of CYP19A1 protein bisphenol A promotes the reaction [Nicotine results in decreased expression of CYP19A1 protein] Nicotine results in increased activity of CYP19A1 protein Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 protein]
Nicotine results in increased expression of CYP1A1 mRNA; Nicotine results in increased expression of CYP1A1 protein Nicotine results in decreased expression of CYP1A1 protein bisphenol A promotes the reaction [Nicotine results in decreased expression of CYP1A1 protein] 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CYP1A1 protein]; CYP1A1 protein affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; diphenyleneiodonium inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]; SB 203580 inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]; SR 11302 inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]
Nicotine results in increased expression of CYP1A2 protein Nicotine results in decreased expression of CYP1A2 mRNA Nicotine results in decreased activity of CYP1A2 protein
Nicotine results in decreased expression of CYP1B1 protein bisphenol A promotes the reaction [Nicotine results in decreased expression of CYP1B1 protein]
Nicotine results in increased expression of CYP2A1 mRNA Nicotine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]; Nicotine inhibits the reaction [CYP2A13 protein results in increased susceptibility to Aflatoxin B1] Nicotine results in decreased activity of CYP2A13 protein CYP2A13 protein results in increased metabolism of Nicotine
[Nicotine co-treated with 2,2',3,5',6-pentachlorobiphenyl] results in increased expression of CYP2B1 mRNA; [Nicotine results in increased expression of CYP2B1 protein] which results in increased abundance of Cotinine; [Nicotine results in increased expression of CYP2B1 protein] which results in increased metabolism of Nicotine; Nicotine results in increased expression of and results in increased activity of CYP2B1 protein Nicotine results in increased expression of CYP2B1 mRNA; Nicotine results in increased expression of CYP2B1 protein CYP2B1 protein results in increased metabolism of Nicotine
CYP2B6 protein results in increased metabolism of Nicotine CYP2B6 protein results in increased oxidation of Nicotine CYP2B6 gene polymorphism affects the oxidation of Nicotine CYP2B6 gene polymorphism affects the reaction [CYP2A6 protein results in increased metabolism of Nicotine]
Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]]; Ketoconazole inhibits the reaction [Nicotine results in increased expression of CYP2D22 mRNA]; Ketoconazole inhibits the reaction [Nicotine results in increased expression of CYP2D22 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]; Nicotine inhibits the reaction [Ketoconazole results in decreased expression of CYP2D22 mRNA]; Nicotine inhibits the reaction [Ketoconazole results in decreased expression of CYP2D22 protein] Nicotine results in increased expression of CYP2D22 mRNA; Nicotine results in increased expression of CYP2D22 protein
[Nicotine co-treated with 2,2',3,5',6-pentachlorobiphenyl] results in increased expression of CYP3A2 mRNA [Nicotine binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA
[methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased expression of DBH mRNA]
Nicotine inhibits the reaction [Cisplatin results in increased expression of DDIT3 mRNA] Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein] Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of DDIT3 protein]
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of DHFR mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of DHFR mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of DHFR mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJA1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJB9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA]
Nicotine results in decreased expression of DNMT1 mRNA Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in decreased expression of DNMT1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DPP4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA]
[SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to Nicotine Nicotine results in decreased expression of DRD1 mRNA
[Raclopride binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Nicotine DRD2 mRNA results in decreased susceptibility to Nicotine
Nicotine results in decreased expression of DVL2 mRNA Nicotine results in increased expression of DVL2 mRNA; Nicotine results in increased expression of DVL2 protein Carbon Tetrachloride promotes the reaction [Nicotine results in increased expression of DVL2 mRNA]; Carbon Tetrachloride promotes the reaction [Nicotine results in increased expression of DVL2 protein]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of DVL2 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of DVL2 protein]
MK-886 inhibits the reaction [Nicotine results in increased expression of E2F1 protein]; Nicotine promotes the reaction [E2F1 protein binds to BIRC5 promoter]; Nicotine promotes the reaction [E2F1 protein binds to CDC25A promoter]; Nicotine promotes the reaction [E2F1 protein binds to CDC6 promoter]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ECM1 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ECM1 mRNA]
MIR98 mRNA inhibits the reaction [Nicotine results in increased expression of EDN1 mRNA]; NGF protein affects the reaction [Nicotine results in increased expression of EDN1 mRNA]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of EDN1 mRNA] Nicotine results in increased expression of EDN1 mRNA; Nicotine results in increased expression of EDN1 protein
Nicotine results in increased expression of EEF2 protein modified form [Nicotine results in increased expression of UBA2 protein] which results in increased sumoylation of EEF2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EFNB3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA]
Nicotine results in decreased expression of EGFR mRNA Nicotine results in increased phosphorylation of EGFR protein AG 1879 inhibits the reaction [Nicotine results in increased phosphorylation of EGFR protein]
Nicotine results in increased expression of EGR1 mRNA; Nicotine results in increased expression of EGR1 protein Nicotine results in decreased expression of EGR1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EGR1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EGR1 mRNA] [triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]] which results in decreased expression of FGF2 mRNA; EGR1 protein inhibits the reaction [triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased secretion of FGF2 protein]]; EGR1 protein promotes the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; EGR1 protein promotes the reaction [Nicotine results in decreased expression of HSD11B2 protein]; Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased expression of EGR1 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 protein]
Mecamylamine inhibits the reaction [Nicotine results in increased phosphorylation of EIF2AK3 protein]; ursodoxicoltaurine inhibits the reaction [Nicotine results in increased phosphorylation of EIF2AK3 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF2B4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF2B4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF4E mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF4E mRNA] EIF4E protein affects the reaction [Nicotine results in increased expression of BCL2 protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of CCND1 protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of MYC protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of VEGFA protein]; Nicotine promotes the reaction [EIF4EBP1 protein binds to EIF4E protein]
[Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Nicotine promotes the reaction [EIF4EBP1 protein binds to EIF4E protein]; Nicotine results in increased expression of and results in increased phosphorylation of EIF4EBP1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA]
Nicotine results in increased phosphorylation of ELK1 protein Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of ELK1 protein]
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of EML4 mRNA]; Mecamylamine promotes the reaction [Nicotine results in decreased expression of EML4 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of EML4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ENO1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERN1 mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ERP44 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ETFA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ETFA mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EZR mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EZR mRNA] Nicotine results in increased expression of EZR mRNA
Nicotine affects the expression of FASLG mRNA Nicotine results in increased expression of FASLG mRNA; Nicotine results in increased expression of FASLG protein Nicotine results in increased expression of FASLG protein alternative form
Nicotine results in increased expression of FASN mRNA; Nicotine results in increased expression of FASN protein Nicotine affects the expression of FASN mRNA Nicotine promotes the reaction [NR1H3 protein binds to FASN promoter]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of FBXL12 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FBXL12 mRNA]
Nicotine results in increased expression of FEZ1 mRNA alpha-cobratoxin promotes the reaction [Nicotine results in decreased expression of FEZ1 mRNA alternative form]; Tubocurarine promotes the reaction [Nicotine results in decreased expression of FEZ1 mRNA]
[triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]] which results in decreased expression of FGF2 mRNA; EGR1 protein inhibits the reaction [triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased secretion of FGF2 protein]]; Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased secretion of FGF2 protein] Nicotine results in increased expression of FGF2 mRNA; Nicotine results in increased expression of FGF2 protein Mecamylamine inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA] Nicotine results in decreased expression of FGF2 protein
Nicotine results in decreased expression of FN1 mRNA Nicotine results in increased expression of FN1 mRNA; Nicotine results in increased expression of FN1 protein MIR98 mRNA inhibits the reaction [Nicotine results in increased expression of FN1 mRNA]; NGF protein affects the reaction [Nicotine results in increased expression of FN1 mRNA]; Nicotine promotes the reaction [Quartz results in increased expression of FN1 protein]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of FN1 mRNA]
Nicotine results in increased expression of FOS; Nicotine results in increased expression of FOS mRNA; Nicotine results in increased expression of FOS protein Nicotine results in increased phosphorylation of FOS protein Nicotine deficiency affects the expression of FOS protein Acetaldehyde promotes the reaction [Nicotine results in increased expression of FOS mRNA]; Saponins inhibits the reaction [Nicotine results in increased expression of FOS protein] Nicotine results in decreased expression of FOS mRNA [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of FOS protein]; SB 203580 inhibits the reaction [Nicotine results in increased phosphorylation of FOS protein]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of FOS]
[Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of FOXO1 protein
LCK protein promotes the reaction [Nicotine results in increased phosphorylation of and results in increased activity of FYN protein]; Nicotine results in increased phosphorylation of and results in increased activity of FYN protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GAB1 mRNA]
Nicotine results in increased expression of GAD1 mRNA; Nicotine results in increased expression of GAD1 protein Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of GAD1 mRNA] Nicotine results in decreased methylation of GAD1 promoter
[Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA]; [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAPDH mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA]
5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone inhibits the reaction [Nicotine results in increased expression of GATA2 mRNA]; 5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone inhibits the reaction [Nicotine results in increased expression of GATA2 protein]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of GATA2 mRNA]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of GATA2 protein]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of GATA2 mRNA]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of GATA2 protein]; GATA2 protein affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; GATA2 protein affects the reaction [Nicotine results in increased expression of CHRNA7 protein]; manumycin inhibits the reaction [Nicotine results in increased expression of GATA2 mRNA]; manumycin inhibits the reaction [Nicotine results in increased expression of GATA2 protein]; U 0126 inhibits the reaction [Nicotine results in increased expression of GATA2 mRNA]; U 0126 inhibits the reaction [Nicotine results in increased expression of GATA2 protein] Nicotine results in increased expression of GATA2 mRNA; Nicotine results in increased expression of GATA2 protein
[GATA4 co-treated with GATA6] affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; Nicotine promotes the reaction [[GATA4 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [GATA4 protein binds to SP1 protein]; Nicotine promotes the reaction [GATA6 protein binds to GATA4 protein binds to SP1 protein binds to CHRNA7 promoter]
[GATA4 co-treated with GATA6] affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; Nicotine promotes the reaction [[GATA6 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [GATA6 protein binds to GATA4 protein binds to SP1 protein binds to CHRNA7 promoter]; Nicotine promotes the reaction [GATA6 protein binds to SP1 protein] [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GATA6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GATA6 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GCLC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GCLC mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GHITM mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GMFB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA]
Nicotine results in increased splicing of GNAI2 mRNA alternative form [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GNAI2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GNAI2 mRNA]
alpha-cobratoxin inhibits the reaction [Nicotine results in increased expression of GOLGA4 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of GOLGA4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GOLT1B mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPRC5C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPRC5C mRNA]
Nicotine inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] Nicotine results in increased expression of GPT protein dexpanthenol inhibits the reaction [Nicotine results in increased expression of GPT protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPX3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPX3 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GRID2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]
[Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of GSK3A protein Nicotine results in increased expression of GSK3A mRNA Nicotine results in increased expression of and results in decreased phosphorylation of GSK3A protein
[Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of GSK3B protein Nicotine results in decreased expression of GSK3B mRNA; Nicotine results in decreased expression of GSK3B protein Nicotine results in increased expression of GSK3B mRNA Carbon Tetrachloride inhibits the reaction [Nicotine results in decreased expression of GSK3B mRNA]; Carbon Tetrachloride inhibits the reaction [Nicotine results in decreased expression of GSK3B protein]; Nicotine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GSK3B mRNA]; Nicotine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GSK3B protein]; Nicotine promotes the reaction [Carbon Tetrachloride results in decreased expression of GSK3B mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in decreased expression of GSK3B protein]; Nicotine results in increased expression of and results in decreased phosphorylation of GSK3B protein
Nicotine results in decreased expression of GSTA4 mRNA Nicotine results in increased expression of GSTA4 mRNA Nicotine results in increased activity of GSTA4 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HBA-A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA]
Nicotine results in increased expression of HDAC1 mRNA Nicotine results in increased expression of HDAC1 mRNA; Nicotine results in increased expression of HDAC1 protein SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC1 mRNA]; SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC1 protein]
Nicotine results in increased expression of HDAC2 mRNA; Nicotine results in increased expression of HDAC2 protein SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC2 mRNA]; SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC2 protein] Nicotine results in decreased expression of HDAC2 protein
Nicotine results in increased expression of HDAC4 mRNA; Nicotine results in increased expression of HDAC4 protein Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HELLS mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA]
Nicotine affects the expression of HGF mRNA Nicotine results in decreased expression of HGF protein [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA
Nicotine results in increased expression of HIF1A protein Nicotine results in decreased expression of HIF1A mRNA resveratrol inhibits the reaction [Nicotine results in decreased expression of HIF1A mRNA] CHRNA5 mutant form inhibits the reaction [Nicotine results in increased expression of HIF1A protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HINT1 mRNA; Mecamylamine inhibits the reaction [Nicotine results in increased expression of HINT1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA] Nicotine results in increased expression of HINT1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HIPK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HIPK1 mRNA]
HMOX1 protein results in increased susceptibility to Nicotine Nicotine affects the expression of HMOX1 mRNA Nicotine results in increased expression of HMOX1 mRNA; Nicotine results in increased expression of HMOX1 protein [Lipopolysaccharides co-treated with Nicotine] results in increased expression of HMOX1 mRNA; [Lipopolysaccharides co-treated with Nicotine] results in increased expression of HMOX1 protein; [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; HMOX1 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of ZFP36 mRNA]; HMOX1 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; HMOX1 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of ZFP36 mRNA]]; HMOX1 protein promotes the reaction [Nicotine results in increased expression of ZFP36 mRNA]; HMOX1 protein promotes the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; STAT3 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of HMOX1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HNRNPC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HNRNPC mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HRAS mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA] Nicotine results in increased activity of HRAS protein
Nicotine results in increased expression of HSD11B1 mRNA Nicotine affects the expression of HSD11B1 mRNA ursodoxicoltaurine inhibits the reaction [Nicotine results in increased expression of HSD11B1 mRNA]
Nicotine results in decreased expression of HSD11B2 mRNA; Nicotine results in decreased expression of HSD11B2 protein Nicotine affects the expression of HSD11B2 mRNA Nicotine results in increased expression of HSD11B2 mRNA; Nicotine results in increased expression of HSD11B2 protein 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 protein]; EGR1 protein promotes the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; EGR1 protein promotes the reaction [Nicotine results in decreased expression of HSD11B2 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 protein]
Taurine inhibits the reaction [Nicotine results in decreased expression of HSD17B1 protein] Nicotine results in decreased expression of HSD17B1 mRNA Nicotine results in decreased expression of HSD17B1 mRNA; Nicotine results in decreased expression of HSD17B1 protein
Nicotine results in decreased activity of HSD17B3 protein Nicotine results in decreased expression of HSD17B3 mRNA; Nicotine results in decreased expression of HSD17B3 protein
Nicotine results in decreased expression of HSD3B1 mRNA; Nicotine results in decreased expression of HSD3B1 protein Nicotine results in decreased activity of HSD3B1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HSP90AA1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA] Nicotine results in increased expression of HSP90AA1 mRNA; Nicotine results in increased expression of HSP90AA1 protein
Nicotine results in increased expression of HSPA5 Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein] Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HSPA5 protein]; Nicotine inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]
[Nicotine co-treated with Benzo(a)pyrene] results in decreased expression of HTR2A protein; Nicotine results in increased activity of [HTR1B protein binds to HTR2A protein] Nicotine results in increased expression of HTR2A protein
IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]
Nicotine results in decreased expression of IGF1 mRNA; Nicotine results in decreased expression of IGF1 protein Nicotine affects the expression of IGF1 mRNA; Nicotine affects the expression of IGF1 protein Nicotine results in increased expression of IGF1 mRNA rosiglitazone inhibits the reaction [Nicotine results in decreased expression of IGF1 protein]
Nicotine results in decreased expression of IGF1R mRNA; Nicotine results in decreased expression of IGF1R protein Nicotine affects the expression of IGF1R mRNA Nicotine results in increased expression of IGF1R mRNA
Nicotine results in decreased expression of IL10 mRNA Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Nicotine results in decreased secretion of IL10 protein [Eugenol co-treated with Acetylcysteine] inhibits the reaction [Nicotine results in decreased secretion of IL10 protein]; Acetylcysteine inhibits the reaction [Nicotine results in decreased expression of IL10 mRNA]; Eugenol inhibits the reaction [Nicotine results in decreased expression of IL10 mRNA]; Nicotine inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]
Acetylcysteine inhibits the reaction [Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]]; Eugenol inhibits the reaction [Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]]; Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]
Acetylcysteine inhibits the reaction [Nicotine results in increased expression of IL12B mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]]; Eugenol inhibits the reaction [Nicotine results in increased expression of IL12B mRNA]; Eugenol inhibits the reaction [Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]]; Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]
[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL17A mRNA; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL17A mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL17A mRNA]
Nicotine results in increased secretion of IL18 protein Nicotine results in increased expression of IL18 protein Nicotine results in increased expression of IL18 mRNA CHRNA5 protein affects the reaction [Nicotine results in increased secretion of IL18 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 protein]]; [Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL1B mRNA; CHRNA5 protein affects the reaction [Nicotine results in increased secretion of IL1B protein]; Nicotine inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 protein]; Nicotine promotes the reaction [IL1B protein results in increased secretion of CXCL8 protein]; Nicotine results in increased expression of and results in increased secretion of IL1B protein; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL1B mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL1B mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased secretion of IL1B protein]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 mRNA]]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased secretion of CXCL8 protein]]; U 0126 inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 protein]] Nicotine results in increased expression of IL1B mRNA Nicotine results in decreased expression of IL1B protein [Nicotine results in increased abundance of Cotinine] which results in increased expression of IL1B mRNA; Nicotine inhibits the reaction [Acetic Acid results in increased expression of IL1B protein]; Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA] Nicotine results in increased expression of IL1B mRNA; Nicotine results in increased expression of IL1B protein Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
methyllycaconitine affects the reaction [Nicotine results in increased expression of IL1R1 mRNA]; methyllycaconitine affects the reaction [Nicotine results in increased expression of IL1R1 protein] Nicotine results in increased expression of IL1R1 mRNA; Nicotine results in increased expression of IL1R1 protein
Nicotine results in increased secretion of IL33 protein [Nicotine co-treated with Quartz] results in increased expression of IL33 protein Nicotine promotes the reaction [Lipopolysaccharides results in increased secretion of IL33 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of IL4RA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA]
[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL6 mRNA; [Nicotine co-treated with Propylene Glycol co-treated with Glycerol co-treated with Flavoring Agents] results in increased secretion of IL6 protein; [Nicotine co-treated with Propylene Glycol co-treated with Glycerol] results in increased secretion of IL6 protein; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Nicotine results in increased expression of and results in increased secretion of IL6 protein; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL6 mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL6 mRNA] Nicotine results in increased secretion of IL6 protein [Nicotine results in increased abundance of Cotinine] which results in increased expression of IL6 mRNA Nicotine results in decreased secretion of IL6 protein Nicotine results in decreased expression of IL6 mRNA; Nicotine results in decreased expression of IL6 protein Nicotine results in increased expression of IL6 mRNA; Nicotine results in increased expression of IL6 protein Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; ZFP36 mutant form inhibits the reaction [Nicotine results in decreased expression of IL6 mRNA]
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA Sodium Acetate inhibits the reaction [Nicotine results in increased expression of INS1 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRAK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA]
IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRX3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IRX3 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ITM2B mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA]
JAK2 results in increased susceptibility to Nicotine Nicotine results in increased phosphorylation of JAK2 protein Bungarotoxins inhibits the reaction [Nicotine results in increased phosphorylation of JAK2 protein] Nicotine results in decreased expression of JAK2 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of JMJD6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of JMJD6 mRNA]
Nicotine results in increased expression of JUN protein Nicotine results in increased phosphorylation of JUN protein Nicotine promotes the reaction [MAPK8 protein results in increased phosphorylation of JUN protein] [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of JUN protein]; Nicotine inhibits the reaction [Cisplatin results in increased expression of JUN mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of KAT6B mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KAT6B mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of KIF3B mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KLF4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA] Nicotine results in increased expression of KLF4 mRNA
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of KMT2C mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of KMT2C mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of KMT2C mRNA]
Nicotine results in decreased activity of KNG1 protein alternative form Capsaicin promotes the reaction [Nicotine results in decreased activity of KNG1 protein alternative form]; Kainic Acid promotes the reaction [Nicotine results in decreased activity of KNG1 protein alternative form]
LCK protein promotes the reaction [Nicotine results in increased phosphorylation of and results in increased activity of FYN protein]; Nicotine results in increased phosphorylation of and results in increased activity of LCK protein
Nicotine results in decreased expression of LHB mRNA; Nicotine results in decreased expression of LHB protein Nicotine results in increased secretion of LHB protein
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of LITAF mRNA]; Mecamylamine promotes the reaction [Nicotine results in decreased expression of LITAF mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of LITAF mRNA] Nicotine results in increased expression of LITAF mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LPAR4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAOA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAP2K7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP2K7 mRNA]
Nicotine results in increased activity of MAPK1 protein Nicotine results in increased phosphorylation of MAPK1 protein Nicotine results in decreased expression of MAPK1 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAPK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAPK1 mRNA] Melatonin inhibits the reaction [Nicotine results in decreased expression of MAPK1 protein]; Melatonin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Nicotine results in increased phosphorylation of and results in increased activity of MAPK1 protein Nicotine results in increased expression of MAPK1 protein modified form 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK1 protein; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased phosphorylation of MAPK1 protein; [Nicotine co-treated with Ethanol] results in increased phosphorylation of MAPK1 protein; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of FOS protein]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of JUN protein]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] which results in decreased susceptibility to Nicotine; Acetylcysteine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine results in decreased activity of MAPK1 protein]; Curcumin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; diphenyleneiodonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]; Nicotine inhibits the reaction [Cisplatin results in increased activity of MAPK1 protein]; Nicotine inhibits the reaction [Fluorouracil results in increased phosphorylation of MAPK1 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein]; Nicotine results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Nicotine results in increased phosphorylation of and results in increased activity of MAPK1 protein; Propranolol inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Staurosporine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Tubocurarine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK3 protein; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased phosphorylation of MAPK3 protein; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of FOS protein]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of JUN protein]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] which results in decreased susceptibility to Nicotine; Acetylcysteine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine results in decreased activity of MAPK3 protein]; Curcumin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; diphenyleneiodonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Nicotine inhibits the reaction [Cisplatin results in increased activity of MAPK3 protein]; Nicotine inhibits the reaction [Fluorouracil results in increased phosphorylation of MAPK3 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein]; Nicotine results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Nicotine results in increased phosphorylation of and results in increased activity of MAPK3 protein; Propranolol inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Staurosporine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Tubocurarine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein] Nicotine results in decreased expression of MAPK3 protein Melatonin inhibits the reaction [Nicotine results in decreased expression of MAPK3 protein]; Melatonin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Nicotine results in increased phosphorylation of and results in increased activity of MAPK3 protein Nicotine results in decreased expression of MAPK3 mRNA; Nicotine results in decreased expression of MAPK3 protein Nicotine results in increased expression of MAPK3 protein modified form Nicotine results in increased activity of MAPK3 protein
Nicotine results in increased phosphorylation of MAPK8 protein Nicotine promotes the reaction [MAPK8 protein results in increased phosphorylation of JUN protein] Nicotine results in increased expression of MAPK8 mRNA Nicotine results in increased activity of MAPK8 protein Curcumin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK8 protein]; Nicotine inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK8 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK8 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of MCL1 protein]; [Nicotine results in increased phosphorylation of MCL1 protein] which results in increased expression of and results in increased stability of MCL1 protein; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of MCL1 protein]
[[Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein] which results in increased ubiquitination of TP53 protein; [Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ME1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ME1 mRNA]
Nicotine results in decreased expression of MIR98 mRNA MIR98 mRNA affects the reaction [Nicotine results in increased expression of NGF protein]; MIR98 mRNA inhibits the reaction [Nicotine results in increased expression of EDN1 mRNA]; MIR98 mRNA inhibits the reaction [Nicotine results in increased expression of FN1 mRNA]; Rosiglitazone inhibits the reaction [Nicotine results in decreased expression of MIR98 mRNA]
[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of MKI67 protein; Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of MKI67 protein]; methyllycaconitine inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of MKI67 protein] [Nicotine co-treated with Quartz] results in increased expression of MKI67 protein Nicotine results in increased expression of MKI67 protein Nicotine results in decreased expression of MKI67 protein
lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 mRNA]; lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 protein]; Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 mRNA]; Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 protein]; Polymyxin B inhibits the reaction [lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 protein]]; Polymyxin B inhibits the reaction [Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of MMP1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of MMP1 protein] Nicotine results in increased expression of MMP1 mRNA; Nicotine results in increased expression of MMP1 protein
Nicotine results in increased expression of MMP13 mRNA; Nicotine results in increased expression of MMP13 protein NLRP3 protein affects the reaction [Nicotine results in increased expression of MMP13 mRNA] Nicotine results in decreased expression of MMP13 mRNA
lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP2 mRNA]; Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP2 mRNA] Nicotine results in decreased expression of MMP2 mRNA [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA Nicotine results in decreased expression of MMP2 protein Nicotine results in increased expression of MMP2 mRNA; Nicotine results in increased expression of MMP2 protein
lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP3 mRNA]; Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP3 mRNA]; NLRP3 protein affects the reaction [Nicotine results in increased expression of MMP3 mRNA] Nicotine results in increased expression of MMP3 mRNA; Nicotine results in increased expression of MMP3 protein
CREB1 protein promotes the reaction [Nicotine results in increased expression of MMP7 mRNA]; MK-886 inhibits the reaction [Nicotine results in increased expression of MMP7 mRNA]; MMP7 promoter SNP affects the reaction [Nicotine results in increased expression of MMP7 mRNA] [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MMP7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA] Nicotine results in increased expression of MMP7 mRNA; Nicotine results in increased expression of MMP7 protein MMP7 promoter SNP affects the susceptibility to Nicotine
Nicotine results in increased expression of MMP9 mRNA; Nicotine results in increased expression of MMP9 protein MK-886 inhibits the reaction [Nicotine results in increased expression of MMP9 mRNA] Nicotine results in decreased expression of MMP9 protein
Nicotine results in decreased activity of MPO protein Nicotine results in increased activity of MPO protein Acetylcysteine inhibits the reaction [Nicotine results in increased activity of MPO protein]; erdosteine inhibits the reaction [Nicotine results in increased activity of MPO protein]; Nicotine inhibits the reaction [Acetic Acid results in increased activity of MPO protein]; Vitamin E inhibits the reaction [Nicotine results in increased activity of MPO protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MRPL10 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL10 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL20 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MT2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA]
[Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MTCH1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTF2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTF2 mRNA]
Nicotine results in decreased expression of MTOR mRNA Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein] dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein] Nicotine results in increased phosphorylation of MTOR protein
Nicotine results in increased activity of MYC protein EIF4E protein affects the reaction [Nicotine results in increased expression of MYC protein] Nicotine results in decreased expression of MYC mRNA Nicotine results in decreased activity of and results in decreased expression of MYC protein
Nicotine results in increased expression of NANOG mRNA; Nicotine results in increased expression of NANOG protein [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased expression of NANOG protein; SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of NANOG mRNA]
[Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA] [nickel chloride co-treated with Nicotine] results in increased expression of NCAM1 mRNA
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Nicotine results in increased expression of NCF1 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NDUFB5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA]
Nicotine results in increased activity of NFKB1 protein Mecamylamine analog inhibits the reaction [Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]]]; methyllycaconitine analog inhibits the reaction [Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]]]; Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]] Nicotine results in decreased expression of NFKB1 mRNA; Nicotine results in decreased expression of NFKB1 protein Nicotine results in increased expression of NFKB1 mRNA Vitamin K 3 inhibits the reaction [Nicotine results in increased activity of NFKB1 protein]
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; NSC 74859 inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]] Nicotine results in increased phosphorylation of NFKBIA protein Nicotine results in increased degradation of NFKBIA protein Nicotine results in increased expression of NFKBIA mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NGB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NGB mRNA]
Nicotine results in increased expression of NGF mRNA MIR98 mRNA affects the reaction [Nicotine results in increased expression of NGF protein]; NGF protein affects the reaction [Nicotine results in increased expression of COL1A1 mRNA]; NGF protein affects the reaction [Nicotine results in increased expression of COL3A1 mRNA]; NGF protein affects the reaction [Nicotine results in increased expression of EDN1 mRNA]; NGF protein affects the reaction [Nicotine results in increased expression of FN1 mRNA]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of NGF mRNA] Nicotine results in increased expression of NGF mRNA; Nicotine results in increased expression of NGF protein Nicotine results in increased expression of and results in increased secretion of NGF protein
Nicotine results in increased expression of NIN mRNA alpha-cobratoxin inhibits the reaction [Nicotine results in increased expression of NIN mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of NIN mRNA]
Bungarotoxins inhibits the reaction [Nicotine results in increased expression of NLRP3 mRNA]; CHRNA5 protein affects the reaction [Nicotine results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [Nicotine results in decreased expression of ACAN mRNA]; NLRP3 protein affects the reaction [Nicotine results in decreased expression of COL2A1 mRNA]; NLRP3 protein affects the reaction [Nicotine results in increased expression of MMP13 mRNA]; NLRP3 protein affects the reaction [Nicotine results in increased expression of MMP3 mRNA] Nicotine results in increased expression of NLRP3 mRNA; Nicotine results in increased expression of NLRP3 protein
Nicotine results in increased expression of NOS2 mRNA; Nicotine results in increased expression of NOS2 protein Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] Nicotine results in decreased expression of NOS2 mRNA; Nicotine results in decreased expression of NOS2 protein Nicotine promotes the reaction [NOS2 protein results in increased abundance of Nitric Oxide] [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; [Nicotine results in decreased expression of NOS2 protein] which results in decreased abundance of Nitric Oxide; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of NOS2 mRNA]; Eugenol inhibits the reaction [Nicotine results in increased expression of NOS2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]
[Saquinavir co-treated with Nicotine co-treated with Ritonavir] results in decreased expression of NOTCH4 protein; [Saquinavir co-treated with Nicotine] results in decreased expression of NOTCH4 protein; Vitamin E inhibits the reaction [[Nicotine co-treated with Ritonavir co-treated with Saquinavir] results in decreased expression of NOTCH4 protein]; Vitamin E inhibits the reaction [[Nicotine co-treated with Saquinavir] results in decreased expression of NOTCH4 protein] Nicotine results in decreased expression of NOTCH4 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NPL mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NPL mRNA]
Hexamethonium inhibits the reaction [Nicotine results in increased expression of NPY mRNA] Nicotine results in decreased expression of NPY protein Nicotine results in increased expression of NPY mRNA; Nicotine results in increased expression of NPY protein
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 protein] Nicotine results in decreased expression of NR1H2 mRNA; Nicotine results in decreased expression of NR1H2 protein
Nicotine promotes the reaction [NR1H3 protein binds to FASN promoter]; Nicotine results in increased expression of and results in increased activity of NR1H3 protein Nicotine results in decreased expression of NR1H3 mRNA; Nicotine results in decreased expression of NR1H3 protein Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 protein]
Nicotine results in decreased expression of NR3C1 mRNA Nicotine results in decreased expression of NR3C1 protein Nicotine results in increased expression of NR3C1 mRNA; Nicotine results in increased expression of NR3C1 protein
Nicotine results in decreased expression of NR5A1 mRNA; Nicotine results in decreased expression of NR5A1 protein trichostatin A inhibits the reaction [Nicotine results in decreased expression of NR5A1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NSF mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA]
Nicotine results in increased expression of NTRK2 protein [Nicotine co-treated with Quartz] results in increased phosphorylation of NTRK2 protein; staurosporine aglycone inhibits the reaction [[Nicotine co-treated with Quartz] results in increased expression of NTRK2 protein] methyllycaconitine inhibits the reaction [Nicotine results in increased expression of NTRK2 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NUPR1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of P3H3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of P3H3 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PAK2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PAK2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PARK7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PARK7 mRNA]
Nicotine inhibits the reaction [Aflatoxin B1 results in increased expression of PARP1 protein modified form]; Nicotine inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; Nicotine inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; Nicotine inhibits the reaction [Fluorouracil results in increased cleavage of PARP1 protein] Folic Acid inhibits the reaction [Nicotine results in decreased expression of PARP1 protein]
Nicotine results in increased expression of PCNA protein Nicotine results in decreased expression of PCNA protein royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein]
6,7-dimethoxy-2-phenylquinoxaline inhibits the reaction [Nicotine results in increased expression of PDGFB mRNA]; 6,7-dimethoxy-2-phenylquinoxaline inhibits the reaction [Nicotine results in increased secretion of PDGFB protein]
Nicotine results in increased expression of PDGFRB protein Nicotine results in decreased phosphorylation of and results in decreased activity of PDGFRB protein 6,7-dimethoxy-2-phenylquinoxaline inhibits the reaction [Nicotine results in increased expression of PDGFRB protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PDIA6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PFDN1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHB1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHTF1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA] Nicotine results in decreased expression of PHTF1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIDD1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIGC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PIN1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIP5K1C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PLAA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PLAA mRNA]
Nicotine affects the expression of PLAT mRNA Nicotine results in increased expression of PLAT mRNA; Nicotine results in increased expression of PLAT protein [Nicotine co-treated with lipopolysaccharide, E. coli O26-B6] affects the expression of PLAT mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA]; MK-886 inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA]; pyrazolanthrone inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA] Nicotine results in increased expression of PLAUR mRNA; Nicotine results in increased expression of PLAUR protein
Nicotine results in increased expression of PNMT mRNA Nicotine results in increased expression of PNMT protein imidacloprid promotes the reaction [Nicotine results in increased expression of PNMT protein]
Nicotine results in decreased expression of PNPLA2 mRNA [Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 mRNA; [Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PNPLA8 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA]
POMC protein affects the susceptibility to Nicotine Nicotine results in decreased expression of POMC protein Nicotine affects the expression of POMC protein POMC protein affects the reaction [Nicotine results in increased abundance of Dopamine] Nicotine results in increased expression of POMC protein alternative form
Nicotine results in increased expression of POU5F1 mRNA; Nicotine results in increased expression of POU5F1 protein Tubocurarine inhibits the reaction [Nicotine results in increased expression of POU5F1 mRNA] SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of POU5F1 mRNA]
Nicotine results in decreased expression of PPARGC1A mRNA; Nicotine results in decreased expression of PPARGC1A protein [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PPM1B mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPP2R3C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA]
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA Nicotine results in decreased expression of PRDM16 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PRDX3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRDX3 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PRKAB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKAB1 mRNA]
PRKCZ protein affects the reaction [Nicotine results in increased phosphorylation of BAX protein] Nicotine results in increased activity of PRKCZ protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMG2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PSMG2 mRNA]
[4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 mRNA; [Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 protein; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of PTGS2]; Curcumin inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of PTGS2 mRNA]; Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 mRNA]; Propranolol inhibits the reaction [Nicotine results in increased activity of PTGS2 protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 protein]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 protein]; Staurosporine inhibits the reaction [Nicotine results in increased expression of PTGS2] Nicotine results in increased expression of PTGS2 mRNA; Nicotine results in increased expression of PTGS2 protein Acetylcysteine inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; ferulic acid inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of PTPRA mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of PTPRA mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of PTPRA mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PYCARD mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD mRNA] Nicotine results in increased expression of PYCARD mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAB2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAB2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAB7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA]
Nicotine results in increased expression of RAD50 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD50 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD50 mRNA]
Aconitine analog inhibits the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; ARRB1 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; Bungarotoxins inhibits the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; CHRNA7 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]; SRC protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]] Nicotine affects the localization of RAF1 protein Nicotine results in increased activity of RAF1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RASA3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA]
4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Nicotine results in increased phosphorylation of RB1 protein]; Aconitine analog inhibits the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; ARRB1 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; Bungarotoxins inhibits the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; CHRNA7 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; MK-886 inhibits the reaction [Nicotine results in increased expression of RB1 protein modified form]; Nicotine inhibits the reaction [RB1 protein binds to BIRC5 promoter]; Nicotine inhibits the reaction [RB1 protein binds to CDC25A promoter]; Nicotine inhibits the reaction [RB1 protein binds to CDC6 promoter]; Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]; SRC protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]] Nicotine results in decreased expression of RB1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RBBP4 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RBBP4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RBBP5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA]
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of RBBP6 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of RBBP6 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of RBBP6 mRNA] Nicotine results in increased expression of RBBP6 mRNA
[alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide co-treated with U 0126] inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of RELA protein]; Acetylcysteine inhibits the reaction [Nicotine results in increased phosphorylation of RELA protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]]; Nicotine affects the localization of and results in increased activity of RELA protein; Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]; U 0126 inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]] Nicotine affects the localization of RELA protein Mecamylamine analog inhibits the reaction [Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]]]; methyllycaconitine analog inhibits the reaction [Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]]]; Nicotine inhibits the reaction [Acetic Acid results in increased expression of RELA protein]; Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]] Nicotine results in decreased expression of RELA mRNA; Nicotine results in decreased expression of RELA protein 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Nicotine results in decreased expression of RELA protein]; Nicotine affects the localization of and results in increased activity of RELA protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RGS2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA] Nicotine results in increased expression of RGS2 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL26 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RPL26 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA]
[[Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein] which results in increased ubiquitination of TP53 protein; [Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein
[Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased phosphorylation of RPS6KB1 protein; dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein] Nicotine results in increased phosphorylation of RPS6KB1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RSPO3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA]
CHRNB2 promotes the reaction [Nicotine results in increased expression of RYR2 mRNA] Nicotine results in increased expression of RYR2 mRNA; Nicotine results in increased expression of RYR2 protein CREB1 protein promotes the reaction [Nicotine results in increased expression of RYR2 mRNA]; Nicotine promotes the reaction [CREB1 protein modified form binds to RYR2 promoter]
GW 3965 inhibits the reaction [Nicotine results in decreased expression of SCARB1 mRNA]; GW 3965 inhibits the reaction [Nicotine results in decreased expression of SCARB1 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 protein] Nicotine results in decreased expression of SCARB1 mRNA; Nicotine results in decreased expression of SCARB1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SENP6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SEPTIN7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA]
Nicotine results in decreased expression of SERPINF1 mRNA Nicotine results in decreased expression of SERPINF1 mRNA; Nicotine results in decreased expression of SERPINF1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SFPQ mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SFPQ mRNA] Nicotine results in increased expression of SFPQ mRNA
Nicotine results in increased expression of SFTPC mRNA [Nicotine co-treated with Quartz] results in increased expression of SFTPC protein; Tubocurarine inhibits the reaction [Nicotine results in increased expression of SFTPC mRNA]
[Lipopolysaccharides co-treated with Nicotine] results in increased expression of SIRT1 mRNA; [Lipopolysaccharides co-treated with Nicotine] results in increased expression of SIRT1 protein; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of CXCL8 mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL17A mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL1B mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL6 mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 protein]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of TNF mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased secretion of IL1B protein]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased secretion of TNF protein] resveratrol inhibits the reaction [Nicotine results in decreased expression of SIRT1 mRNA]
Nicotine results in decreased expression of SLBP mRNA; Nicotine results in decreased expression of SLBP protein 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole inhibits the reaction [Nicotine results in decreased expression of SLBP protein]; Bungarotoxins inhibits the reaction [Nicotine results in decreased expression of SLBP protein]; CHRNA7 affects the reaction [Nicotine results in decreased expression of SLBP protein]; CSNK2A1 affects the reaction [Nicotine results in decreased expression of SLBP protein]; Roscovitine inhibits the reaction [Nicotine results in decreased expression of SLBP protein]
Nicotine inhibits the reaction [Vanadium results in decreased expression of SLC18A3 protein]; Nicotine promotes the reaction [Bucladesine results in increased expression of SLC18A3 protein]
Nicotine results in decreased activity of SLC1A1 protein Tetradecanoylphorbol Acetate inhibits the reaction [Nicotine results in decreased activity of SLC1A1 protein]
Nicotine inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] SLC22A2 gene SNP affects the susceptibility to Nicotine
Nicotine inhibits the reaction [Paraquat results in decreased expression of SLC6A3 protein] Nicotine results in decreased expression of SLC6A3 mRNA; Nicotine results in decreased expression of SLC6A3 protein Nicotine results in increased methylation of SLC6A3 promoter Nicotine results in decreased activity of SLC6A3 protein Dihydro-beta-Erythroidine affects the reaction [Nicotine results in decreased activity of SLC6A3 protein]; Mecamylamine affects the reaction [Nicotine results in decreased activity of SLC6A3 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SMAD3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA] Nicotine results in increased expression of and results in increased phosphorylation of SMAD3 protein Nicotine results in decreased expression of SMAD3 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SMPD3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA]
Nicotine results in increased expression of SNAI1 mRNA; Nicotine results in increased expression of SNAI1 protein SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC1 mRNA]; SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC1 protein]; SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC2 mRNA]; SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC2 protein] SNAI1 results in increased susceptibility to Nicotine SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of BMI1 mRNA]; SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of NANOG mRNA]; SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of POU5F1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SNCG mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCG mRNA]
Nicotine results in decreased expression of SOD1 protein [Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD1 mRNA; [Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD1 protein
Nicotine results in decreased expression of SOD2 protein SOD2 gene SNP affects the susceptibility to [Pesticides co-treated with Nicotine] [Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD2 protein resveratrol inhibits the reaction [Nicotine results in decreased expression of SOD2 protein] Nicotine results in increased expression of SOD2 protein
alpha-cobratoxin inhibits the reaction [Nicotine results in increased expression of SOS1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of SOS1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of SOS1 mRNA]
Nicotine promotes the reaction [[GATA4 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [[GATA6 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [GATA4 protein binds to SP1 protein]; Nicotine promotes the reaction [GATA6 protein binds to GATA4 protein binds to SP1 protein binds to CHRNA7 promoter]; Nicotine promotes the reaction [GATA6 protein binds to SP1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein] Nicotine results in increased expression of SQSTM1 protein
Nicotine results in increased phosphorylation of SRC protein ARRB1 protein affects the reaction [Nicotine results in increased phosphorylation of and results in increased activity of SRC protein]; Nicotine results in increased phosphorylation of and results in increased activity of SRC protein; RTKI cpd inhibits the reaction [Nicotine results in increased phosphorylation of SRC protein]; SRC protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]
Nicotine results in decreased expression of SREBF1 mRNA Nicotine results in increased expression of SREBF1 mRNA [Nicotine results in increased abundance of Cotinine] which results in increased expression of SREBF1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SRP9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA]
Nicotine results in increased methylation of STAR promoter Nicotine results in decreased expression of STAR mRNA; Nicotine results in decreased expression of STAR protein LMK-235 inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; LMK-235 inhibits the reaction [Nicotine results in decreased expression of STAR protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR protein] Taurine inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; Taurine inhibits the reaction [Nicotine results in decreased expression of STAR protein] Nicotine results in decreased expression of STAR; Nicotine results in decreased expression of STAR mRNA; Nicotine results in decreased expression of STAR protein trichostatin A inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]
[alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide co-treated with U 0126] inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; [Nicotine co-treated with Lipopolysaccharides] results in increased phosphorylation of STAT3 protein; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]]; CHRNA5 protein affects the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [Cisplatin results in decreased activity of STAT3 protein]; Nicotine inhibits the reaction [Paclitaxel results in decreased activity of STAT3 protein]; Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]; Nicotine promotes the reaction [STAT3 protein binds to ZFP36 promoter]; Nicotine results in increased phosphorylation of and results in increased activity of STAT3 protein; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Staurosporine inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; U 0126 inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]]; U 0126 inhibits the reaction [Nicotine results in increased activity of STAT3 protein]; U 0126 inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein] [Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of STAT3 protein modified form; Bungarotoxins inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of STAT3 protein modified form]; methyllycaconitine inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of STAT3 protein modified form] Nicotine affects the expression of STAT3 mRNA STAT3 protein results in increased susceptibility to Nicotine HMOX1 protein promotes the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [Quartz results in decreased phosphorylation of STAT3 protein]; STAT3 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of HMOX1 mRNA]; STAT3 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of ZFP36 mRNA]; STAT3 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; STAT3 protein promotes the reaction [Nicotine results in increased expression of ZFP36 mRNA]; staurosporine aglycone inhibits the reaction [[Nicotine co-treated with Quartz] results in increased phosphorylation of STAT3 protein]; ZFP36 protein promotes the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; zinc protoporphyrin inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein] STAT3 results in increased susceptibility to Nicotine
Nicotine results in decreased phosphorylation of STAT5 protein Cholesterol inhibits the reaction [Nicotine results in decreased phosphorylation of STAT5 protein]
Nicotine results in decreased expression of STIP1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of STIP1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA] Tubocurarine inhibits the reaction [Nicotine results in decreased expression of STIP1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of STX4A mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SYNGR2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYNGR2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SYT4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SYT4 mRNA]
Nicotine results in decreased expression of TACR1 mRNA; Nicotine results in decreased expression of TACR1 protein Nicotine results in increased expression of TACR1 mRNA; Nicotine results in increased expression of TACR1 protein Mecamylamine inhibits the reaction [Nicotine results in increased expression of TACR1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of TACR1 protein]; methyllycaconitine inhibits the reaction [Nicotine results in increased expression of TACR1 mRNA]; methyllycaconitine inhibits the reaction [Nicotine results in increased expression of TACR1 protein]
MK-886 inhibits the reaction [Nicotine results in increased expression of TFDP1 protein] Nicotine results in increased expression of TFDP1 mRNA Nicotine results in decreased expression of TFDP1 mRNA
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of TFPI2 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of TFPI2 mRNA] Nicotine results in increased expression of TFPI2 mRNA
Nicotine results in increased expression of TFRC mRNA [Nicotine co-treated with Propylene Glycol co-treated with Glycerol] results in increased expression of TFRC mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TFRC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA]
Nicotine results in decreased expression of TGFB1 mRNA Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein] Nicotine affects the expression of TGFB1 mRNA Nicotine results in increased expression of TGFB1 mRNA Nicotine results in increased expression of TGFB1 protein Nicotine results in decreased expression of TGFB1 mRNA; Nicotine results in decreased expression of TGFB1 protein
Nicotine results in increased expression of TH mRNA; Nicotine results in increased expression of TH protein [conotoxin AuIB co-treated with triethyl-(beta-4-stilbenoxyethyl)ammonium co-treated with ZM 241385] inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; [conotoxin AuIB co-treated with triethyl-(beta-4-stilbenoxyethyl)ammonium co-treated with ZM 241385] inhibits the reaction [Nicotine results in increased expression of TH mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with exoenzyme C3, Clostridium botulinum] inhibits the reaction [Nicotine results in increased expression of TH mRNA]; conotoxin AuIB inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; conotoxin AuIB inhibits the reaction [Nicotine results in increased expression of TH mRNA]; exoenzyme C3, Clostridium botulinum inhibits the reaction [Nicotine results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Nicotine results in increased expression of TH protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nicotine results in increased expression of TH mRNA]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased expression of TH mRNA]; ZM 241385 inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; ZM 241385 inhibits the reaction [Nicotine results in increased expression of TH mRNA] [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TH mRNA; [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased expression of TH mRNA]
Nicotine affects the expression of TIMP1 mRNA Nicotine results in increased expression of TIMP1 mRNA [Nicotine co-treated with lipopolysaccharide, E. coli O26-B6] affects the expression of TIMP1 mRNA
Nicotine affects the expression of TIMP3 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIMP3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TIMP3 mRNA] [Nicotine co-treated with lipopolysaccharide, E. coli O26-B6] affects the expression of TIMP3 mRNA
[Nicotine co-treated with lipopolysaccharide, E. coli O26-B6] affects the expression of TIMP4 mRNA Nicotine results in decreased expression of TIMP4 protein Nicotine affects the expression of TIMP4 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIRAP mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA]
Nicotine results in decreased expression of TJP1 protein [Saquinavir co-treated with Nicotine co-treated with Ritonavir] results in decreased expression of TJP1 protein; [Saquinavir co-treated with Nicotine] results in decreased expression of TJP1 protein; Vitamin E inhibits the reaction [[Nicotine co-treated with Ritonavir co-treated with Saquinavir] results in decreased expression of TJP1 protein]; Vitamin E inhibits the reaction [[Nicotine co-treated with Saquinavir] results in decreased expression of TJP1 protein]
Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TLR4 mRNA] [Aerosols co-treated with Nicotine] results in increased expression of TLR4 mRNA
[Lipopolysaccharides co-treated with Nicotine] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with Nicotine] results in increased secretion of TNF protein; Bungarotoxins inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF mRNA]]; methyllycaconitine inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF mRNA]]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Nicotine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of TNF mRNA]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased secretion of TNF protein]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of TNF mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased secretion of TNF protein]; ZFP36 mRNA affects the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; ZFP36 mRNA affects the reaction [Nicotine results in increased degradation of TNF mRNA] Nicotine affects the expression of TNF mRNA Nicotine results in increased secretion of TNF protein Nicotine results in decreased expression of TNF protein Nicotine results in increased expression of TNF mRNA; Nicotine results in increased expression of TNF protein [Nicotine results in increased abundance of Cotinine] which results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of TNF protein]; erdosteine inhibits the reaction [Nicotine results in increased expression of TNF protein]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of TNF mRNA]; Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Nicotine results in increased expression of TNF protein] Acetylcysteine inhibits the reaction [Nicotine results in increased expression of TNF mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased secretion of TNF protein]; Eugenol inhibits the reaction [Nicotine results in increased expression of TNF mRNA]; Eugenol inhibits the reaction [Nicotine results in increased secretion of TNF protein]; HMOX1 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Nicotine inhibits the reaction [IFNG protein results in increased expression of TNF mRNA]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; STAT3 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ZFP36 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ZFP36 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
Nicotine results in increased expression of TNFRSF11B mRNA Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in increased expression of TNFRSF11B mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TNK2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNK2 mRNA]
Nicotine results in decreased expression of TP53 mRNA; Nicotine results in decreased expression of TP53 protein Nicotine results in increased expression of TRP53 mRNA; Nicotine results in increased expression of TRP53 protein Nicotine results in decreased expression of TRP53 protein [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein]; royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA] Nicotine results in increased expression of TP53 mRNA TP53 protein affects the susceptibility to Nicotine Nicotine affects the expression of TP53 mRNA 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Nicotine results in decreased expression of TP53 protein]; [[Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein] which results in increased ubiquitination of TP53 protein; Nicotine inhibits the reaction [aflatoxin G1 results in increased expression of TP53 protein modified form]; Nicotine inhibits the reaction [Cisplatin results in increased expression of TP53 protein]; Nicotine inhibits the reaction [Gemcitabine results in increased expression of TP53 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased expression of TP53 protein]; Rosiglitazone inhibits the reaction [Nicotine results in decreased expression of TP53 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK8 protein] Nicotine results in increased expression of TP53 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPH2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPH2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPP2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA]
Mecamylamine inhibits the reaction [Nicotine results in increased expression of TRPV1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of TRPV1 protein]; methyllycaconitine inhibits the reaction [Nicotine results in increased expression of TRPV1 mRNA]; methyllycaconitine inhibits the reaction [Nicotine results in increased expression of TRPV1 protein] TRPV1 protein affects the susceptibility to Nicotine Nicotine results in increased expression of TRPV1 mRNA; Nicotine results in increased expression of TRPV1 protein Nicotine results in increased activity of TRPV1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TSC22D1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TSC22D1 mRNA]
Nicotine results in increased expression of TWIST1 mRNA Nicotine promotes the reaction [Quartz results in increased expression of TWIST1 protein]; staurosporine aglycone inhibits the reaction [[Nicotine co-treated with Quartz] results in increased expression of TWIST1 protein]
Nicotine results in increased expression of TXN1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TXN1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased expression of TXN1 protein]; methyllycaconitine inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TXN1 protein]]; methyllycaconitine inhibits the reaction [Nicotine results in increased expression of TXN1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TXN1 protein] Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN1 protein]
Nicotine results in increased expression of UBA2 protein [Nicotine results in increased expression of UBA2 protein] which results in increased sumoylation of EEF2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA]
Nicotine results in increased expression of UBE2C mRNA Nicotine results in decreased expression of UBE2C mRNA Tubocurarine inhibits the reaction [Nicotine results in decreased expression of UBE2C mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UBE2D2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBE2D2 mRNA]
Mecamylamine inhibits the reaction [Nicotine results in decreased expression of UBE3A mRNA]; Nicotine inhibits the reaction [alpha-cobratoxin results in decreased expression of UBE3A mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of UBE3A mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UCHL1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA]
Nicotine results in decreased expression of UCP1 mRNA; Nicotine results in decreased expression of UCP1 protein [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UROS mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA]
Nicotine results in increased expression of VEGFA mRNA; Nicotine results in increased expression of VEGFA protein [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA Nicotine results in decreased expression of VEGFA protein Nicotine results in increased secretion of VEGFA protein Nicotine affects the susceptibility to VEGFA Nicotine results in decreased secretion of VEGFA protein CHRNA5 mutant form inhibits the reaction [Nicotine results in increased expression of VEGFA protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of VEGFA protein]
Nicotine results in decreased expression of VIM mRNA Nicotine promotes the reaction [Quartz results in increased expression of VIM protein]; staurosporine aglycone inhibits the reaction [[Nicotine co-treated with Quartz] results in increased expression of VIM protein] Nicotine results in increased expression of VIM mRNA; Nicotine results in increased expression of VIM protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of VPS28 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of VPS28 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of VPS41 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of WBP4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of WBP4 mRNA]
Carbon Tetrachloride promotes the reaction [Nicotine results in increased expression of WNT4 mRNA]; Carbon Tetrachloride promotes the reaction [Nicotine results in increased expression of WNT4 protein]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of WNT4 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of WNT4 protein] Nicotine results in increased expression of WNT4 mRNA; Nicotine results in increased expression of WNT4 protein
[Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased expression of XIAP protein; Curcumin inhibits the reaction [Nicotine results in increased expression of XIAP protein]; Hexamethonium affects the reaction [Nicotine results in increased expression of XIAP protein] Nicotine results in increased expression of XIAP mRNA; Nicotine results in increased expression of XIAP protein
[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA; [Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 protein; Bungarotoxins inhibits the reaction [[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA]; methyllycaconitine inhibits the reaction [[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA]; Nicotine promotes the reaction [STAT3 protein binds to ZFP36 promoter]; ZFP36 mRNA affects the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; ZFP36 mRNA affects the reaction [Nicotine results in increased degradation of TNF mRNA] ZFP36 protein results in increased susceptibility to Nicotine [Lipopolysaccharides co-treated with Nicotine] results in increased expression of ZFP36 mRNA; HMOX1 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of ZFP36 mRNA]; HMOX1 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of ZFP36 mRNA]]; HMOX1 protein promotes the reaction [Nicotine results in increased expression of ZFP36 mRNA]; STAT3 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of ZFP36 mRNA]; STAT3 protein promotes the reaction [Nicotine results in increased expression of ZFP36 mRNA]; tin protoporphyrin IX inhibits the reaction [Nicotine results in increased expression of ZFP36 mRNA]; ZFP36 mutant form inhibits the reaction [Nicotine results in decreased expression of CCL2 mRNA]; ZFP36 mutant form inhibits the reaction [Nicotine results in decreased expression of IL6 mRNA]; ZFP36 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ZFP36 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; ZFP36 protein promotes the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; zinc protoporphyrin inhibits the reaction [[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [Nicotine results in increased expression of ZFP36 mRNA] Nicotine results in increased expression of ZFP36 mRNA; Nicotine results in increased expression of ZFP36 protein Nicotine results in increased activity of ZFP36 promoter
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of ZFR mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of ZFR mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of ZFR mRNA]
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein]
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein]
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein]
Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein] CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein
Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] 1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein]
Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]
acetamiprid results in increased expression of BCL2 protein Resveratrol inhibits the reaction [acetamiprid results in decreased expression of BCL2 mRNA]
acetamiprid results in increased expression of CASP3 mRNA; acetamiprid results in increased expression of CASP3 protein Resveratrol inhibits the reaction [acetamiprid results in increased expression of CASP3 mRNA]; Resveratrol inhibits the reaction [acetamiprid results in increased expression of CASP3 protein]
acetamiprid results in decreased expression of CHRNA7 mRNA acetamiprid results in increased activity of CHRNA7 protein; acetamiprid results in increased activity of CHRNA7 protein mutant form Resveratrol inhibits the reaction [acetamiprid results in decreased expression of CHRNA7 mRNA]
acetamiprid results in decreased expression of CHRNB2 acetamiprid results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; acetamiprid results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein]
acetamiprid results in decreased expression of COX4I1 mRNA Berberine inhibits the reaction [acetamiprid results in decreased expression of COX4I1 mRNA]
Vitamin E inhibits the reaction [acetamiprid results in decreased expression of CYP11A mRNA]; Vitamin E inhibits the reaction [acetamiprid results in decreased expression of CYP11A protein] acetamiprid results in decreased expression of CYP11A1 mRNA acetamiprid results in decreased expression of CYP11A1 mRNA; acetamiprid results in decreased expression of CYP11A1 protein
acetamiprid results in increased expression of FASN protein Folic Acid inhibits the reaction [acetamiprid results in increased expression of FASN protein]
acetamiprid results in decreased expression of STAR mRNA; acetamiprid results in decreased expression of STAR protein Vitamin E inhibits the reaction [acetamiprid results in decreased expression of STAR mRNA]; Vitamin E inhibits the reaction [acetamiprid results in decreased expression of STAR protein]
acetamiprid results in increased expression of TNNI3 protein Resveratrol inhibits the reaction [acetamiprid results in increased expression of TNNI3 protein]
Carbachol binds to ACHE protein ACHE protein results in increased hydrolysis of Carbachol Atropine inhibits the reaction [Carbachol results in increased metabolism of and results in increased secretion of ACHE protein]; Carbachol results in increased metabolism of and results in increased secretion of ACHE protein
Carbachol inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; Carbachol inhibits the reaction [APP protein modified form results in increased expression of BAX protein]; Carbachol inhibits the reaction [APP protein modified form results in increased expression of FOS protein]; Carbachol inhibits the reaction [APP protein modified form results in increased expression of TRP53 protein]
Carbachol promotes the reaction [[NC 1900 results in increased activity of AVPR1A protein] which results in increased abundance of Calcium]; Nicardipine inhibits the reaction [Carbachol promotes the reaction [[NC 1900 results in increased activity of AVPR1A protein] which results in increased abundance of Calcium]]
Carbachol inhibits the reaction [APP protein modified form results in increased expression of BAX protein]; Carbachol inhibits the reaction [domoic acid results in increased localization of BAX protein]
Carbachol results in increased expression of BCL2 protein Carbachol inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]
Carbachol results in increased expression of BTG2 mRNA Tetradecanoylphorbol Acetate inhibits the reaction [Carbachol results in increased expression of BTG2 mRNA]
Carbachol inhibits the reaction [domoic acid results in increased activity of CASP3 protein] Carbachol results in decreased expression of CASP3 protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Carbachol results in increased expression of CD40 protein]; 4-diphenylacetoxy-1,1-dimethylpiperidinium inhibits the reaction [Carbachol results in increased expression of CD40 protein]; Atropine inhibits the reaction [Carbachol results in increased expression of CD40 protein]; Pirenzepine inhibits the reaction [Carbachol results in increased expression of CD40 protein]
Carbachol results in increased activity of CHRM1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; 1-oleoyl-2-acetylglycerol promotes the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; 2-aminoethoxydiphenyl borate inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; [Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium; Atropine inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; Flufenamic Acid inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; Gadolinium inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; Lanthanum inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; Pirenzepine inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; Thapsigargin inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium] CHRM1 protein binds to Carbachol [Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium; [Carbachol results in increased activity of CHRM1 protein] which results in increased expression of FASLG mRNA; [Carbachol results in increased activity of CHRM1 protein] which results in increased expression of FASLG protein; brucine promotes the reaction [Carbachol binds to CHRM1 protein]
eburnamonine promotes the reaction [Carbachol binds to CHRM2 protein] Carbachol binds to and results in increased activity of CHRM2 protein; Carbachol promotes the reaction [CHRM2 protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; otenzepad inhibits the reaction [Carbachol promotes the reaction [CHRM2 protein results in increased abundance of Inositol 1,4,5-Trisphosphate]] CHRM2 protein binds to Carbachol
Atropine inhibits the reaction [Carbachol results in increased activity of CHRM3 protein]; brucine promotes the reaction [Carbachol binds to CHRM3 protein]; brucine promotes the reaction [Carbachol results in increased activity of CHRM3 protein mutant form]; Carbachol binds to and results in increased activity of CHRM3 protein; Carbachol binds to and results in increased activity of CHRM3 protein mutant form; Carbachol inhibits the reaction [N-Methylscopolamine binds to CHRM3 protein]; Guanylyl Imidodiphosphate inhibits the reaction [Carbachol inhibits the reaction [N-Methylscopolamine binds to CHRM3 protein]]; Zinc Oxide promotes the reaction [Carbachol inhibits the reaction [N-Methylscopolamine binds to CHRM3 protein]] [Metoclopramide binds to and results in decreased activity of CHRM3 protein] which results in decreased susceptibility to Carbachol CHRM3 protein results in increased susceptibility to Carbachol CHRM3 protein affects the susceptibility to Carbachol CHRM3 protein binds to Carbachol
Carbachol inhibits the reaction [decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol inhibits the reaction [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol inhibits the reaction [methyllycaconitine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] carbachol affects binding to Chrna4 protein; carbachol competes with [Epibatidine binds to Chrna4 protein] Carbachol binds to [CHRNA4 protein binds to CHRNB2 protein]
1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea promotes the reaction [Carbachol affects the activity of CHRNA7 protein]; Carbachol inhibits the reaction [Bungarotoxins binds to CHRNA7 protein]; Carbachol inhibits the reaction [epibatidine binds to CHRNA7 protein] Carbachol affects the reaction [iodo-alpha-bungarotoxin binds to CHRNA7 protein]
Carbachol inhibits the reaction [decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol inhibits the reaction [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol inhibits the reaction [methyllycaconitine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Carbachol results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] carbachol affects binding to Chrnb2 protein; carbachol competes with [Epibatidine binds to Chrnb2 protein] Carbachol binds to [CHRNA4 protein binds to CHRNB2 protein]
[Carbachol results in increased activity of CHRM1 protein] which results in increased expression of FASLG mRNA; [Carbachol results in increased activity of CHRM1 protein] which results in increased expression of FASLG protein
Carbachol results in increased expression of FGF1 protein KT 5720 inhibits the reaction [Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein]]; Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein]
Carbachol results in increased expression of FOS protein Carbachol inhibits the reaction [APP protein modified form results in increased expression of FOS protein]
[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium; Atropine inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]; Pertussis Toxin inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Scopolamine inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; tertiapin inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Tropicamide inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]
[Carbachol co-treated with Glucose] results in increased secretion of INS1 protein Carbachol results in increased secretion of INS1 protein Sirolimus inhibits the reaction [Carbachol results in increased secretion of INS1 protein]
[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium; Atropine inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]; Pertussis Toxin inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Scopolamine inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; tertiapin inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]; Tropicamide inhibits the reaction [[Carbachol results in increased activity of [GRM4 protein binds to KCNJ3 protein]] which results in increased import of Thallium]
Calcium deficiency inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; calphostin C inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Carbachol results in increased phosphorylation of and results in increased activity of MAPK1 protein; PTK2B protein affects the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Ro 31-8220 inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; SRC protein affects the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK1 protein] Carbachol results in decreased phosphorylation of MAPK1 protein Carbachol results in increased activity of MAPK1 protein
Calcium deficiency inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; calphostin C inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Carbachol results in increased phosphorylation of and results in increased activity of MAPK3 protein; PTK2B protein affects the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Ro 31-8220 inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; SRC protein affects the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK3 protein] Carbachol results in increased activity of MAPK3 protein Carbachol results in decreased phosphorylation of MAPK3 protein
Carbachol results in increased expression of NR4A1 mRNA Tetradecanoylphorbol Acetate inhibits the reaction [Carbachol results in increased expression of NR4A1 mRNA]
1-Butanol inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of PRKCZ protein]; Carbachol results in increased phosphorylation of and results in increased activity of PRKCZ protein Carbachol results in increased activity of PRKCZ protein
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of PTK2B protein]; Carbachol results in increased phosphorylation of and results in increased activity of PTK2B protein; Egtazic Acid inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of PTK2B protein]; PTK2B protein affects the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; PTK2B protein affects the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; SRC protein affects the reaction [Carbachol results in increased phosphorylation of and results in increased activity of PTK2B protein]
1-Butanol inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Carbachol results in increased phosphorylation of and results in increased activity of RPS6KB1 protein
Carbachol results in increased phosphorylation of and results in increased activity of SRC protein; SRC protein affects the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; SRC protein affects the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; SRC protein affects the reaction [Carbachol results in increased phosphorylation of and results in increased activity of PTK2B protein]
Carbachol results in increased expression of TNF protein TNF results in increased activity of Carbachol Carbachol results in decreased expression of TNF mRNA TNF protein inhibits the reaction [Carbachol results in increased abundance of Phosphatidic Acids]; TNF protein inhibits the reaction [Carbachol results in increased abundance of phosphatidylbutanol] Carbachol affects the expression of TNF protein
ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [Carbachol results in increased activity of TRPC3 protein]
TRPC4 protein affects the reaction [Carbachol results in increased transport of Barium]; TRPC4 protein affects the reaction [Carbachol results in increased transport of Calcium] Carbachol results in increased activity of TRPC4 protein TRPC4 protein results in increased susceptibility to Carbachol
Carbachol promotes the reaction [TRPC5 protein results in increased transport of Calcium]; resveratrol inhibits the reaction [Carbachol promotes the reaction [TRPC5 protein results in increased transport of Calcium]]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Carbachol results in increased activity of TRPC6 protein]
[enilconazole co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with clothianidin] results in increased expression of ABCC3 mRNA clothianidin results in increased expression of ABCC3 mRNA
clothianidin results in increased expression of ALDH1A1 mRNA [enilconazole co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA
clothianidin results in decreased expression of CHRNA7 mRNA clothianidin results in increased activity of CHRNA7 protein; clothianidin results in increased activity of CHRNA7 protein mutant form
clothianidin results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; clothianidin results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein] clothianidin promotes the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]
[clothianidin co-treated with enilconazole] results in increased expression of CYP1A2 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA clothianidin results in increased expression of CYP1A2 mRNA
clothianidin results in increased expression of CYP2B2 mRNA [enilconazole co-treated with clothianidin] results in increased expression of CYP2B2 mRNA; [thiacloprid co-treated with clothianidin] results in increased expression of CYP2B2 mRNA
clothianidin results in decreased expression of CYP2E1 mRNA [clothianidin co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA; [clothianidin co-treated with thiacloprid] results in increased expression of CYP2E1 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA
clothianidin results in increased expression of CYP3A4 mRNA [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 mRNA; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 protein; [clothianidin co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA
[enilconazole co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA; [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA clothianidin results in increased expression of CYP3A23-3A1 mRNA
[clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein; [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A5 mRNA clothianidin results in increased expression of CYP3A5 mRNA
[enilconazole co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA clothianidin results in decreased expression of CYP7A1 mRNA
[enilconazole co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of ELN mRNA clothianidin results in decreased expression of ELN mRNA
[enilconazole co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of KY mRNA clothianidin results in decreased expression of KY mRNA
[enilconazole co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of MEGF11 mRNA clothianidin results in decreased expression of MEGF11 mRNA
[enilconazole co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with clothianidin] results in increased expression of MME mRNA clothianidin results in increased expression of MME mRNA
clothianidin results in decreased expression of SLC6A1 mRNA [enilconazole co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA
clothianidin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; clothianidin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
cytisine results in increased activity of [CHRNB4 protein binds to CHRNA2 protein] cytisine affects binding to Chrna2 protein; cytisine inhibits the reaction [epibatidine affects binding to Chrna2 protein] in rat retina
cytisine results in increased activity of [CHRNB4 protein binds to CHRNA3 protein] cytisine affects binding [Epibatidine binds to Chrna3 protein] cytisine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]
cytisine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; cytisine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; cytisine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; cytisine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]; Nicotine inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]; pozanicline inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]] cytisine affects binding to Chrna4 protein; cytisine inhibits the reaction [epibatidine affects binding to Chrna4 protein] in rat retina cytisine affects binding to Chrna4 protein; cytisine competes with [Epibatidine binds to Chrna4 protein] cytisine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] cytisine affects the expression of CHRNA4 protein
cytisine inhibits the reaction [Bungarotoxins binds to CHRNA7 protein] cytisine inhibits the reaction [iodo-alpha-bungarotoxin binds to CHRNA7 protein]
cytisine binds to [CHRNA4 protein binds to CHRNB2 protein] cytisine affects binding to Chrnb2 protein; cytisine inhibits the reaction [epibatidine affects binding to Chrnb2 protein] in rat retina cytisine affects binding to Chrnb2 protein; cytisine competes with [Epibatidine binds to Chrnb2 protein] cytisine affects the expression of CHRNB2 protein cytisine inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein] cytisine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; cytisine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; cytisine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]; pozanicline inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]
cytisine results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; cytisine results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; cytisine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] cytisine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]
Carbachol inhibits the reaction [decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; decamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
Carbachol inhibits the reaction [decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; decamethonium inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; decamethonium results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
dinotefuran results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; dinotefuran results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein]
3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased transport of flupyradifurone]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of 1700012B07RIKL gene
imidacloprid results in increased activity of ACHE protein imidacloprid results in decreased activity of ACHE protein imidacloprid results in increased expression of ACHE protein
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ACOT2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACOT4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ACY1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAM15 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of ADAMTSL3 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ADCY6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ADRM1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AFP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of AGT mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of AIG1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of AKAP8L mRNA
[imidacloprid co-treated with sodium arsenate] results in decreased expression of ALB protein imidacloprid results in decreased expression of ALB protein
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALDH9A1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ALG2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANGPTL4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ANKS3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ANXA11 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APLF mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of APOF mRNA
imidacloprid results in decreased expression of AR mRNA; imidacloprid results in decreased expression of AR protein imidacloprid affects the expression of AR mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ARF2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ARPC1A gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ASB7 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ASS1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ATOSA mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP5MC1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ATP6V0D1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BAG3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BANP mRNA
imidacloprid results in increased expression of BAX mRNA; imidacloprid results in increased expression of BAX protein Thymol inhibits the reaction [imidacloprid results in increased expression of BAX mRNA]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of BCL9 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of BHMT mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C1QC mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of C8H11ORF54 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAMK2G mRNA
imidacloprid results in decreased expression of CAMKK2 protein Dietary Fats promotes the reaction [imidacloprid results in decreased expression of CAMKK2 protein]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CAP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CAPS2 mRNA
imidacloprid results in increased expression of CASP3 mRNA; imidacloprid results in increased expression of CASP3 protein Thymol inhibits the reaction [imidacloprid results in increased expression of CASP3 mRNA]; Thymol inhibits the reaction [imidacloprid results in increased expression of CASP3 protein]
imidacloprid results in decreased activity of CAT protein imidacloprid results in decreased expression of CAT protein imidacloprid promotes the reaction [sodium arsenate results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [imidacloprid results in decreased expression of CAT protein]; sodium arsenate promotes the reaction [imidacloprid results in decreased activity of CAT protein]; Thymol inhibits the reaction [imidacloprid results in decreased activity of CAT protein]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CBS mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCDC125 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CCNL1 mRNA
imidacloprid results in increased expression of CD36 mRNA [imidacloprid co-treated with Dietary Fats] results in decreased expression of CD36 mRNA; [imidacloprid co-treated with Dietary Fats] results in increased expression of CD36 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CDKN1A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CEBPD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CEP85 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CERK mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFB mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CFL1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CHCHD10 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CHEK2 mRNA
imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]; LYNX1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]; LYPD1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]
imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; imidacloprid binds to [CHRNA4 protein co-treated with CHRNB2 protein] imidacloprid inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB4 protein]
imidacloprid metabolite results in increased activity of CHRNA7 protein; imidacloprid results in increased activity of CHRNA7 protein; imidacloprid results in increased activity of CHRNA7 protein mutant form
[NACHRA8 protein co-treated with CHRNB2 protein] affects the susceptibility to imidacloprid; imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; imidacloprid binds to [CHRNA4 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRALPHA1 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRALPHA2 protein co-treated with CHRNB2 protein]; imidacloprid binds to [NACHRALPHA3 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]; imidacloprid results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [NACHRALPHA1 protein co-treated with NACHRALPHA2 protein co-treated with CHRNB2 protein]; imidacloprid results in increased activity of [NACHRALPHA2 protein co-treated with CHRNB2 protein]; LYNX1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]]; LYPD1 protein promotes the reaction [imidacloprid results in increased activity of [CHRNA1 protein binds to CHRNB2 protein]] imidacloprid results in decreased expression of CHRNB2 mRNA imidacloprid inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]
imidacloprid results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; imidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB4 protein]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CIRBP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CLCF1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CLU mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CNDP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CPT2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CRY1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSPP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CSRNP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of CTH gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CTNNAL1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CUX2 mRNA
imidacloprid results in decreased expression of CYP11A1 mRNA Thymol inhibits the reaction [imidacloprid results in decreased expression of CYP11A1 mRNA]
imidacloprid results in decreased expression of CYP17A1 mRNA Thymol inhibits the reaction [imidacloprid results in decreased expression of CYP17A1 mRNA]
imidacloprid results in increased activity of CYP19A1 protein imidacloprid results in decreased expression of CYP19A1 mRNA Thymol inhibits the reaction [imidacloprid results in decreased expression of CYP19A1 mRNA] imidacloprid affects the expression of CYP19A1 mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione affects the reaction [imidacloprid affects the expression of CYP19A1 mRNA]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP2C22 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4A1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of CYP4F1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of CYTIP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DBP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DCLRE1C mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX20 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DDX5 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DFFB mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DLG2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DLL1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DMRT3 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DNAJB9 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of DPP4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DUSP5 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of DUSP6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of DZIP1L gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of EMILIN1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ENPP3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of EPB41L3 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of EPM2AIP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ERF mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ESD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM135A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM177A1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FAM204A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of FAM53A gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FICD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of FKBP4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of FKBP5 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FMN1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FRMD4B mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of FZD6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GADD45G mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GATD3A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GDF15 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIN1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GIT2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GLB1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GNPDA2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GPRASP3 mRNA
imidacloprid results in increased activity of GPT protein [imidacloprid co-treated with Dietary Fats] results in increased expression of GPT protein imidacloprid results in increased expression of GPT protein [imidacloprid co-treated with fipronil co-treated with Glyphosate] results in increased activity of and results in increased secretion of GPT protein [imidacloprid co-treated with sodium arsenate] results in increased activity of GPT protein
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of GRAMD1A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GRIA1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GRINA mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of GSDMA gene
imidacloprid promotes the reaction [sodium arsenate results in decreased activity of GSR protein]; sodium arsenate promotes the reaction [imidacloprid results in decreased activity of GSR protein]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of GSTK1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of HAPSTR2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HARS1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HEBP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HES1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HS3ST3B1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD11B2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSD17B10 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of HSD17B2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPA1B mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of HSPBP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IER3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of IFNA12L gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IGFBP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of IGKV2-112L2 gene
imidacloprid results in increased expression of IL1B mRNA [imidacloprid co-treated with Dietary Fats] results in decreased expression of IL1B mRNA Plant Extracts inhibits the reaction [imidacloprid results in increased expression of IL1B mRNA]
Plant Extracts inhibits the reaction [imidacloprid results in increased expression of IL6 mRNA] imidacloprid affects the expression of IL6 mRNA [imidacloprid co-treated with Dietary Fats] results in decreased expression of IL6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of INPP5F mRNA
imidacloprid results in decreased expression of INS1 protein imidacloprid results in increased secretion of INS1 protein Dietary Fats promotes the reaction [imidacloprid results in increased secretion of INS1 protein]; imidacloprid promotes the reaction [Dietary Fats results in increased secretion of INS1 protein]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of IQCB1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of IRF2BP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of ITPRIP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of JUNB mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KATNIP gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KHDC4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of KLF10 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of KLF2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of KLHL10 gene
Dietary Fats promotes the reaction [imidacloprid results in increased secretion of LEP protein]; imidacloprid promotes the reaction [Dietary Fats results in increased secretion of LEP protein]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LGALSL mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of LHX2 gene
LIF protein affects the reaction [imidacloprid affects the methylation of APC promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of CDH1 promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of CDKN2A promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of MLH1 promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of RARB promoter]; LIF protein affects the reaction [imidacloprid affects the methylation of TIMP3 promoter]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LITAF mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LNX2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LOXL3 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPCAT1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LPGAT1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LPIN3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of LTA4H mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of LURAP1L gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MAPKAPK2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MARF1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MED12L mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of METTL14 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of MFAP5 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIF mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR122 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR130A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR146A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR193 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR22 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR32 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MIR33 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MIR486 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MLYCD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MORC3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRGBP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of MRNIP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPL44 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MRPS18B mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MTARC1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MYO10 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of N4BP2L2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NAE1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of NDUFB11 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NFE2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NFIL3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR0B2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of NR1D2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of NUCKS1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of OLR943 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of OPLAH mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of ORAI3 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PABIR1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of PARPBP gene
imidacloprid results in increased expression of PCK2 mRNA Dietary Fats promotes the reaction [imidacloprid results in increased expression of PCK2 mRNA]; imidacloprid promotes the reaction [Dietary Fats results in increased expression of PCK2 mRNA]
Thymol inhibits the reaction [imidacloprid results in decreased expression of PCNA protein] imidacloprid results in decreased expression of PCNA mRNA; imidacloprid results in decreased expression of PCNA protein
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PDLIM1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PDP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PDZD2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PER1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PER3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PGK1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIAS3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PIP4P1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of LILRB3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLEKHG5 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PLK2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of PLPP4 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PMVK mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNKD mRNA
imidacloprid promotes the reaction [Nicotine results in increased expression of PNMT protein] imidacloprid results in increased expression of PNMT protein
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PNRC1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of POR gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PPARD mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRDM15 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELID2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PRELP mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PROSER2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PRPF39 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PSMC5 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of PTPA mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of PUS10 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABEP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RABL2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RAMAC gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RANGAP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RARS1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RBM14 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RBM3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RBPMS gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RESF1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of REV1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RFX7 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RGCC gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RGS16 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RHOBTB3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RNASE10 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of RND3 gene; [azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of RND3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of RORC mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of RXYLT1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SALL4 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SARDH mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SCNN1A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SDR42E1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SERPINA1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SESN2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SETD6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SFRP2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SH3BP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SIGIRR mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SIK2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC12A6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC20A1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC25A39 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SLC26A6 mRNA
imidacloprid results in decreased expression of SLC2A4 mRNA imidacloprid results in decreased expression of SLC2A4 mRNA; imidacloprid results in decreased expression of SLC2A4 protein
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SLC37A2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SLK gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SMAD7 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SMPX gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SNRNP200 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SNX4 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SOCS3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SOD3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of SOHLH1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SPAG1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of SRD5A2 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRRM2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of SRSF5 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of STARD9 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SUSD2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of SYMPK mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TAT mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TDP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TEAD2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TECR mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TGDS mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TGFBI mRNA
[conotoxin AuIB co-treated with triethyl-(beta-4-stilbenoxyethyl)ammonium co-treated with ZM 241385] inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; [conotoxin AuIB co-treated with triethyl-(beta-4-stilbenoxyethyl)ammonium co-treated with ZM 241385] inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with exoenzyme C3, Clostridium botulinum] inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; conotoxin AuIB inhibits the reaction [imidacloprid promotes the reaction [Acetylcholine results in increased expression of TH mRNA]]; conotoxin AuIB inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; conotoxin AuIB inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; exoenzyme C3, Clostridium botulinum inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Acetylcholine results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Nicotine results in increased expression of TH protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid promotes the reaction [Acetylcholine results in increased expression of TH mRNA]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid results in increased expression of TH mRNA]; ZM 241385 inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; ZM 241385 inhibits the reaction [imidacloprid results in increased expression of TH mRNA] imidacloprid results in increased expression of TH mRNA; imidacloprid results in increased expression of TH protein
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TJAP1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TKT mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TMBIM6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TMEM268 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TMT1B mRNA
Dietary Fats promotes the reaction [imidacloprid results in increased expression of TNF mRNA]; imidacloprid promotes the reaction [Dietary Fats results in increased expression of TNF mRNA] imidacloprid results in increased expression of TNF mRNA; imidacloprid results in increased expression of TNF protein Plant Extracts inhibits the reaction [imidacloprid results in increased expression of TNF mRNA]
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TNFAIP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TOR3A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAF3IP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRAFD1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of TRIM34 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of TSC22D3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UBA3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBB mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UBC mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of UCKL1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of UNC45A mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of USP2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of USP40 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of VEGFA mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VNN3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of VTN mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of WDR11 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of WEE1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased methylation of WFDC9 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased methylation of YOD1 gene
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFC3H1 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP280D mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP36L2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP422 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZFP598 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM3 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZMYM6 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with Glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in increased expression of ZRANB2 mRNA
Nicotine results in decreased expression of ABCA1 mRNA; Nicotine results in decreased expression of ABCA1 protein GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCA1 mRNA]; GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCA1 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCA1 protein]
Nicotine results in decreased expression of ABCG1 mRNA; Nicotine results in decreased expression of ABCG1 protein Nicotine results in increased expression of ABCG1 protein GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCG1 mRNA]; GW 3965 inhibits the reaction [Nicotine results in decreased expression of ABCG1 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of ABCG1 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ACAA2 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACAA2 mRNA]
Nicotine results in decreased expression of ACAN mRNA; Nicotine results in decreased expression of ACAN protein NLRP3 protein affects the reaction [Nicotine results in decreased expression of ACAN mRNA]
Nicotine results in decreased activity of ACHE protein Nicotine results in increased activity of ACHE protein Nicotine inhibits the reaction [Chlorpyrifos results in decreased activity of ACHE protein]
Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; Nicotine promotes the reaction [Quartz results in increased expression of ACTA2 protein] Nicotine results in increased expression of ACTA2 protein Bungarotoxins inhibits the reaction [Nicotine results in increased expression of ACTA2 protein]; Nicotine promotes the reaction [Arginine results in increased expression of ACTA2 protein] Nicotine results in increased expression of ACTA2 mRNA; Nicotine results in increased expression of ACTA2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ACTR1A mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ADCY7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADGRL1 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADNP mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADNP mRNA]
[Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased susceptibility to Nicotine Nicotine results in increased expression of ADRB1 mRNA
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased susceptibility to Nicotine Nicotine results in increased expression of ADRB2 mRNA
Nicotine results in decreased expression of AGTR2 mRNA; Nicotine results in decreased expression of AGTR2 protein Nicotine affects the expression of AGTR2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of AKR1A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein]; [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of FOXO1 protein; [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of GSK3A protein; [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of GSK3B protein; CDK1 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; CDK2 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; CHRNA7 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; CSNK2A1 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; Curcumin inhibits the reaction [Nicotine results in increased expression of AKT1 protein modified form]; CYP1A1 protein affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein]; Nicotine affects the reaction [Camptothecin affects the phosphorylation of AKT1 protein]; Nicotine affects the reaction [Fluorouracil affects the phosphorylation of AKT1 protein]; Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein Nicotine results in decreased phosphorylation of AKT1 protein Nicotine results in increased expression of AKT1 mRNA
Nicotine results in increased expression of ALB protein Nicotine results in decreased expression of ALB protein dexpanthenol inhibits the reaction [Nicotine results in decreased expression of ALB protein]
Nicotine results in increased activity of ALDH1A1 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ALDH1A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA]
[RTKI cpd co-treated with AG 1879] inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; AG 1879 inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; MK-886 inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; RTKI cpd inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; U 0126 inhibits the reaction [Nicotine results in increased expression of ALOX5 mRNA] Nicotine results in increased expression of ALOX5 mRNA; Nicotine results in increased expression of ALOX5 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of APEX1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of APEX1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of API5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of API5 mRNA]
[Nicotine results in increased metabolism of APP protein] which results in increased secretion of APP protein modified form; Bungarotoxins inhibits the reaction [Nicotine inhibits the reaction [Copper results in increased expression of APP protein]]; Mecamylamine inhibits the reaction [Nicotine inhibits the reaction [Copper results in increased expression of APP protein]]; Nicotine inhibits the reaction [Copper promotes the reaction [APP protein binds to APP protein]]; Nicotine inhibits the reaction [Copper results in increased expression of APP mRNA]; Nicotine inhibits the reaction [Copper results in increased expression of APP protein]; Tubocurarine inhibits the reaction [[Nicotine results in increased metabolism of APP protein] which results in increased secretion of APP protein modified form]; Tubocurarine inhibits the reaction [Nicotine results in increased metabolism of APP protein] APP protein modified form inhibits the reaction [Nicotine results in increased secretion of Acetylcholine]; spiro(imidazo-(1,2-a)pyridine-3,2-indan)-2(3H)-one inhibits the reaction [APP protein modified form inhibits the reaction [Nicotine results in increased secretion of Acetylcholine]] Nicotine results in decreased expression of APP protein alternative form Nicotine results in decreased expression of APP mRNA; Nicotine results in decreased expression of APP protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ARF1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ARF3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF3 mRNA]
ARRB1 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; ARRB1 protein affects the reaction [Nicotine results in increased phosphorylation of and results in increased activity of SRC protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ASPM mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ASPM mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ATP6V0A4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0A4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ATP9A mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP9A mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATRN mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BAP1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAP1 mRNA]
Nicotine results in increased phosphorylation of BAX protein Nicotine results in decreased expression of BAX protein Nicotine results in increased expression of BAX protein dexpanthenol inhibits the reaction [Nicotine results in increased expression of BAX protein]; Folic Acid inhibits the reaction [Nicotine results in increased expression of BAX protein] Nicotine results in increased expression of BAX mRNA; Nicotine results in increased expression of BAX protein Nicotine affects the localization of BAX protein Nicotine results in decreased expression of BAX mRNA; Nicotine results in decreased expression of BAX protein 3-methyladenine inhibits the reaction [Nicotine results in increased expression of BAX protein]; [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in decreased expression of BAX protein; MK-886 inhibits the reaction [Nicotine results in decreased expression of BAX protein]; Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] affects the localization of BAX protein]; PRKCZ protein affects the reaction [Nicotine results in increased phosphorylation of BAX protein]
3-methyladenine inhibits the reaction [Nicotine results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [Nicotine results in increased expression of BCL2 protein]; edelfosine inhibits the reaction [Nicotine results in increased phosphorylation of BCL2 protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of BCL2 protein]; MK-886 inhibits the reaction [Nicotine results in increased expression of BCL2 protein]; Nicotine inhibits the reaction [Aflatoxin B1 results in decreased expression of BCL2 protein] royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA] Folic Acid inhibits the reaction [Nicotine results in decreased expression of BCL2 protein] Nicotine results in decreased expression of BCL2 mRNA; Nicotine results in decreased expression of BCL2 protein Nicotine results in increased expression of BCL2 mRNA; Nicotine results in increased expression of BCL2 protein; Nicotine results in increased expression of BCL2 protein modified form
Nicotine results in decreased expression of BCL2L1 mRNA Nicotine results in decreased expression of BCL2L1 protein resveratrol inhibits the reaction [Nicotine results in decreased expression of BCL2L1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2L10 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2L10 mRNA]
BDNF gene polymorphism affects the susceptibility to Nicotine [Nicotine co-treated with Quartz] results in increased expression of BDNF protein Nicotine results in increased expression of BDNF mRNA Nicotine affects the expression of BDNF mRNA Nicotine results in increased secretion of BDNF protein methyllycaconitine inhibits the reaction [Nicotine results in increased secretion of BDNF protein]
Nicotine results in increased expression of BECN1 mRNA dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]
Nicotine results in increased expression of BGLAP Nicotine results in decreased expression of BGLAP mRNA Tubocurarine inhibits the reaction [Nicotine results in increased expression of BGLAP]
Curcumin inhibits the reaction [Nicotine results in increased expression of BIRC5 protein]; Hexamethonium affects the reaction [Nicotine results in increased expression of BIRC5 protein]; Nicotine inhibits the reaction [RB1 protein binds to BIRC5 promoter]; Nicotine promotes the reaction [E2F1 protein binds to BIRC5 promoter] Nicotine results in increased expression of BIRC5 mRNA; Nicotine results in increased expression of BIRC5 protein
Nicotine results in increased expression of BMI1 mRNA; Nicotine results in increased expression of BMI1 protein SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of BMI1 mRNA]
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BNIP3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA]
Nicotine results in decreased expression of BRCA1 mRNA Nicotine inhibits the reaction [aflatoxin G1 results in increased expression of BRCA1 protein modified form]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of C1R mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA]
alpha-cobratoxin inhibits the reaction [Nicotine results in increased expression of C7 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of C7 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of C7 mRNA]
Nicotine results in increased expression of CALB1 protein Mecamylamine inhibits the reaction [Nicotine results in increased expression of CALB1 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CALM1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA]
CHRNA5 protein affects the reaction [Nicotine results in increased expression of and results in increased cleavage of CASP1 protein]; Nicotine affects the reaction [Staurosporine affects the localization of CASP1 protein]; Nicotine inhibits the reaction [Staurosporine results in increased activity of CASP1 protein]; Nicotine results in increased expression of and results in increased cleavage of CASP1 protein Nicotine results in increased expression of CASP1 mRNA Nicotine results in increased expression of CASP1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP12 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP12 mRNA] Nicotine inhibits the reaction [Tunicamycin results in increased activity of CASP12 protein]
geldanamycin inhibits the reaction [Nicotine results in increased activity of CASP3 protein]; MK-886 inhibits the reaction [Nicotine results in decreased expression of CASP3 protein]; Nicotine inhibits the reaction [Aflatoxin B1 results in increased cleavage of CASP3 protein]; Nicotine inhibits the reaction [aflatoxin G1 results in increased expression of CASP3 protein modified form]; Nicotine inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein] Nicotine results in increased cleavage of CASP3 protein Nicotine results in increased activity of CASP3 protein; Nicotine results in increased activity of CASP3 protein alternative form Nicotine results in increased expression of CASP3 mRNA; Nicotine results in increased expression of CASP3 protein Nicotine affects the expression of CASP3 mRNA [Ethanol co-treated with Nicotine] results in increased expression of CASP3 protein; Nicotine inhibits the reaction [Ethanol results in increased activity of CASP3 protein] Nicotine results in increased expression of CASP3 mRNA; Nicotine results in increased expression of CASP3 protein modified form Nicotine results in increased expression of CASP3; Nicotine results in increased expression of CASP3 mRNA; Nicotine results in increased expression of CASP3 protein; Nicotine results in increased expression of CASP3 protein modified form Nicotine results in decreased expression of CASP3 mRNA; Nicotine results in decreased expression of CASP3 protein [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein]; Resveratrol inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA]; royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA] Nicotine results in decreased activity of CASP3 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CASP9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA] dexpanthenol inhibits the reaction [Nicotine results in increased expression of CASP9 protein]; Folic Acid inhibits the reaction [Nicotine results in increased expression of CASP9 protein] Nicotine inhibits the reaction [[Cisplatin co-treated with Etoposide] results in increased activity of CASP9 protein] Nicotine results in decreased expression of CASP9 mRNA
[acephate co-treated with methamidophos co-treated with Nicotine] results in increased activity of CAT protein; [Ethanol co-treated with Nicotine] results in decreased activity of CAT protein; [Ethanol co-treated with Nicotine] results in increased activity of CAT protein; Folic Acid inhibits the reaction [Nicotine results in decreased activity of CAT protein] royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein] Nicotine results in increased activity of CAT protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CBX5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CBX5 mRNA]
Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; ZFP36 mutant form inhibits the reaction [Nicotine results in decreased expression of CCL2 mRNA] Nicotine results in decreased expression of CCL2 mRNA; Nicotine results in decreased expression of CCL2 protein Nicotine results in decreased secretion of CCL2 protein
Nicotine results in increased expression of CCNB1 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNB1 mRNA]
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Nicotine results in increased expression of CCND1 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine results in increased expression of CCND1 protein]; Curcumin inhibits the reaction [Nicotine results in increased expression of CCND1 protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of CCND1 protein]; MK-886 inhibits the reaction [Nicotine results in increased expression of CCND1 mRNA]; MK-886 inhibits the reaction [Nicotine results in increased expression of CCND1 protein]; Nicotine promotes the reaction [CDK4 protein binds to CCND1 protein]; Nicotine promotes the reaction [CDK6 protein binds to CCND1 protein]; U 0126 inhibits the reaction [Nicotine results in increased expression of CCND1 protein] Nicotine results in decreased expression of CCND1 mRNA; Nicotine results in decreased expression of CCND1 protein Nicotine results in increased activity of CCND1 promoter Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of CCND1 mRNA] Nicotine results in increased expression of CCND1 mRNA; Nicotine results in increased expression of CCND1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCND2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCND2 mRNA] Nicotine results in decreased expression of CCND2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNL2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNL2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CD151 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CD151 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CD44 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD44 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CD9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD9 mRNA]
Nicotine inhibits the reaction [E2F4 protein binds to CDC25A promoter]; Nicotine inhibits the reaction [E2F5 protein binds to CDC25A promoter]; Nicotine inhibits the reaction [RB1 protein binds to CDC25A promoter]; Nicotine inhibits the reaction [RBL1 protein binds to CDC25A promoter]; Nicotine inhibits the reaction [RBL2 protein binds to CDC25A promoter]; Nicotine promotes the reaction [E2F1 protein binds to CDC25A promoter]; Nicotine promotes the reaction [E2F2 protein binds to CDC25A promoter]; Nicotine promotes the reaction [E2F3 protein binds to CDC25A promoter]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CDC42 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CDC42 mRNA]
Nicotine inhibits the reaction [E2F4 protein binds to CDC6 promoter]; Nicotine inhibits the reaction [E2F5 protein binds to CDC6 promoter]; Nicotine inhibits the reaction [RB1 protein binds to CDC6 promoter]; Nicotine inhibits the reaction [RBL1 protein binds to CDC6 promoter]; Nicotine inhibits the reaction [RBL2 protein binds to CDC6 promoter]; Nicotine promotes the reaction [E2F1 protein binds to CDC6 promoter]; Nicotine promotes the reaction [E2F2 protein binds to CDC6 promoter]; Nicotine promotes the reaction [E2F3 protein binds to CDC6 promoter]
MK-886 inhibits the reaction [Nicotine results in decreased expression of CDH1 mRNA]; U 0126 inhibits the reaction [Nicotine results in decreased expression of CDH1 mRNA] [Nicotine co-treated with Quartz] results in increased expression of CDH1 protein Nicotine results in decreased expression of CDH1 mRNA; Nicotine results in decreased expression of CDH1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CDH11 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CDH11 mRNA]
[Nicotine co-treated with Quartz] results in increased expression of CDH2 protein; staurosporine aglycone inhibits the reaction [[Nicotine co-treated with Quartz] results in increased expression of CDH2 protein]
Nicotine results in increased expression of CDK1 protein CDK1 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; CHRNA7 affects the reaction [Nicotine results in increased expression of CDK1 protein]
Bungarotoxins inhibits the reaction [Nicotine results in decreased expression of CDK4 protein]; Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of CDK4 protein]; Hexamethonium inhibits the reaction [Nicotine results in decreased expression of CDK4 protein]; Nicotine promotes the reaction [CDK4 protein binds to CCND1 protein]; Nicotine promotes the reaction [NFATC2 protein results in decreased expression of CDK4 protein]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of CDK4 protein] Nicotine results in decreased expression of CDK4 mRNA; Nicotine results in decreased expression of CDK4 protein
Nicotine results in decreased expression of CDKN1A protein Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CDKN1A mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CDKN1A protein]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN1A mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN1A protein] Nicotine results in increased expression of CDKN1A mRNA; Nicotine results in increased expression of CDKN1A protein 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Nicotine results in decreased expression of CDKN1A protein]; Nicotine inhibits the reaction [Cisplatin results in increased expression of CDKN1A protein]; Nicotine inhibits the reaction [Gemcitabine results in increased expression of CDKN1A protein]; Nicotine inhibits the reaction [Paclitaxel results in increased expression of CDKN1A protein]
Nicotine results in decreased expression of CDKN1B protein 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Nicotine results in decreased expression of CDKN1B protein]; Nicotine results in increased expression of and results in increased stability of CDKN1B protein
Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CDKN2A mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CDKN2A protein]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN2A mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN2A protein] Nicotine results in increased expression of CDKN2A mRNA; Nicotine results in increased expression of CDKN2A protein
[Nicotine results in increased abundance of Cotinine] which results in increased expression of CEBPA protein Nicotine affects the expression of CEBPA mRNA Nicotine results in increased expression of CEBPA mRNA
Nicotine results in increased expression of CEBPB mRNA [Nicotine results in increased abundance of Cotinine] which results in increased expression of CEBPB mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CETN3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA]
Nicotine results in decreased activity of CHAT protein Nicotine results in increased activity of CHAT protein Nicotine inhibits the reaction [Vanadium results in decreased expression of CHAT protein]; Nicotine promotes the reaction [Bucladesine results in increased expression of CHAT protein]
CHGA protein alternative form inhibits the reaction [Nicotine results in increased activity of CHGA promoter]; Chlorisondamine inhibits the reaction [Nicotine results in increased activity of CHGA promoter] Nicotine results in increased expression of CHGA mRNA
CHRNA2 gene mutant form affects the susceptibility to Nicotine nicotine affects binding to Chrna2 protein; nicotine inhibits the reaction [epibatidine affects binding to Chrna2 protein] in rat retina nicotine affects binding competes with [Epibatidine binds to Chrna2 protein] Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]
Nicotine results in decreased expression of CHRNA3 mRNA nicotine affects binding [Epibatidine binds to Chrna3 protein] Nicotine affects binding [Epibatidine binds to Chrna3 protein] Nicotine results in increased activity of CHRNA3 protein Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Nicotine analog binds to and results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine binds to and results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein] Nicotine results in increased expression of CHRNA3 mRNA CHRNA3 protein affects the susceptibility to Nicotine CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA5 protein]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA7 protein]; Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]
Nicotine binds to [CHRNA4 protein binds to CHRNB2 protein] nicotine affects binding to Chrna4 protein; nicotine inhibits the reaction [epibatidine affects binding to Chrna4 protein] in rat retina nicotine affects binding to Chrna4 protein; nicotine competes with [Epibatidine binds to Chrna4 protein] Nicotine results in increased expression of CHRNA4 mRNA; Nicotine results in increased expression of CHRNA4 protein Nicotine results in decreased expression of CHRNA4 mRNA Nicotine analog binds to [CHRNA4 protein binds to CHRNB2 protein]; Nicotine binds to [CHRNA4 protein binds to CHRNB2 protein] 1-(5-azido-6-chloropyridin-3-ylmethyl)-2-nitroiminoimidazolidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; [Nicotine co-treated with Benzo(a)pyrene] results in decreased expression of [CHRNA4 protein binds to CHRNB2 protein]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of CHRNA4 mRNA]; imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; N-(5-azido-6-chloropyridin-3-ylmethyl)-N'-methyl-N''-nitroguanidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased expression of [CHRNA4 protein binds to CHRNB2 protein] [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide co-treated with Nicotine] inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in increased expression of CHRNA4 protein]; cytisine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]; Nicotine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CHRNA4 protein]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein] CHRNA4 protein mutant form results in increased susceptibility to Nicotine CHRNA4 gene polymorphism affects the susceptibility to Nicotine; CHRNA4 protein affects the susceptibility to Nicotine; CHRNA4 protein mutant form affects the susceptibility to Nicotine [CHRNA4 protein binds to CHRNB2 protein] which results in increased susceptibility to Nicotine; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of CHRNA4 protein]
CHRNA5 gene polymorphism results in increased susceptibility to Nicotine Nicotine results in increased expression of CHRNA5 mRNA CHRNA5 gene polymorphism affects the susceptibility to Nicotine Nicotine results in increased expression of CHRNA5 mRNA; Nicotine results in increased expression of CHRNA5 protein Nicotine results in decreased expression of CHRNA5 mRNA 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; 5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; 5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; alpha-conotoxin MII inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; alpha-conotoxin MII inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA5 protein]; CHRNA5 mutant form inhibits the reaction [Nicotine results in increased expression of HIF1A protein]; CHRNA5 mutant form inhibits the reaction [Nicotine results in increased expression of VEGFA protein]; CHRNA5 protein affects the reaction [Nicotine results in increased expression of and results in increased cleavage of CASP1 protein]; CHRNA5 protein affects the reaction [Nicotine results in increased expression of NLRP3 protein]; CHRNA5 protein affects the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; CHRNA5 protein affects the reaction [Nicotine results in increased secretion of IL18 protein]; CHRNA5 protein affects the reaction [Nicotine results in increased secretion of IL1B protein]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of CHRNA5 protein]; Go 6976 inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; Go 6976 inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; KN 62 inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; KN 62 inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; manumycin inhibits the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; manumycin inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]
Nicotine results in decreased expression of CHRNA6 mRNA nicotine binds to Chrna6 protein nicotine inhibits the reaction [alpha-Conotoxin MII binds to Chrna6]; nicotine inhibits the reaction [epibatidine binds to Chrna6]. Nicotine results in increased expression of CHRNA6 mRNA Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine]; Nicotine inhibits the reaction [Paraquat results in decreased expression of [CHRNA6 protein binds to CHRNB2 protein]] CHRNA6 gene polymorphism affects the susceptibility to Nicotine
CHRNA7 protein mutant form results in increased susceptibility to Nicotine nicotine affects binding of the neuronal nicotinic acetylcholine receptor Chrna7 in rat hippocampal neurons Nicotine results in increased expression of CHRNA7 mRNA; Nicotine results in increased expression of CHRNA7 protein Nicotine affects the activity of CHRNA7 protein Nicotine results in increased activity of CHRNA7 protein Nicotine results in decreased expression of CHRNA7 mRNA; Nicotine results in decreased expression of CHRNA7 protein [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] which affects the susceptibility to Nicotine; [Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of CHRNA7 protein; [Nicotine results in increased activity of CHRNA7 protein] which results in increased transport of Calcium; Nicotine inhibits the reaction [iodo-alpha-bungarotoxin binds to CHRNA7 protein]; Nicotine inhibits the reaction [methyllycaconitine binds to CHRNA7 protein]; Nicotine results in increased expression of and results in increased phosphorylation of CHRNA7 protein [Bungarotoxins results in decreased activity of CHRNA7 protein] which results in decreased susceptibility to Nicotine; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] which results in decreased susceptibility to Nicotine; [triethyl-(beta-4-stilbenoxyethyl)ammonium results in decreased activity of CHRNA7 protein] which results in decreased susceptibility to Nicotine CHRNA7 gene polymorphism affects the susceptibility to Nicotine; CHRNA7 protein affects the susceptibility to Nicotine Nicotine results in increased expression of CHRNA7; Nicotine results in increased expression of CHRNA7 mRNA; Nicotine results in increased expression of CHRNA7 protein Nicotine results in increased activity of CHRNA7 protein; Nicotine results in increased activity of CHRNA7 protein mutant form 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased expression of CHRNA7 protein]; 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea promotes the reaction [Nicotine affects the activity of CHRNA7 protein]; 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea promotes the reaction [Nicotine results in increased activity of CHRNA7 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Nicotine results in increased expression of CHRNA7 protein]; [GATA4 co-treated with GATA6] affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased abundance of Epinephrine]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased expression of DBH mRNA]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased expression of TH mRNA]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; [Nicotine results in increased activity of CHRNA7 protein] which results in increased transport of Calcium; Bungarotoxins inhibits the reaction [Nicotine binds to and results in increased activity of CHRNA7 protein]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of CHRNA7 protein]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; CHRNA3 protein affects the reaction [Nicotine results in increased expression of CHRNA7 protein]; CHRNA7 affects the reaction [Nicotine results in decreased expression of SLBP protein]; CHRNA7 affects the reaction [Nicotine results in increased expression of CDK1 protein]; CHRNA7 affects the reaction [Nicotine results in increased expression of CSNK2A1 protein]; CHRNA7 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; CHRNA7 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of CHRNA5 mRNA]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of CHRNA5 protein]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of GATA2 mRNA]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of GATA2 protein]; GATA2 protein affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; GATA2 protein affects the reaction [Nicotine results in increased expression of CHRNA7 protein]; KN 62 inhibits the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; KN 62 inhibits the reaction [Nicotine results in increased expression of CHRNA7 protein]; MB327 analog promotes the reaction [Nicotine affects the activity of CHRNA7 protein]; MB327 promotes the reaction [Nicotine affects the activity of CHRNA7 protein]; MB327 promotes the reaction [Nicotine results in increased activity of CHRNA7 protein]; methyllycaconitine inhibits the reaction [Nicotine binds to and results in increased activity of CHRNA7 protein]; methyllycaconitine promotes the reaction [[Nicotine results in increased activity of CHRNA7 protein] which results in increased transport of Calcium]; Nicotine binds to and results in increased activity of CHRNA7 protein; Nicotine inhibits the reaction [Bungarotoxins binds to CHRNA7 protein]; Nicotine promotes the reaction [[GATA4 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [[GATA6 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [GATA6 protein binds to GATA4 protein binds to SP1 protein binds to CHRNA7 promoter]; Nicotine results in increased expression of and results in increased phosphorylation of CHRNA7 protein; Pyridinium Compounds analog promotes the reaction [Nicotine results in increased activity of CHRNA7 protein]
Nicotine results in increased expression of CHRNA9 mRNA [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased expression of CHRNA9 protein
[CHRNA4 protein binds to CHRNB2 protein] which results in increased susceptibility to Nicotine; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [cytisine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] nicotine affects binding to Chrnb2 protein; nicotine inhibits the reaction [epibatidine affects binding to Chrnb2 protein] in rat retina nicotine affects binding to Chrnb2 protein; nicotine competes with [Epibatidine binds to Chrnb2 protein] Nicotine results in increased expression of CHRNB2 mRNA 1-(5-azido-6-chloropyridin-3-ylmethyl)-2-nitroiminoimidazolidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; [Dihydro-beta-Erythroidine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in decreased susceptibility to Nicotine; [Nicotine co-treated with Benzo(a)pyrene] results in decreased expression of [CHRNA4 protein binds to CHRNB2 protein]; Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]]; Cocaine inhibits the reaction [Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; imidacloprid analog inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; N-(5-azido-6-chloropyridin-3-ylmethyl)-N'-methyl-N''-nitroguanidine inhibits the reaction [Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]]; Nicotine analog binds to [CHRNA4 protein co-treated with CHRNB2 protein]; Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein]; Nicotine results in increased expression of [CHRNA4 protein binds to CHRNB2 protein] Nicotine results in decreased expression of CHRNB2 mRNA Nicotine analog binds to [CHRNA4 protein binds to CHRNB2 protein]; Nicotine binds to [CHRNA4 protein binds to CHRNB2 protein] Nicotine results in increased expression of CHRNB2 mRNA; Nicotine results in increased expression of CHRNB2 protein CHRNB2 protein affects the susceptibility to Nicotine CHRNB2 promotes the reaction [Nicotine results in increased expression of RYR2 mRNA]; cytisine inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein]; Nicotine binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine]; Nicotine inhibits the reaction [Paraquat results in decreased expression of [CHRNA6 protein binds to CHRNB2 protein]]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CHRNB2 protein]
Nicotine results in increased expression of CHRNB3 mRNA nicotine affects binding to Chrnb3 protein; nicotine inhibits the reaction [epibatidine affects binding to Chrnb3 protein] in rat retina
Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Nicotine results in increased activity of [CHRNB4 protein binds to CHRNA4 protein] Nicotine results in increased expression of CHRNB4 mRNA Nicotine results in increased activity of CHRNB4 protein Nicotine analog binds to and results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine binds to and results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]; Nicotine results in increased activity of [CHRNA3 protein binds to CHRNB4 protein] CHRNB4 protein affects the susceptibility to Nicotine
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CIB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CIB1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CKMT1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CKMT1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CLCA2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLCA2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CLSTN1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLSTN1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CNN2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA]
CNR1 protein affects the susceptibility to Nicotine Nicotine results in increased expression of CNR1 mRNA [rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to Nicotine
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of CNTN1 mRNA]; alpha-cobratoxin inhibits the reaction [Nicotine results in increased expression of CNTN1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of CNTN1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CNTN1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of CNTN1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of CNTN1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL1A1 mRNA; NGF protein affects the reaction [Nicotine results in increased expression of COL1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL1A1 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of COL1A1 protein]; Nicotine promotes the reaction [Thioacetamide results in increased expression of COL1A1] Nicotine results in increased expression of COL1A1 mRNA; Nicotine results in increased expression of COL1A1 protein
Nicotine promotes the reaction [Arginine results in increased expression of COL1A2 protein] Nicotine promotes the reaction [Quartz results in increased expression of COL1A2 protein]
Nicotine results in decreased expression of COL2A1 mRNA; Nicotine results in decreased expression of COL2A1 protein NLRP3 protein affects the reaction [Nicotine results in decreased expression of COL2A1 mRNA]
Nicotine results in increased expression of COL3A1 mRNA Nicotine promotes the reaction [Arginine results in increased expression of COL3A1 protein] Nicotine results in increased expression of COL3A1 mRNA; Nicotine results in increased expression of COL3A1 protein NGF protein affects the reaction [Nicotine results in increased expression of COL3A1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL6A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL6A1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of COX7A2L mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA]
CREB1 protein promotes the reaction [Nicotine results in increased expression of MMP7 mRNA] Nicotine results in increased expression of CREB1 mRNA Nicotine results in increased phosphorylation of CREB1 protein CREB1 protein promotes the reaction [Nicotine results in increased expression of RYR2 mRNA]; Excitatory Amino Acid Antagonists inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein]; KN 93 inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein]; Mecamylamine inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein]; Nicotine promotes the reaction [CREB1 protein modified form binds to RYR2 promoter]; Nifedipine inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein]; Ryanodine inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein] Nicotine results in decreased expression of CREB1 mRNA
Nicotine results in decreased expression of CRH mRNA; Nicotine results in decreased expression of CRH protein Nicotine results in increased expression of CRH protein
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA
Nicotine results in increased expression of and results in increased secretion of CSF2 protein; Tubocurarine inhibits the reaction [Nicotine results in increased secretion of CSF2 protein]
CHRNA7 affects the reaction [Nicotine results in increased expression of CSNK2A1 protein]; CSNK2A1 affects the reaction [Nicotine results in decreased expression of SLBP protein]; CSNK2A1 affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CST3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA]
Carbon Tetrachloride inhibits the reaction [Nicotine results in decreased expression of CTNNB1 mRNA]; Nicotine inhibits the reaction [Carbon Tetrachloride results in decreased expression of CTNNB1 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of CTNNB1 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of CTNNB1 protein] Nicotine results in increased expression of CTNNB1 mRNA; Nicotine results in increased expression of CTNNB1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CTSL mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA]
Nicotine results in decreased expression of CXCL1 mRNA Nicotine results in decreased secretion of CXCL1 protein Nicotine results in increased expression of CXCL1 protein
[Mecamylamine co-treated with Dihydro-beta-Erythroidine co-treated with Bungarotoxins] inhibits the reaction [Nicotine results in increased expression of CXCR4 protein] Nicotine results in increased expression of CXCR4 mRNA; Nicotine results in increased expression of CXCR4 protein
Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium affects the localization of CYCS protein] Nicotine results in increased expression of CYCS protein Nicotine results in increased secretion of CYCS protein Folic Acid inhibits the reaction [Nicotine results in increased expression of CYCS protein]; Nicotine inhibits the reaction [[Calcium co-treated with Phosphates] affects the localization of CYCS protein] Nicotine affects the localization of CYCS protein Nicotine results in decreased secretion of CYCS protein
Nicotine results in decreased expression of CYP11A1 mRNA; Nicotine results in decreased expression of CYP11A1 protein Nicotine results in decreased activity of CYP11A1 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYP11A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP11A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP11A1 protein]
Nicotine results in decreased expression of CYP17A1 mRNA Nicotine results in decreased expression of CYP17A1 mRNA; Nicotine results in decreased expression of CYP17A1 protein
Nicotine results in decreased expression of CYP19A1 mRNA; Nicotine results in decreased expression of CYP19A1 protein bisphenol A promotes the reaction [Nicotine results in decreased expression of CYP19A1 protein] Nicotine results in increased activity of CYP19A1 protein Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of CYP19A1 protein]
Nicotine results in increased expression of CYP1A1 mRNA; Nicotine results in increased expression of CYP1A1 protein bisphenol A promotes the reaction [Nicotine results in decreased expression of CYP1A1 protein] 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CYP1A1 protein]; CYP1A1 protein affects the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; diphenyleneiodonium inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]; SB 203580 inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]; SR 11302 inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA]
Nicotine results in increased expression of CYP1A2 protein Nicotine results in decreased expression of CYP1A2 mRNA Nicotine results in decreased activity of CYP1A2 protein
Nicotine results in decreased expression of CYP1B1 protein bisphenol A promotes the reaction [Nicotine results in decreased expression of CYP1B1 protein]
Nicotine results in increased expression of CYP2A1 mRNA Nicotine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]; Nicotine inhibits the reaction [CYP2A13 protein results in increased susceptibility to Aflatoxin B1] Nicotine results in decreased activity of CYP2A13 protein CYP2A13 protein results in increased metabolism of Nicotine
CYP2B1 protein results in increased metabolism of Nicotine [Nicotine co-treated with 2,2',3,5',6-pentachlorobiphenyl] results in increased expression of CYP2B1 mRNA; [Nicotine results in increased expression of CYP2B1 protein] which results in increased abundance of Cotinine; [Nicotine results in increased expression of CYP2B1 protein] which results in increased metabolism of Nicotine; Nicotine results in increased expression of and results in increased activity of CYP2B1 protein Nicotine results in increased expression of CYP2B1 mRNA; Nicotine results in increased expression of CYP2B1 protein
CYP2B6 protein results in increased metabolism of Nicotine CYP2B6 gene polymorphism affects the oxidation of Nicotine CYP2B6 protein results in increased oxidation of Nicotine CYP2B6 gene polymorphism affects the reaction [CYP2A6 protein results in increased metabolism of Nicotine]
Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]]; Ketoconazole inhibits the reaction [Nicotine results in increased expression of CYP2D22 mRNA]; Ketoconazole inhibits the reaction [Nicotine results in increased expression of CYP2D22 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]; Nicotine inhibits the reaction [Ketoconazole results in decreased expression of CYP2D22 mRNA]; Nicotine inhibits the reaction [Ketoconazole results in decreased expression of CYP2D22 protein] Nicotine results in increased expression of CYP2D22 mRNA; Nicotine results in increased expression of CYP2D22 protein
[Nicotine co-treated with 2,2',3,5',6-pentachlorobiphenyl] results in increased expression of CYP3A2 mRNA [Nicotine binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA
[methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased expression of DBH mRNA]
Nicotine inhibits the reaction [Cisplatin results in increased expression of DDIT3 mRNA] Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of DDIT3 protein] Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of DHFR mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of DHFR mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of DHFR mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJA1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJB9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA]
Nicotine results in decreased expression of DNMT1 mRNA Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in decreased expression of DNMT1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DPP4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA]
[SCH 23390 binds to and results in decreased activity of DRD1 protein] which results in decreased susceptibility to Nicotine Nicotine results in decreased expression of DRD1 mRNA
[Raclopride binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Nicotine DRD2 mRNA results in decreased susceptibility to Nicotine
Nicotine results in decreased expression of DVL2 mRNA Carbon Tetrachloride promotes the reaction [Nicotine results in increased expression of DVL2 mRNA]; Carbon Tetrachloride promotes the reaction [Nicotine results in increased expression of DVL2 protein]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of DVL2 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of DVL2 protein] Nicotine results in increased expression of DVL2 mRNA; Nicotine results in increased expression of DVL2 protein
MK-886 inhibits the reaction [Nicotine results in increased expression of E2F1 protein]; Nicotine promotes the reaction [E2F1 protein binds to BIRC5 promoter]; Nicotine promotes the reaction [E2F1 protein binds to CDC25A promoter]; Nicotine promotes the reaction [E2F1 protein binds to CDC6 promoter]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ECM1 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ECM1 mRNA]
Nicotine results in increased expression of EDN1 mRNA; Nicotine results in increased expression of EDN1 protein MIR98 mRNA inhibits the reaction [Nicotine results in increased expression of EDN1 mRNA]; NGF protein affects the reaction [Nicotine results in increased expression of EDN1 mRNA]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of EDN1 mRNA]
Nicotine results in increased expression of EEF2 protein modified form [Nicotine results in increased expression of UBA2 protein] which results in increased sumoylation of EEF2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EFNB3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA]
Nicotine results in decreased expression of EGFR mRNA Nicotine results in increased phosphorylation of EGFR protein AG 1879 inhibits the reaction [Nicotine results in increased phosphorylation of EGFR protein]
Nicotine results in increased expression of EGR1 mRNA; Nicotine results in increased expression of EGR1 protein Nicotine results in decreased expression of EGR1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EGR1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EGR1 mRNA] [triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]] which results in decreased expression of FGF2 mRNA; EGR1 protein inhibits the reaction [triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased secretion of FGF2 protein]]; EGR1 protein promotes the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; EGR1 protein promotes the reaction [Nicotine results in decreased expression of HSD11B2 protein]; Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased expression of EGR1 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of EGR1 protein]
Mecamylamine inhibits the reaction [Nicotine results in increased phosphorylation of EIF2AK3 protein]; ursodoxicoltaurine inhibits the reaction [Nicotine results in increased phosphorylation of EIF2AK3 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF2B4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF2B4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF4E mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF4E mRNA] EIF4E protein affects the reaction [Nicotine results in increased expression of BCL2 protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of CCND1 protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of MYC protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of VEGFA protein]; Nicotine promotes the reaction [EIF4EBP1 protein binds to EIF4E protein]
[Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Nicotine promotes the reaction [EIF4EBP1 protein binds to EIF4E protein]; Nicotine results in increased expression of and results in increased phosphorylation of EIF4EBP1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA]
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of EML4 mRNA]; Mecamylamine promotes the reaction [Nicotine results in decreased expression of EML4 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of EML4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ENO1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERN1 mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ERP44 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ETFA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ETFA mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EZR mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EZR mRNA] Nicotine results in increased expression of EZR mRNA
Nicotine affects the expression of FASLG mRNA Nicotine results in increased expression of FASLG mRNA; Nicotine results in increased expression of FASLG protein Nicotine results in increased expression of FASLG protein alternative form
Nicotine results in increased expression of FASN mRNA; Nicotine results in increased expression of FASN protein Nicotine affects the expression of FASN mRNA Nicotine promotes the reaction [NR1H3 protein binds to FASN promoter]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of FBXL12 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FBXL12 mRNA]
Nicotine results in increased expression of FEZ1 mRNA alpha-cobratoxin promotes the reaction [Nicotine results in decreased expression of FEZ1 mRNA alternative form]; Tubocurarine promotes the reaction [Nicotine results in decreased expression of FEZ1 mRNA]
[triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]] which results in decreased expression of FGF2 mRNA; EGR1 protein inhibits the reaction [triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased secretion of FGF2 protein]]; Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine promotes the reaction [EGR1 protein binds to FGF2 promoter]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased secretion of FGF2 protein] Nicotine results in increased expression of FGF2 mRNA; Nicotine results in increased expression of FGF2 protein Mecamylamine inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA] Nicotine results in decreased expression of FGF2 protein
Nicotine results in decreased expression of FN1 mRNA MIR98 mRNA inhibits the reaction [Nicotine results in increased expression of FN1 mRNA]; NGF protein affects the reaction [Nicotine results in increased expression of FN1 mRNA]; Nicotine promotes the reaction [Quartz results in increased expression of FN1 protein]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of FN1 mRNA] Nicotine results in increased expression of FN1 mRNA; Nicotine results in increased expression of FN1 protein
Nicotine results in increased expression of FOS; Nicotine results in increased expression of FOS mRNA; Nicotine results in increased expression of FOS protein Nicotine results in increased phosphorylation of FOS protein Nicotine deficiency affects the expression of FOS protein Acetaldehyde promotes the reaction [Nicotine results in increased expression of FOS mRNA]; Saponins inhibits the reaction [Nicotine results in increased expression of FOS protein] Nicotine results in decreased expression of FOS mRNA [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of FOS protein]; SB 203580 inhibits the reaction [Nicotine results in increased phosphorylation of FOS protein]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of FOS]
Nicotine results in increased expression of FOSB mRNA nicotine increases expression of Fosb protein in nucleus accumbens and dentate gyrus of hippocampal formation nicotine increases expression of FosB protein in nucleus accumbens and caudate-putamen Nicotine results in increased expression of FOSB protein
[Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of FOXO1 protein
LCK protein promotes the reaction [Nicotine results in increased phosphorylation of and results in increased activity of FYN protein]; Nicotine results in increased phosphorylation of and results in increased activity of FYN protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GAB1 mRNA]
Nicotine results in increased expression of GAD1 mRNA; Nicotine results in increased expression of GAD1 protein Nicotine results in decreased methylation of GAD1 promoter Dihydro-beta-Erythroidine analog inhibits the reaction [Nicotine results in increased expression of GAD1 mRNA]
[Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA]; [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAPDH mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA]
5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone inhibits the reaction [Nicotine results in increased expression of GATA2 mRNA]; 5-iodo-3-((3,5-dibromo-4-hydroxyphenyl)methylene)-2-indolinone inhibits the reaction [Nicotine results in increased expression of GATA2 protein]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of GATA2 mRNA]; Bungarotoxins inhibits the reaction [Nicotine results in increased expression of GATA2 protein]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of GATA2 mRNA]; CHRNA7 protein affects the reaction [Nicotine results in increased expression of GATA2 protein]; GATA2 protein affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; GATA2 protein affects the reaction [Nicotine results in increased expression of CHRNA7 protein]; manumycin inhibits the reaction [Nicotine results in increased expression of GATA2 mRNA]; manumycin inhibits the reaction [Nicotine results in increased expression of GATA2 protein]; U 0126 inhibits the reaction [Nicotine results in increased expression of GATA2 mRNA]; U 0126 inhibits the reaction [Nicotine results in increased expression of GATA2 protein] Nicotine results in increased expression of GATA2 mRNA; Nicotine results in increased expression of GATA2 protein
[GATA4 co-treated with GATA6] affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; Nicotine promotes the reaction [[GATA4 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [GATA4 protein binds to SP1 protein]; Nicotine promotes the reaction [GATA6 protein binds to GATA4 protein binds to SP1 protein binds to CHRNA7 promoter]
[GATA4 co-treated with GATA6] affects the reaction [Nicotine results in increased expression of CHRNA7 mRNA]; Nicotine promotes the reaction [[GATA6 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [GATA6 protein binds to GATA4 protein binds to SP1 protein binds to CHRNA7 promoter]; Nicotine promotes the reaction [GATA6 protein binds to SP1 protein] [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GATA6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GATA6 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GCLC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GCLC mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GHITM mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GMFB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA]
Nicotine results in increased splicing of GNAI2 mRNA alternative form [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GNAI2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GNAI2 mRNA]
alpha-cobratoxin inhibits the reaction [Nicotine results in increased expression of GOLGA4 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of GOLGA4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GOLT1B mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPRC5C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPRC5C mRNA]
Nicotine inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] dexpanthenol inhibits the reaction [Nicotine results in increased expression of GPT protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPX3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPX3 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GRID2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]
[Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of GSK3A protein Nicotine results in increased expression of and results in decreased phosphorylation of GSK3A protein Nicotine results in increased expression of GSK3A mRNA
[Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in increased phosphorylation of GSK3B protein Nicotine results in decreased expression of GSK3B mRNA; Nicotine results in decreased expression of GSK3B protein Nicotine results in increased expression of GSK3B mRNA Carbon Tetrachloride inhibits the reaction [Nicotine results in decreased expression of GSK3B mRNA]; Carbon Tetrachloride inhibits the reaction [Nicotine results in decreased expression of GSK3B protein]; Nicotine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GSK3B mRNA]; Nicotine inhibits the reaction [Carbon Tetrachloride results in decreased expression of GSK3B protein]; Nicotine promotes the reaction [Carbon Tetrachloride results in decreased expression of GSK3B mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in decreased expression of GSK3B protein]; Nicotine results in increased expression of and results in decreased phosphorylation of GSK3B protein
Nicotine results in decreased expression of GSTA4 mRNA Nicotine results in increased expression of GSTA4 mRNA Nicotine results in increased activity of GSTA4 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HBA-A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA]
Nicotine results in increased expression of HDAC1 mRNA Nicotine results in increased expression of HDAC1 mRNA; Nicotine results in increased expression of HDAC1 protein SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC1 mRNA]; SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC1 protein]
Nicotine results in increased expression of HDAC2 mRNA; Nicotine results in increased expression of HDAC2 protein SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC2 mRNA]; SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC2 protein] Nicotine results in decreased expression of HDAC2 protein
Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased expression of HDAC4 protein] Nicotine results in increased expression of HDAC4 mRNA; Nicotine results in increased expression of HDAC4 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HELLS mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA]
Nicotine affects the expression of HGF mRNA Nicotine results in decreased expression of HGF protein [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA
Nicotine results in increased expression of HIF1A protein Nicotine results in decreased expression of HIF1A mRNA resveratrol inhibits the reaction [Nicotine results in decreased expression of HIF1A mRNA] CHRNA5 mutant form inhibits the reaction [Nicotine results in increased expression of HIF1A protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HINT1 mRNA; Mecamylamine inhibits the reaction [Nicotine results in increased expression of HINT1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA] Nicotine results in increased expression of HINT1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HIPK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HIPK1 mRNA]
HMOX1 protein results in increased susceptibility to Nicotine Nicotine affects the expression of HMOX1 mRNA Nicotine results in increased expression of HMOX1 mRNA; Nicotine results in increased expression of HMOX1 protein [Lipopolysaccharides co-treated with Nicotine] results in increased expression of HMOX1 mRNA; [Lipopolysaccharides co-treated with Nicotine] results in increased expression of HMOX1 protein; [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; HMOX1 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of ZFP36 mRNA]; HMOX1 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; HMOX1 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of ZFP36 mRNA]]; HMOX1 protein promotes the reaction [Nicotine results in increased expression of ZFP36 mRNA]; HMOX1 protein promotes the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; STAT3 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of HMOX1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HNRNPC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HNRNPC mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HRAS mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA] Nicotine results in increased activity of HRAS protein
Nicotine results in increased expression of HSD11B1 mRNA Nicotine affects the expression of HSD11B1 mRNA ursodoxicoltaurine inhibits the reaction [Nicotine results in increased expression of HSD11B1 mRNA]
Nicotine results in decreased expression of HSD11B2 mRNA; Nicotine results in decreased expression of HSD11B2 protein Nicotine affects the expression of HSD11B2 mRNA Nicotine results in increased expression of HSD11B2 mRNA; Nicotine results in increased expression of HSD11B2 protein 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 protein]; EGR1 protein promotes the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; EGR1 protein promotes the reaction [Nicotine results in decreased expression of HSD11B2 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of HSD11B2 protein]
Taurine inhibits the reaction [Nicotine results in decreased expression of HSD17B1 protein] Nicotine results in decreased expression of HSD17B1 mRNA Nicotine results in decreased expression of HSD17B1 mRNA; Nicotine results in decreased expression of HSD17B1 protein
Nicotine results in decreased activity of HSD17B3 protein Nicotine results in decreased expression of HSD17B3 mRNA; Nicotine results in decreased expression of HSD17B3 protein
Nicotine results in decreased activity of HSD3B1 protein Nicotine results in decreased expression of HSD3B1 mRNA Nicotine results in decreased expression of HSD3B1 mRNA; Nicotine results in decreased expression of HSD3B1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HSP90AA1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA] Nicotine results in increased expression of HSP90AA1 mRNA; Nicotine results in increased expression of HSP90AA1 protein
Nicotine results in increased expression of HSPA5 Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein] Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HSPA5 protein]; Nicotine inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]
Nicotine results in decreased expression of HTR1A protein Nicotine decreases expression of Htr1a protein in the diencephalon Nicotine results in increased expression of HTR1A protein
[Nicotine co-treated with Benzo(a)pyrene] results in decreased expression of HTR2A protein; Nicotine results in increased activity of [HTR1B protein binds to HTR2A protein] Nicotine results in increased expression of HTR2A protein
IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]
Nicotine results in decreased expression of IGF1 mRNA; Nicotine results in decreased expression of IGF1 protein Nicotine affects the expression of IGF1 mRNA; Nicotine affects the expression of IGF1 protein Nicotine results in increased expression of IGF1 mRNA rosiglitazone inhibits the reaction [Nicotine results in decreased expression of IGF1 protein]
Nicotine results in decreased expression of IGF1R mRNA; Nicotine results in decreased expression of IGF1R protein Nicotine affects the expression of IGF1R mRNA Nicotine results in increased expression of IGF1R mRNA
Nicotine results in decreased expression of IL10 mRNA Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Nicotine results in decreased secretion of IL10 protein [Eugenol co-treated with Acetylcysteine] inhibits the reaction [Nicotine results in decreased secretion of IL10 protein]; Acetylcysteine inhibits the reaction [Nicotine results in decreased expression of IL10 mRNA]; Eugenol inhibits the reaction [Nicotine results in decreased expression of IL10 mRNA]; Nicotine inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]
Acetylcysteine inhibits the reaction [Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]]; Eugenol inhibits the reaction [Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]]; Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]
Acetylcysteine inhibits the reaction [Nicotine results in increased expression of IL12B mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]]; Eugenol inhibits the reaction [Nicotine results in increased expression of IL12B mRNA]; Eugenol inhibits the reaction [Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]]; Nicotine results in increased secretion of [IL12A protein co-treated with IL12B protein]
[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL17A mRNA; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL17A mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL17A mRNA]
CHRNA5 protein affects the reaction [Nicotine results in increased secretion of IL18 protein] Nicotine results in increased expression of IL18 protein Nicotine results in increased expression of IL18 mRNA
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 protein]]; [Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL1B mRNA; CHRNA5 protein affects the reaction [Nicotine results in increased secretion of IL1B protein]; Nicotine inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 protein]; Nicotine promotes the reaction [IL1B protein results in increased secretion of CXCL8 protein]; Nicotine results in increased expression of and results in increased secretion of IL1B protein; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL1B mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL1B mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased secretion of IL1B protein]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 mRNA]]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased secretion of CXCL8 protein]]; U 0126 inhibits the reaction [Nicotine promotes the reaction [IL1B protein results in increased expression of CXCL8 protein]] Nicotine results in increased expression of IL1B mRNA Nicotine results in decreased expression of IL1B protein [Nicotine results in increased abundance of Cotinine] which results in increased expression of IL1B mRNA; Nicotine inhibits the reaction [Acetic Acid results in increased expression of IL1B protein]; Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA] Nicotine results in increased expression of IL1B mRNA; Nicotine results in increased expression of IL1B protein Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]
methyllycaconitine affects the reaction [Nicotine results in increased expression of IL1R1 mRNA]; methyllycaconitine affects the reaction [Nicotine results in increased expression of IL1R1 protein] Nicotine results in increased expression of IL1R1 mRNA; Nicotine results in increased expression of IL1R1 protein
Nicotine results in increased secretion of IL33 protein [Nicotine co-treated with Quartz] results in increased expression of IL33 protein Nicotine promotes the reaction [Lipopolysaccharides results in increased secretion of IL33 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of IL4RA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA]
[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL6 mRNA; [Nicotine co-treated with Propylene Glycol co-treated with Glycerol co-treated with Flavoring Agents] results in increased secretion of IL6 protein; [Nicotine co-treated with Propylene Glycol co-treated with Glycerol] results in increased secretion of IL6 protein; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Nicotine results in increased expression of and results in increased secretion of IL6 protein; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL6 mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL6 mRNA] Nicotine results in increased secretion of IL6 protein [Nicotine results in increased abundance of Cotinine] which results in increased expression of IL6 mRNA Nicotine results in decreased secretion of IL6 protein Nicotine results in decreased expression of IL6 mRNA; Nicotine results in decreased expression of IL6 protein Nicotine results in increased expression of IL6 mRNA; Nicotine results in increased expression of IL6 protein Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; ZFP36 mutant form inhibits the reaction [Nicotine results in decreased expression of IL6 mRNA]
Sodium Acetate inhibits the reaction [Nicotine results in increased expression of INS1 protein] [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of CS mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of HGF mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRAK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA]
IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRX3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IRX3 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ITM2B mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA]
JAK2 results in increased susceptibility to Nicotine Nicotine results in increased phosphorylation of JAK2 protein Bungarotoxins inhibits the reaction [Nicotine results in increased phosphorylation of JAK2 protein] Nicotine results in decreased expression of JAK2 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of JMJD6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of JMJD6 mRNA]
Nicotine results in increased expression of JUN protein Nicotine results in increased phosphorylation of JUN protein Nicotine promotes the reaction [MAPK8 protein results in increased phosphorylation of JUN protein] [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of JUN protein]; Nicotine inhibits the reaction [Cisplatin results in increased expression of JUN mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of KAT6B mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KAT6B mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of KIF3B mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KLF4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA] Nicotine results in increased expression of KLF4 mRNA
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of KMT2C mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of KMT2C mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of KMT2C mRNA]
Capsaicin promotes the reaction [Nicotine results in decreased activity of KNG1 protein alternative form]; Kainic Acid promotes the reaction [Nicotine results in decreased activity of KNG1 protein alternative form]
LCK protein promotes the reaction [Nicotine results in increased phosphorylation of and results in increased activity of FYN protein]; Nicotine results in increased phosphorylation of and results in increased activity of LCK protein
Nicotine results in decreased expression of LHB mRNA; Nicotine results in decreased expression of LHB protein Nicotine results in increased secretion of LHB protein
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of LITAF mRNA]; Mecamylamine promotes the reaction [Nicotine results in decreased expression of LITAF mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of LITAF mRNA] Nicotine results in increased expression of LITAF mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LPAR4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAOA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAP2K7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP2K7 mRNA]
Nicotine results in increased activity of MAPK1 protein Nicotine results in increased phosphorylation of MAPK1 protein Nicotine results in decreased expression of MAPK1 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAPK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAPK1 mRNA] Melatonin inhibits the reaction [Nicotine results in decreased expression of MAPK1 protein]; Melatonin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Nicotine results in increased phosphorylation of and results in increased activity of MAPK1 protein Nicotine results in increased expression of MAPK1 protein modified form 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK1 protein; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased phosphorylation of MAPK1 protein; [Nicotine co-treated with Ethanol] results in increased phosphorylation of MAPK1 protein; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of FOS protein]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of JUN protein]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] which results in decreased susceptibility to Nicotine; Acetylcysteine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine results in decreased activity of MAPK1 protein]; Curcumin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; diphenyleneiodonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]; Nicotine inhibits the reaction [Cisplatin results in increased activity of MAPK1 protein]; Nicotine inhibits the reaction [Fluorouracil results in increased phosphorylation of MAPK1 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK1 protein]; Nicotine results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; Nicotine results in increased phosphorylation of and results in increased activity of MAPK1 protein; Propranolol inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein]; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Staurosporine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Tubocurarine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK3 protein; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased phosphorylation of MAPK3 protein; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of FOS protein]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of JUN protein]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] which results in decreased susceptibility to Nicotine; Acetylcysteine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine results in decreased activity of MAPK3 protein]; Curcumin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; diphenyleneiodonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Hexamethonium inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Nicotine inhibits the reaction [Cisplatin results in increased activity of MAPK3 protein]; Nicotine inhibits the reaction [Fluorouracil results in increased phosphorylation of MAPK3 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased activity of MAPK3 protein]; Nicotine results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; Nicotine results in increased phosphorylation of and results in increased activity of MAPK3 protein; Propranolol inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein]; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Staurosporine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Tubocurarine inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein] Nicotine results in decreased expression of MAPK3 protein Melatonin inhibits the reaction [Nicotine results in decreased expression of MAPK3 protein]; Melatonin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Nicotine results in increased phosphorylation of and results in increased activity of MAPK3 protein Nicotine results in decreased expression of MAPK3 mRNA; Nicotine results in decreased expression of MAPK3 protein Nicotine results in increased expression of MAPK3 protein modified form Nicotine results in increased activity of MAPK3 protein
Nicotine results in increased phosphorylation of MAPK8 protein Nicotine promotes the reaction [MAPK8 protein results in increased phosphorylation of JUN protein] Nicotine results in increased expression of MAPK8 mRNA Nicotine results in increased activity of MAPK8 protein Curcumin inhibits the reaction [Nicotine results in increased phosphorylation of MAPK8 protein]; Nicotine inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK8 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK8 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of MCL1 protein]; [Nicotine results in increased phosphorylation of MCL1 protein] which results in increased expression of and results in increased stability of MCL1 protein; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of MCL1 protein]
[[Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein] which results in increased ubiquitination of TP53 protein; [Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ME1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ME1 mRNA]
Nicotine results in decreased expression of MIR98 mRNA MIR98 mRNA affects the reaction [Nicotine results in increased expression of NGF protein]; MIR98 mRNA inhibits the reaction [Nicotine results in increased expression of EDN1 mRNA]; MIR98 mRNA inhibits the reaction [Nicotine results in increased expression of FN1 mRNA]; Rosiglitazone inhibits the reaction [Nicotine results in decreased expression of MIR98 mRNA]
[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of MKI67 protein; Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of MKI67 protein]; methyllycaconitine inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of MKI67 protein] [Nicotine co-treated with Quartz] results in increased expression of MKI67 protein Nicotine results in increased expression of MKI67 protein Nicotine results in decreased expression of MKI67 protein
lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 mRNA]; lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 protein]; Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 mRNA]; Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 protein]; Polymyxin B inhibits the reaction [lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 protein]]; Polymyxin B inhibits the reaction [Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP1 protein]]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of MMP1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of MMP1 protein] Nicotine results in increased expression of MMP1 mRNA; Nicotine results in increased expression of MMP1 protein
Nicotine results in increased expression of MMP13 mRNA; Nicotine results in increased expression of MMP13 protein NLRP3 protein affects the reaction [Nicotine results in increased expression of MMP13 mRNA] Nicotine results in decreased expression of MMP13 mRNA
lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP2 mRNA]; Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP2 mRNA] Nicotine results in decreased expression of MMP2 mRNA [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of MMP2 mRNA Nicotine results in decreased expression of MMP2 protein Nicotine results in increased expression of MMP2 mRNA; Nicotine results in increased expression of MMP2 protein
lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of MMP3 mRNA]; Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MMP3 mRNA]; NLRP3 protein affects the reaction [Nicotine results in increased expression of MMP3 mRNA] Nicotine results in increased expression of MMP3 mRNA; Nicotine results in increased expression of MMP3 protein
CREB1 protein promotes the reaction [Nicotine results in increased expression of MMP7 mRNA]; MK-886 inhibits the reaction [Nicotine results in increased expression of MMP7 mRNA]; MMP7 promoter SNP affects the reaction [Nicotine results in increased expression of MMP7 mRNA] [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MMP7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA] Nicotine results in increased expression of MMP7 mRNA; Nicotine results in increased expression of MMP7 protein MMP7 promoter SNP affects the susceptibility to Nicotine
Nicotine results in increased expression of MMP9 mRNA; Nicotine results in increased expression of MMP9 protein MK-886 inhibits the reaction [Nicotine results in increased expression of MMP9 mRNA] Nicotine results in decreased expression of MMP9 protein
Nicotine results in decreased activity of MPO protein Nicotine results in increased activity of MPO protein Acetylcysteine inhibits the reaction [Nicotine results in increased activity of MPO protein]; erdosteine inhibits the reaction [Nicotine results in increased activity of MPO protein]; Nicotine inhibits the reaction [Acetic Acid results in increased activity of MPO protein]; Vitamin E inhibits the reaction [Nicotine results in increased activity of MPO protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MRPL10 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL10 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL20 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MT2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA]
[Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MTCH1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTF2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTF2 mRNA]
Nicotine results in decreased expression of MTOR mRNA Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein] dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein] Nicotine results in increased phosphorylation of MTOR protein
Nicotine results in increased activity of MYC protein Nicotine results in increased expression of MYC protein EIF4E protein affects the reaction [Nicotine results in increased expression of MYC protein] Nicotine results in decreased expression of MYC mRNA Nicotine results in decreased activity of and results in decreased expression of MYC protein
Nicotine results in increased expression of NANOG mRNA; Nicotine results in increased expression of NANOG protein [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased expression of NANOG protein; SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of NANOG mRNA]
[Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA] [nickel chloride co-treated with Nicotine] results in increased expression of NCAM1 mRNA
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Nicotine results in increased expression of NCF1 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NDUFB5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA]
Nicotine results in increased activity of NFKB1 protein Mecamylamine analog inhibits the reaction [Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]]]; methyllycaconitine analog inhibits the reaction [Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]]]; Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]] Nicotine results in decreased expression of NFKB1 mRNA; Nicotine results in decreased expression of NFKB1 protein Nicotine results in increased expression of NFKB1 mRNA Vitamin K 3 inhibits the reaction [Nicotine results in increased activity of NFKB1 protein]
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]; NSC 74859 inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]] Nicotine results in increased phosphorylation of NFKBIA protein Nicotine results in increased degradation of NFKBIA protein Nicotine results in increased expression of NFKBIA mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NGB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NGB mRNA]
Nicotine results in increased expression of NGF mRNA Nicotine results in increased expression of NGF mRNA; Nicotine results in increased expression of NGF protein MIR98 mRNA affects the reaction [Nicotine results in increased expression of NGF protein]; NGF protein affects the reaction [Nicotine results in increased expression of COL1A1 mRNA]; NGF protein affects the reaction [Nicotine results in increased expression of COL3A1 mRNA]; NGF protein affects the reaction [Nicotine results in increased expression of EDN1 mRNA]; NGF protein affects the reaction [Nicotine results in increased expression of FN1 mRNA]; Rosiglitazone inhibits the reaction [Nicotine results in increased expression of NGF mRNA] Nicotine results in increased expression of and results in increased secretion of NGF protein
Nicotine results in increased expression of NIN mRNA alpha-cobratoxin inhibits the reaction [Nicotine results in increased expression of NIN mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of NIN mRNA]
Nicotine results in increased expression of NLRP3 mRNA; Nicotine results in increased expression of NLRP3 protein Bungarotoxins inhibits the reaction [Nicotine results in increased expression of NLRP3 mRNA]; CHRNA5 protein affects the reaction [Nicotine results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [Nicotine results in decreased expression of ACAN mRNA]; NLRP3 protein affects the reaction [Nicotine results in decreased expression of COL2A1 mRNA]; NLRP3 protein affects the reaction [Nicotine results in increased expression of MMP13 mRNA]; NLRP3 protein affects the reaction [Nicotine results in increased expression of MMP3 mRNA]
Nicotine results in increased expression of NOS2 mRNA; Nicotine results in increased expression of NOS2 protein Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] Nicotine results in decreased expression of NOS2 mRNA; Nicotine results in decreased expression of NOS2 protein Nicotine promotes the reaction [NOS2 protein results in increased abundance of Nitric Oxide] [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; [Nicotine results in decreased expression of NOS2 protein] which results in decreased abundance of Nitric Oxide; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of NOS2 mRNA]; Eugenol inhibits the reaction [Nicotine results in increased expression of NOS2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]
[Saquinavir co-treated with Nicotine co-treated with Ritonavir] results in decreased expression of NOTCH4 protein; [Saquinavir co-treated with Nicotine] results in decreased expression of NOTCH4 protein; Vitamin E inhibits the reaction [[Nicotine co-treated with Ritonavir co-treated with Saquinavir] results in decreased expression of NOTCH4 protein]; Vitamin E inhibits the reaction [[Nicotine co-treated with Saquinavir] results in decreased expression of NOTCH4 protein] Nicotine results in decreased expression of NOTCH4 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NPL mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NPL mRNA]
Hexamethonium inhibits the reaction [Nicotine results in increased expression of NPY mRNA] Nicotine results in decreased expression of NPY protein Nicotine results in increased expression of NPY mRNA; Nicotine results in increased expression of NPY protein
Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H2 protein] Nicotine results in decreased expression of NR1H2 mRNA; Nicotine results in decreased expression of NR1H2 protein
Nicotine promotes the reaction [NR1H3 protein binds to FASN promoter]; Nicotine results in increased expression of and results in increased activity of NR1H3 protein Nicotine results in decreased expression of NR1H3 mRNA; Nicotine results in decreased expression of NR1H3 protein Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of NR1H3 protein]
Nicotine results in decreased expression of NR3C1 mRNA Nicotine results in decreased expression of NR3C1 protein Nicotine results in increased expression of NR3C1 mRNA; Nicotine results in increased expression of NR3C1 protein
Nicotine results in decreased expression of NR5A1 mRNA; Nicotine results in decreased expression of NR5A1 protein trichostatin A inhibits the reaction [Nicotine results in decreased expression of NR5A1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NSF mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA]
Nicotine results in increased expression of NTRK2 protein [Nicotine co-treated with Quartz] results in increased phosphorylation of NTRK2 protein; staurosporine aglycone inhibits the reaction [[Nicotine co-treated with Quartz] results in increased expression of NTRK2 protein] methyllycaconitine inhibits the reaction [Nicotine results in increased expression of NTRK2 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NUPR1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of P3H3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of P3H3 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PAK2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PAK2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PARK7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PARK7 mRNA]
Nicotine inhibits the reaction [Aflatoxin B1 results in increased expression of PARP1 protein modified form]; Nicotine inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; Nicotine inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein]; Nicotine inhibits the reaction [Fluorouracil results in increased cleavage of PARP1 protein] Nicotine results in decreased expression of PARP1 protein Folic Acid inhibits the reaction [Nicotine results in decreased expression of PARP1 protein]
Nicotine results in increased expression of PCNA protein Nicotine results in decreased expression of PCNA protein royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein]
6,7-dimethoxy-2-phenylquinoxaline inhibits the reaction [Nicotine results in increased expression of PDGFB mRNA]; 6,7-dimethoxy-2-phenylquinoxaline inhibits the reaction [Nicotine results in increased secretion of PDGFB protein]
Nicotine results in increased expression of PDGFRB protein Nicotine results in decreased phosphorylation of and results in decreased activity of PDGFRB protein 6,7-dimethoxy-2-phenylquinoxaline inhibits the reaction [Nicotine results in increased expression of PDGFRB protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PDIA6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PFDN1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHB1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHTF1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA] Nicotine results in decreased expression of PHTF1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIDD1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIGC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PIN1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIP5K1C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PLAA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PLAA mRNA]
Nicotine affects the expression of PLAT mRNA Nicotine results in increased expression of PLAT mRNA; Nicotine results in increased expression of PLAT protein [Nicotine co-treated with lipopolysaccharide, E. coli O26-B6] affects the expression of PLAT mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA]; MK-886 inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA]; pyrazolanthrone inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA] Nicotine results in increased expression of PLAUR mRNA; Nicotine results in increased expression of PLAUR protein
Nicotine results in increased expression of PNMT mRNA Nicotine results in increased expression of PNMT protein imidacloprid promotes the reaction [Nicotine results in increased expression of PNMT protein]
Nicotine results in decreased expression of PNPLA2 mRNA [Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 mRNA; [Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PNPLA8 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA]
POMC protein affects the susceptibility to Nicotine Nicotine results in decreased expression of POMC protein Nicotine affects the expression of POMC protein POMC protein affects the reaction [Nicotine results in increased abundance of Dopamine] Nicotine results in increased expression of POMC protein alternative form
Nicotine results in increased expression of POU5F1 mRNA; Nicotine results in increased expression of POU5F1 protein Tubocurarine inhibits the reaction [Nicotine results in increased expression of POU5F1 mRNA] SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of POU5F1 mRNA]
Nicotine results in decreased expression of PPARGC1A mRNA; Nicotine results in decreased expression of PPARGC1A protein [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PPARGC1A protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PPM1B mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPP2R3C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA]
[BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of PRDM16 mRNA Nicotine results in decreased expression of PRDM16 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PRDX3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRDX3 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PRKAB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKAB1 mRNA]
PRKCZ protein affects the reaction [Nicotine results in increased phosphorylation of BAX protein] Nicotine results in increased activity of PRKCZ protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMG2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PSMG2 mRNA]
[4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 mRNA; [Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 protein; [U 0126 results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [Nicotine results in increased expression of PTGS2]; Curcumin inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; lipopolysaccharide, E. coli O26-B6 promotes the reaction [Nicotine results in increased expression of PTGS2 mRNA]; Nicotine promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 mRNA]; Propranolol inhibits the reaction [Nicotine results in increased activity of PTGS2 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 protein]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 protein]; Staurosporine inhibits the reaction [Nicotine results in increased expression of PTGS2] Nicotine results in increased expression of PTGS2 mRNA; Nicotine results in increased expression of PTGS2 protein Acetylcysteine inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; ferulic acid inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of PTPRA mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of PTPRA mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of PTPRA mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PYCARD mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD mRNA] Nicotine results in increased expression of PYCARD mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAB2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAB2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAB7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA]
Nicotine results in increased expression of RAD50 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD50 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD50 mRNA]
Aconitine analog inhibits the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; ARRB1 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; Bungarotoxins inhibits the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; CHRNA7 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]; SRC protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]] Nicotine affects the localization of RAF1 protein Nicotine results in increased activity of RAF1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RASA3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA]
4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Nicotine results in increased phosphorylation of RB1 protein]; Aconitine analog inhibits the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; ARRB1 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; Bungarotoxins inhibits the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; CHRNA7 protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]; MK-886 inhibits the reaction [Nicotine results in increased expression of RB1 protein modified form]; Nicotine inhibits the reaction [RB1 protein binds to BIRC5 promoter]; Nicotine inhibits the reaction [RB1 protein binds to CDC25A promoter]; Nicotine inhibits the reaction [RB1 protein binds to CDC6 promoter]; Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]; SRC protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]] Nicotine results in decreased expression of RB1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RBBP4 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RBBP4 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RBBP5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA]
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of RBBP6 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of RBBP6 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of RBBP6 mRNA] Nicotine results in increased expression of RBBP6 mRNA
[alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide co-treated with U 0126] inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]]; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of RELA protein]; Acetylcysteine inhibits the reaction [Nicotine results in increased phosphorylation of RELA protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]]; Nicotine affects the localization of and results in increased activity of RELA protein; Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]; U 0126 inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]] Nicotine affects the localization of RELA protein Mecamylamine analog inhibits the reaction [Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]]]; methyllycaconitine analog inhibits the reaction [Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]]]; Nicotine inhibits the reaction [Acetic Acid results in increased expression of RELA protein]; Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]] Nicotine results in decreased expression of RELA mRNA; Nicotine results in decreased expression of RELA protein 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Nicotine results in decreased expression of RELA protein]; Nicotine affects the localization of and results in increased activity of RELA protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RGS2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA] Nicotine results in increased expression of RGS2 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL26 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RPL26 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA]
[[Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein] which results in increased ubiquitination of TP53 protein; [Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein
Nicotine results in increased phosphorylation of RPS6 protein Cholesterol inhibits the reaction [Nicotine results in increased phosphorylation of RPS6 protein]
[Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased phosphorylation of RPS6KB1 protein; dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein] Nicotine results in increased phosphorylation of RPS6KB1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RSPO3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA]
CHRNB2 promotes the reaction [Nicotine results in increased expression of RYR2 mRNA] Nicotine results in increased expression of RYR2 mRNA; Nicotine results in increased expression of RYR2 protein CREB1 protein promotes the reaction [Nicotine results in increased expression of RYR2 mRNA]; Nicotine promotes the reaction [CREB1 protein modified form binds to RYR2 promoter]
Nicotine results in decreased expression of SCARB1 mRNA; Nicotine results in decreased expression of SCARB1 protein GW 3965 inhibits the reaction [Nicotine results in decreased expression of SCARB1 mRNA]; GW 3965 inhibits the reaction [Nicotine results in decreased expression of SCARB1 protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of SCARB1 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SENP6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SEPTIN7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA]
Nicotine results in decreased expression of SERPINF1 mRNA Nicotine results in decreased expression of SERPINF1 mRNA; Nicotine results in decreased expression of SERPINF1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SFPQ mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SFPQ mRNA] Nicotine results in increased expression of SFPQ mRNA
Nicotine results in increased expression of SFTPC mRNA [Nicotine co-treated with Quartz] results in increased expression of SFTPC protein; Tubocurarine inhibits the reaction [Nicotine results in increased expression of SFTPC mRNA]
[Lipopolysaccharides co-treated with Nicotine] results in increased expression of SIRT1 mRNA; [Lipopolysaccharides co-treated with Nicotine] results in increased expression of SIRT1 protein; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of CXCL8 mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL17A mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL1B mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of IL6 mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of PTGS2 protein]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of TNF mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased secretion of IL1B protein]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased secretion of TNF protein] resveratrol inhibits the reaction [Nicotine results in decreased expression of SIRT1 mRNA]
2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole inhibits the reaction [Nicotine results in decreased expression of SLBP protein]; Bungarotoxins inhibits the reaction [Nicotine results in decreased expression of SLBP protein]; CHRNA7 affects the reaction [Nicotine results in decreased expression of SLBP protein]; CSNK2A1 affects the reaction [Nicotine results in decreased expression of SLBP protein]; Roscovitine inhibits the reaction [Nicotine results in decreased expression of SLBP protein] Nicotine results in decreased expression of SLBP mRNA; Nicotine results in decreased expression of SLBP protein
Nicotine inhibits the reaction [Vanadium results in decreased expression of SLC18A3 protein]; Nicotine promotes the reaction [Bucladesine results in increased expression of SLC18A3 protein]
Nicotine results in decreased activity of SLC1A1 protein Tetradecanoylphorbol Acetate inhibits the reaction [Nicotine results in decreased activity of SLC1A1 protein]
Nicotine inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] SLC22A2 gene SNP affects the susceptibility to Nicotine
Nicotine inhibits the reaction [Paraquat results in decreased expression of SLC6A3 protein] Nicotine results in decreased expression of SLC6A3 mRNA; Nicotine results in decreased expression of SLC6A3 protein Nicotine results in increased methylation of SLC6A3 promoter Nicotine results in decreased activity of SLC6A3 protein Dihydro-beta-Erythroidine affects the reaction [Nicotine results in decreased activity of SLC6A3 protein]; Mecamylamine affects the reaction [Nicotine results in decreased activity of SLC6A3 protein]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SMAD3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA] Nicotine results in decreased expression of SMAD3 mRNA Nicotine results in increased expression of and results in increased phosphorylation of SMAD3 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SMPD3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA]
Nicotine results in increased expression of SNAI1 mRNA; Nicotine results in increased expression of SNAI1 protein SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC1 mRNA]; SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC1 protein]; SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC2 mRNA]; SNAI1 protein affects the reaction [Nicotine results in increased expression of HDAC2 protein] SNAI1 results in increased susceptibility to Nicotine SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of BMI1 mRNA]; SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of NANOG mRNA]; SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of POU5F1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SNCG mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCG mRNA]
Nicotine results in decreased expression of SOD1 protein [Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD1 mRNA; [Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD1 protein
Nicotine results in decreased expression of SOD2 protein SOD2 gene SNP affects the susceptibility to [Pesticides co-treated with Nicotine] [Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD2 protein resveratrol inhibits the reaction [Nicotine results in decreased expression of SOD2 protein] Nicotine results in increased expression of SOD2 protein
alpha-cobratoxin inhibits the reaction [Nicotine results in increased expression of SOS1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of SOS1 mRNA]; Tubocurarine inhibits the reaction [Nicotine results in increased expression of SOS1 mRNA]
Nicotine promotes the reaction [[GATA4 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [[GATA6 protein binds to SP1 protein] which binds to CHRNA7 protein]; Nicotine promotes the reaction [GATA4 protein binds to SP1 protein]; Nicotine promotes the reaction [GATA6 protein binds to GATA4 protein binds to SP1 protein binds to CHRNA7 promoter]; Nicotine promotes the reaction [GATA6 protein binds to SP1 protein]
Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein] Nicotine results in increased expression of SQSTM1 protein dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]
ARRB1 protein affects the reaction [Nicotine results in increased phosphorylation of and results in increased activity of SRC protein]; Nicotine results in increased phosphorylation of and results in increased activity of SRC protein; RTKI cpd inhibits the reaction [Nicotine results in increased phosphorylation of SRC protein]; SRC protein affects the reaction [Nicotine promotes the reaction [RB1 protein binds to RAF1 protein]]
Nicotine results in decreased expression of SREBF1 mRNA Nicotine results in increased expression of SREBF1 mRNA [Nicotine results in increased abundance of Cotinine] which results in increased expression of SREBF1 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SRP9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA]
Nicotine results in increased methylation of STAR promoter LMK-235 inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; LMK-235 inhibits the reaction [Nicotine results in decreased expression of STAR protein]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; Vecuronium Bromide inhibits the reaction [Nicotine results in decreased expression of STAR protein] Nicotine results in decreased expression of STAR mRNA; Nicotine results in decreased expression of STAR protein Taurine inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]; Taurine inhibits the reaction [Nicotine results in decreased expression of STAR protein] Nicotine results in decreased expression of STAR; Nicotine results in decreased expression of STAR mRNA; Nicotine results in decreased expression of STAR protein trichostatin A inhibits the reaction [Nicotine results in decreased expression of STAR mRNA]
[alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide co-treated with U 0126] inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; [Nicotine co-treated with Lipopolysaccharides] results in increased phosphorylation of STAT3 protein; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]]; CHRNA5 protein affects the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Hexamethonium inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [Cisplatin results in decreased activity of STAT3 protein]; Nicotine inhibits the reaction [Paclitaxel results in decreased activity of STAT3 protein]; Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]; Nicotine promotes the reaction [STAT3 protein binds to ZFP36 promoter]; Nicotine results in increased phosphorylation of and results in increased activity of STAT3 protein; Propranolol inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Staurosporine inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; U 0126 inhibits the reaction [Nicotine promotes the reaction [RELA protein binds to STAT3 protein modified form]]; U 0126 inhibits the reaction [Nicotine results in increased activity of STAT3 protein]; U 0126 inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein] [Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of STAT3 protein modified form; Bungarotoxins inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Hexamethonium inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of STAT3 protein modified form]; methyllycaconitine inhibits the reaction [[Nicotine co-treated with Butylhydroxybutylnitrosamine] results in increased expression of STAT3 protein modified form] Nicotine affects the expression of STAT3 mRNA STAT3 protein results in increased susceptibility to Nicotine HMOX1 protein promotes the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Nicotine inhibits the reaction [Quartz results in decreased phosphorylation of STAT3 protein]; STAT3 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of HMOX1 mRNA]; STAT3 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of ZFP36 mRNA]; STAT3 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; STAT3 protein promotes the reaction [Nicotine results in increased expression of ZFP36 mRNA]; staurosporine aglycone inhibits the reaction [[Nicotine co-treated with Quartz] results in increased phosphorylation of STAT3 protein]; ZFP36 protein promotes the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; zinc protoporphyrin inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein] STAT3 results in increased susceptibility to Nicotine
Nicotine results in decreased expression of STIP1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of STIP1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA] Tubocurarine inhibits the reaction [Nicotine results in decreased expression of STIP1 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of STX4A mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SYNGR2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYNGR2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SYT4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SYT4 mRNA]
Nicotine results in decreased expression of TACR1 mRNA; Nicotine results in decreased expression of TACR1 protein Nicotine results in increased expression of TACR1 mRNA; Nicotine results in increased expression of TACR1 protein Mecamylamine inhibits the reaction [Nicotine results in increased expression of TACR1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of TACR1 protein]; methyllycaconitine inhibits the reaction [Nicotine results in increased expression of TACR1 mRNA]; methyllycaconitine inhibits the reaction [Nicotine results in increased expression of TACR1 protein]
MK-886 inhibits the reaction [Nicotine results in increased expression of TFDP1 protein] Nicotine results in increased expression of TFDP1 mRNA Nicotine results in decreased expression of TFDP1 mRNA
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of TFPI2 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of TFPI2 mRNA] Nicotine results in increased expression of TFPI2 mRNA
Nicotine results in increased expression of TFRC mRNA [Nicotine co-treated with Propylene Glycol co-treated with Glycerol] results in increased expression of TFRC mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TFRC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA]
Nicotine results in decreased expression of TGFB1 mRNA Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein] Nicotine results in increased expression of TGFB1 mRNA Nicotine affects the expression of TGFB1 mRNA Nicotine results in decreased expression of TGFB1 mRNA; Nicotine results in decreased expression of TGFB1 protein Nicotine results in increased expression of TGFB1 protein
Nicotine results in increased expression of TH mRNA; Nicotine results in increased expression of TH protein [conotoxin AuIB co-treated with triethyl-(beta-4-stilbenoxyethyl)ammonium co-treated with ZM 241385] inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; [conotoxin AuIB co-treated with triethyl-(beta-4-stilbenoxyethyl)ammonium co-treated with ZM 241385] inhibits the reaction [Nicotine results in increased expression of TH mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with exoenzyme C3, Clostridium botulinum] inhibits the reaction [Nicotine results in increased expression of TH mRNA]; conotoxin AuIB inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; conotoxin AuIB inhibits the reaction [Nicotine results in increased expression of TH mRNA]; exoenzyme C3, Clostridium botulinum inhibits the reaction [Nicotine results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]; imidacloprid promotes the reaction [Nicotine results in increased expression of TH protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Nicotine results in increased expression of TH mRNA]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; triethyl-(beta-4-stilbenoxyethyl)ammonium inhibits the reaction [Nicotine results in increased expression of TH mRNA]; ZM 241385 inhibits the reaction [imidacloprid promotes the reaction [Nicotine results in increased expression of TH mRNA]]; ZM 241385 inhibits the reaction [Nicotine results in increased expression of TH mRNA] [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TH mRNA; [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] [methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased expression of TH mRNA]
Nicotine affects the expression of TIMP1 mRNA Nicotine results in increased expression of TIMP1 mRNA [Nicotine co-treated with lipopolysaccharide, E. coli O26-B6] affects the expression of TIMP1 mRNA
Nicotine affects the expression of TIMP3 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIMP3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TIMP3 mRNA] [Nicotine co-treated with lipopolysaccharide, E. coli O26-B6] affects the expression of TIMP3 mRNA
[Nicotine co-treated with lipopolysaccharide, E. coli O26-B6] affects the expression of TIMP4 mRNA Nicotine results in decreased expression of TIMP4 protein Nicotine affects the expression of TIMP4 mRNA
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIRAP mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA]
Nicotine results in decreased expression of TJP1 protein [Saquinavir co-treated with Nicotine co-treated with Ritonavir] results in decreased expression of TJP1 protein; [Saquinavir co-treated with Nicotine] results in decreased expression of TJP1 protein; Vitamin E inhibits the reaction [[Nicotine co-treated with Ritonavir co-treated with Saquinavir] results in decreased expression of TJP1 protein]; Vitamin E inhibits the reaction [[Nicotine co-treated with Saquinavir] results in decreased expression of TJP1 protein]
Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TLR4 mRNA] [Aerosols co-treated with Nicotine] results in increased expression of TLR4 mRNA
[Lipopolysaccharides co-treated with Nicotine] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with Nicotine] results in increased secretion of TNF protein; Bungarotoxins inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF mRNA]]; methyllycaconitine inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF mRNA]]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Nicotine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of TNF mRNA]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased secretion of TNF protein]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of TNF mRNA]; SIRT1 protein inhibits the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased secretion of TNF protein]; ZFP36 mRNA affects the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; ZFP36 mRNA affects the reaction [Nicotine results in increased degradation of TNF mRNA] Nicotine affects the expression of TNF mRNA Nicotine results in increased secretion of TNF protein Nicotine results in decreased expression of TNF protein Nicotine results in increased expression of TNF mRNA; Nicotine results in increased expression of TNF protein [Nicotine results in increased abundance of Cotinine] which results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [Nicotine results in increased expression of TNF protein]; erdosteine inhibits the reaction [Nicotine results in increased expression of TNF protein]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of TNF mRNA]; Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Nicotine results in increased expression of TNF protein] Acetylcysteine inhibits the reaction [Nicotine results in increased expression of TNF mRNA]; Acetylcysteine inhibits the reaction [Nicotine results in increased secretion of TNF protein]; Eugenol inhibits the reaction [Nicotine results in increased expression of TNF mRNA]; Eugenol inhibits the reaction [Nicotine results in increased secretion of TNF protein]; HMOX1 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Nicotine inhibits the reaction [IFNG protein results in increased expression of TNF mRNA]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; STAT3 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ZFP36 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ZFP36 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; zinc protoporphyrin inhibits the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]
Nicotine results in increased expression of TNFRSF11B mRNA Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in increased expression of TNFRSF11B mRNA]
Nicotine results in decreased expression of TNFSF11 mRNA Dihydro-beta-Erythroidine inhibits the reaction [Nicotine results in decreased expression of TNFSF11 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TNK2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNK2 mRNA]
Nicotine results in decreased expression of TP53 mRNA; Nicotine results in decreased expression of TP53 protein Nicotine results in increased expression of TRP53 mRNA; Nicotine results in increased expression of TRP53 protein Nicotine results in decreased expression of TRP53 protein [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein]; royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA] Nicotine results in increased expression of TP53 mRNA TP53 protein affects the susceptibility to Nicotine Nicotine affects the expression of TP53 mRNA 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Nicotine results in decreased expression of TP53 protein]; [[Nicotine results in decreased expression of RPS27A protein] which results in increased phosphorylation of MDM2 protein] which results in increased ubiquitination of TP53 protein; Nicotine inhibits the reaction [aflatoxin G1 results in increased expression of TP53 protein modified form]; Nicotine inhibits the reaction [Cisplatin results in increased expression of TP53 protein]; Nicotine inhibits the reaction [Gemcitabine results in increased expression of TP53 protein]; Nicotine inhibits the reaction [Paclitaxel results in increased expression of TP53 protein]; Rosiglitazone inhibits the reaction [Nicotine results in decreased expression of TP53 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; TP53 protein affects the reaction [Nicotine results in increased phosphorylation of MAPK8 protein] Nicotine results in increased expression of TP53 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPH2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPH2 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPP2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA]
Mecamylamine inhibits the reaction [Nicotine results in increased expression of TRPV1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of TRPV1 protein]; methyllycaconitine inhibits the reaction [Nicotine results in increased expression of TRPV1 mRNA]; methyllycaconitine inhibits the reaction [Nicotine results in increased expression of TRPV1 protein] TRPV1 protein affects the susceptibility to Nicotine Nicotine results in increased expression of TRPV1 mRNA; Nicotine results in increased expression of TRPV1 protein Nicotine results in increased activity of TRPV1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TSC22D1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TSC22D1 mRNA]
Nicotine results in increased expression of TWIST1 mRNA Nicotine promotes the reaction [Quartz results in increased expression of TWIST1 protein]; staurosporine aglycone inhibits the reaction [[Nicotine co-treated with Quartz] results in increased expression of TWIST1 protein]
Nicotine results in increased expression of TXN1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TXN1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased expression of TXN1 protein]; methyllycaconitine inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TXN1 protein]]; methyllycaconitine inhibits the reaction [Nicotine results in increased expression of TXN1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TXN1 protein] Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN1 protein]
Nicotine results in increased expression of UBA2 protein [Nicotine results in increased expression of UBA2 protein] which results in increased sumoylation of EEF2 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA]
Nicotine results in increased expression of UBE2C mRNA Nicotine results in decreased expression of UBE2C mRNA Tubocurarine inhibits the reaction [Nicotine results in decreased expression of UBE2C mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UBE2D2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBE2D2 mRNA]
Mecamylamine inhibits the reaction [Nicotine results in decreased expression of UBE3A mRNA]; Nicotine inhibits the reaction [alpha-cobratoxin results in decreased expression of UBE3A mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of UBE3A mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UCHL1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA]
Nicotine results in decreased expression of UCP1 mRNA; Nicotine results in decreased expression of UCP1 protein [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 mRNA; [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of UCP1 protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UROS mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA]
Nicotine results in increased expression of VEGFA mRNA; Nicotine results in increased expression of VEGFA protein Nicotine results in decreased expression of VEGFA protein [BMP7 protein co-treated with INS1 protein co-treated with Triiodothyronine co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with Indomethacin co-treated with Nicotine] affects the expression of VEGFA mRNA Nicotine results in increased secretion of VEGFA protein Nicotine affects the susceptibility to VEGFA Nicotine results in decreased secretion of VEGFA protein CHRNA5 mutant form inhibits the reaction [Nicotine results in increased expression of VEGFA protein]; EIF4E protein affects the reaction [Nicotine results in increased expression of VEGFA protein]
Nicotine results in decreased expression of VIM mRNA Nicotine promotes the reaction [Quartz results in increased expression of VIM protein]; staurosporine aglycone inhibits the reaction [[Nicotine co-treated with Quartz] results in increased expression of VIM protein] Nicotine results in increased expression of VIM mRNA; Nicotine results in increased expression of VIM protein
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of VPS28 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of VPS28 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of VPS41 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of WBP4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of WBP4 mRNA]
Nicotine results in increased expression of WNT4 mRNA; Nicotine results in increased expression of WNT4 protein Carbon Tetrachloride promotes the reaction [Nicotine results in increased expression of WNT4 mRNA]; Carbon Tetrachloride promotes the reaction [Nicotine results in increased expression of WNT4 protein]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of WNT4 mRNA]; Nicotine promotes the reaction [Carbon Tetrachloride results in increased expression of WNT4 protein]
[Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased expression of XIAP protein; Curcumin inhibits the reaction [Nicotine results in increased expression of XIAP protein]; Hexamethonium affects the reaction [Nicotine results in increased expression of XIAP protein] Nicotine results in increased expression of XIAP mRNA; Nicotine results in increased expression of XIAP protein
[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA; [Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 protein; Bungarotoxins inhibits the reaction [[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA]; methyllycaconitine inhibits the reaction [[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA]; Nicotine promotes the reaction [STAT3 protein binds to ZFP36 promoter]; ZFP36 mRNA affects the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; ZFP36 mRNA affects the reaction [Nicotine results in increased degradation of TNF mRNA] ZFP36 protein results in increased susceptibility to Nicotine [Lipopolysaccharides co-treated with Nicotine] results in increased expression of ZFP36 mRNA; HMOX1 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of ZFP36 mRNA]; HMOX1 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of ZFP36 mRNA]]; HMOX1 protein promotes the reaction [Nicotine results in increased expression of ZFP36 mRNA]; STAT3 protein promotes the reaction [[Lipopolysaccharides co-treated with Nicotine] results in increased expression of ZFP36 mRNA]; STAT3 protein promotes the reaction [Nicotine results in increased expression of ZFP36 mRNA]; tin protoporphyrin IX inhibits the reaction [Nicotine results in increased expression of ZFP36 mRNA]; ZFP36 mutant form inhibits the reaction [Nicotine results in decreased expression of CCL2 mRNA]; ZFP36 mutant form inhibits the reaction [Nicotine results in decreased expression of IL6 mRNA]; ZFP36 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ZFP36 protein promotes the reaction [Nicotine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; ZFP36 protein promotes the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; zinc protoporphyrin inhibits the reaction [[Nicotine co-treated with Lipopolysaccharides] results in increased expression of ZFP36 mRNA]; zinc protoporphyrin inhibits the reaction [Nicotine results in increased expression of ZFP36 mRNA] Nicotine results in increased expression of ZFP36 mRNA; Nicotine results in increased expression of ZFP36 protein Nicotine results in increased activity of ZFP36 promoter
alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of ZFR mRNA]; Mecamylamine inhibits the reaction [Nicotine results in decreased expression of ZFR mRNA]; Tubocurarine inhibits the reaction [Nicotine results in decreased expression of ZFR mRNA]
sulfoxaflor binds to and results in increased activity of [CHRNA1 protein binds to CHRNA1 protein binds to CHRNB1 protein binds to CHRNG protein binds to CHRND protein]
sulfoxaflor binds to and results in increased activity of [CHRNA1 protein binds to CHRNA1 protein binds to CHRNB1 protein binds to CHRNG protein binds to CHRND protein]
sulfoxaflor binds to and results in increased activity of [CHRNA1 protein binds to CHRNA1 protein binds to CHRNB1 protein binds to CHRNG protein binds to CHRND protein]
sulfoxaflor binds to and results in increased activity of [CHRNA1 protein binds to CHRNA1 protein binds to CHRNB1 protein binds to CHRNG protein binds to CHRND protein]
NR1I2 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP2B10 mRNA]; NR1I3 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP2B10 mRNA]
sulfoxaflor results in increased expression of IL10 protein Resveratrol inhibits the reaction [sulfoxaflor results in increased expression of IL10 protein]
sulfoxaflor results in increased expression of IL1B protein Resveratrol inhibits the reaction [sulfoxaflor results in increased expression of IL1B protein]
sulfoxaflor results in increased expression of IL6 protein Resveratrol affects the reaction [sulfoxaflor results in increased expression of IL6 protein]
NR1I2 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP2B10 mRNA]; NR1I2 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP3A11 mRNA] NR1I2 protein results in increased susceptibility to sulfoxaflor
NR1I3 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP2B10 mRNA]; NR1I3 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP3A11 mRNA] NR1I3 protein results in increased susceptibility to sulfoxaflor
sulfoxaflor results in increased expression of TNF protein Resveratrol inhibits the reaction [sulfoxaflor results in increased expression of TNF protein]
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC2 mRNA
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC3 mRNA thiacloprid results in increased expression of ABCC3 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ABCC3 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ACOX1 mRNA
thiacloprid results in increased expression of ALDH1A1 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ALDH1A1 mRNA [thiacloprid co-treated with enilconazole] results in decreased expression of ALDH1A1 mRNA
thiacloprid results in decreased activity of CAT protein astaxanthine inhibits the reaction [thiacloprid results in decreased activity of CAT protein]; Polysaccharides inhibits the reaction [thiacloprid results in decreased activity of CAT protein]; Polysaccharides inhibits the reaction [thiacloprid results in decreased expression of CAT mRNA]
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CD36 mRNA
[clothianidin co-treated with thiacloprid] results in increased expression of CES2 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CES2 protein
thiacloprid results in increased activity of [NACHRA8 protein co-treated with CHRNB2 protein]; thiacloprid results in increased activity of [NACHRALPHA1 protein co-treated with CHRNB2 protein]
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CPT1A mRNA
thiacloprid results in increased activity of CYP19A1 protein thiacloprid affects the expression of CYP19A1 mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione affects the reaction [thiacloprid affects the expression of CYP19A1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one affects the reaction [thiacloprid affects the expression of CYP19A1 mRNA] thiacloprid results in increased expression of CYP19A1 mRNA
thiacloprid results in increased expression of CYP1A2 mRNA; thiacloprid results in increased expression of CYP1A2 protein [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP1A2 mRNA
thiacloprid results in increased expression of CYP2B2 mRNA [thiacloprid co-treated with clothianidin] results in increased expression of CYP2B2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B2 mRNA
[clothianidin co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B9 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B6 mRNA [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2B10 mRNA; [Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2B10 mRNA thiacloprid results in increased expression of CYP2B6 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA
thiacloprid results in increased expression of CYP2C19 mRNA [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA thiacloprid results in decreased expression of CYP2C19 protein
thiacloprid results in decreased expression of CYP2E1 mRNA [clothianidin co-treated with thiacloprid] results in increased expression of CYP2E1 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA
thiacloprid results in increased expression of CYP3A4 mRNA; thiacloprid results in increased expression of CYP3A4 protein [clothianidin co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A4 mRNA
[thiacloprid co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A23-3A1 mRNA thiacloprid results in increased expression of CYP3A23-3A1 mRNA
thiacloprid results in increased expression of CYP3A5 mRNA [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein; [thiacloprid co-treated with clothianidin] results in increased expression of CYP3A5 mRNA
thiacloprid results in decreased expression of CYP7A1 protein thiacloprid results in decreased expression of CYP7A1 mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP7A1 mRNA
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of DIO1 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ECI1 mRNA
[thiacloprid co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of ELN mRNA thiacloprid results in decreased expression of ELN mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of GFAP protein
thiacloprid results in increased expression of GPT protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of GPT protein]; Polysaccharides inhibits the reaction [thiacloprid results in increased expression of GPT protein]
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of HMGCS2 mRNA
thiacloprid results in increased expression of IL10 protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of IL10 protein]
thiacloprid results in increased expression of IL1B protein astaxanthine inhibits the reaction [thiacloprid results in increased expression of IL1B protein]
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of INS1 protein
thiacloprid results in decreased expression of KY mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of KY mRNA
thiacloprid results in decreased expression of MEGF11 mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of MEGF11 mRNA
thiacloprid results in increased expression of MME mRNA [thiacloprid co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of MME mRNA
NR1I3 protein affects the susceptibility to [2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with Thiophanate co-treated with thiacloprid co-treated with Ziram]
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of PDGFRB protein
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SERPINE1 mRNA
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SLC16A2 mRNA
thiacloprid results in decreased expression of SLC6A1 mRNA [thiacloprid co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of SLC6A1 mRNA
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SULT1B1 mRNA
[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA; [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in decreased expression of THRSP mRNA; Dietary Fats inhibits the reaction [[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA]
[fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of ALPL protein] Thiamethoxam results in increased activity of ALPL protein
Thiamethoxam results in increased expression of CAT mRNA Thiamethoxam results in decreased expression of CAT mRNA [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased activity of CAT protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of CAT mRNA]
Thiamethoxam results in decreased expression of CYP17A1 mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in decreased expression of CYP17A1 mRNA]
thiamethoxam results in increased expression of CYP19A1 mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in increased expression of CYP19A1 mRNA] thiamethoxam results in increased activity of CYP19A1 protein
Thiamethoxam results in increased activity of GOT1 protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of GOT1 protein]
Thiamethoxam results in increased expression of GPX1 mRNA Thiamethoxam results in decreased expression of GPX1 mRNA Thiamethoxam results in decreased activity of GPX1 protein [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of GPX1 protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of GPX1 mRNA]
Thiamethoxam results in decreased expression of HSD3B1 mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in decreased expression of HSD3B1 mRNA]
Silymarin inhibits the reaction [Thiamethoxam results in increased expression of IL1B protein] Thiamethoxam results in increased expression of IL1B mRNA; Thiamethoxam results in increased expression of IL1B protein
[fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of LDHA protein] Thiamethoxam results in increased activity of LDHA protein
Thiamethoxam results in decreased expression of LHCGR protein Thiamethoxam results in increased expression of LHCGR mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in increased expression of LHCGR mRNA]
[thiamethoxam metabolite results in decreased activity of NOS2 protein] which results in increased chemical synthesis of Formaldehyde Thiamethoxam results in increased expression of NOS2 mRNA Silymarin inhibits the reaction [Thiamethoxam results in increased expression of NOS2 mRNA]
Thiamethoxam results in decreased activity of SOD1 protein Thiamethoxam results in decreased expression of SOD1 mRNA [fenugreek seed meal results in increased abundance of Polysaccharides] inhibits the reaction [Thiamethoxam results in decreased activity of SOD1 protein]; Silymarin inhibits the reaction [Thiamethoxam results in decreased expression of SOD1 mRNA]
Thiamethoxam results in decreased expression of STAR mRNA Plant Extracts inhibits the reaction [Thiamethoxam results in decreased expression of STAR mRNA]
Silymarin inhibits the reaction [Thiamethoxam results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Thiamethoxam results in increased expression of TNF protein] Thiamethoxam results in increased expression of TNF mRNA; Thiamethoxam results in increased expression of TNF protein
Thiamethoxam results in increased secretion of TNNT2 protein fenugreek seed meal inhibits the reaction [Thiamethoxam results in increased secretion of TNNT2 protein]; Polysaccharides inhibits the reaction [Thiamethoxam results in increased secretion of TNNT2 protein]
methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of AKT1 protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased phosphorylation of AKT1 protein]
methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of BAX protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of BAX protein]
methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased expression of BCL2 protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased expression of BCL2 protein]
Tropisetron results in increased expression of CASP3 protein modified form methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of CASP3 protein]]; methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of CASP3 protein]; Tropisetron inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein]; Tropisetron inhibits the reaction [Streptozocin results in increased expression of CASP3 protein] Paclitaxel inhibits the reaction [Tropisetron results in increased expression of CASP3 protein modified form]
chromium mesoporphyrin inhibits the reaction [tropisetron results in decreased expression of CXCL1 protein]; SB 203580 inhibits the reaction [tropisetron results in decreased expression of CXCL1 protein]
chromium mesoporphyrin inhibits the reaction [tropisetron results in decreased expression of CXCL2 protein]; SB 203580 inhibits the reaction [tropisetron results in decreased expression of CXCL2 protein]
tropisetron results in increased expression of HMOX1 protein methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased activity of HMOX1 protein]]; SB 203580 inhibits the reaction [Tropisetron results in increased expression of HMOX1 protein]; Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased activity of HMOX1 protein]; Tropisetron inhibits the reaction [Hydrogen Peroxide results in decreased expression of HMOX1 protein]
chromium mesoporphyrin inhibits the reaction [tropisetron results in decreased expression of ICAM1 protein]; SB 203580 inhibits the reaction [tropisetron results in decreased expression of ICAM1 protein]
tropisetron inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of IL1B protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of IL1B protein]; Tropisetron inhibits the reaction [Streptozocin results in increased expression of IL1B protein]
chromium mesoporphyrin inhibits the reaction [Tropisetron results in decreased expression of IL6 protein]; SB 203580 inhibits the reaction [Tropisetron results in decreased expression of IL6 protein] tropisetron results in decreased expression of IL6 protein
methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased phosphorylation of JAK2 protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased phosphorylation of JAK2 protein]
chromium mesoporphyrin inhibits the reaction [tropisetron results in decreased activity of MPO protein]; SB 203580 inhibits the reaction [tropisetron results in decreased activity of MPO protein] tropisetron inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]
methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased expression of NFE2L2 protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in decreased expression of NFE2L2 protein]; Tropisetron inhibits the reaction [Hydrogen Peroxide results in decreased expression of NFE2L2 protein]
[Paclitaxel co-treated with Tropisetron] results in decreased expression of RELA protein methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased phosphorylation of RELA protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased phosphorylation of RELA protein]; Tropisetron inhibits the reaction [Streptozocin results in increased expression of RELA protein]
chromium mesoporphyrin inhibits the reaction [Tropisetron results in decreased expression of TNF protein]; methyllycaconitine inhibits the reaction [Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of TNF protein]]; Tropisetron inhibits the reaction [3-nitropropionic acid results in increased expression of TNF protein]; Tropisetron inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Tropisetron inhibits the reaction [Vincristine results in increased expression of TNF protein] tropisetron inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] tropisetron results in decreased expression of TNF protein
methyllycaconitine inhibits the reaction [Varenicline results in increased expression of CD36 mRNA]; methyllycaconitine inhibits the reaction [Varenicline results in increased expression of CD36 protein] Varenicline results in increased expression of CD36 mRNA; Varenicline results in increased expression of CD36 protein
Varenicline results in decreased expression of CDH5 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Varenicline results in decreased expression of CDH5]; methyllycaconitine inhibits the reaction [Varenicline results in decreased expression of CDH5]; pyrazolanthrone inhibits the reaction [Varenicline results in decreased expression of CDH5]; SB 203580 inhibits the reaction [Varenicline results in decreased expression of CDH5]
Varenicline binds to and results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]; Varenicline binds to and results in increased activity of [CHRNA3 protein binds to CHRNB4 protein]
Varenicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] Varenicline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] varenicline binds to Chrna4 protein; varenicline inhibits [alpha-conotoxin MII binds to Chrna4 protein] in rat brain striatal sections
Varenicline binds to and results in increased activity of CHRNA6 protein Varenicline binds to Chrna6 protein Varenicline inhibits the reaction [alpha-Conotoxin MII binds to Chrna6]; Varenicline inhibits the reaction [epibatidine binds to Chrna6].
Varenicline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Varenicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein] Varenicline binds to and results in increased activity of [CHRNA3 protein binds to CHRNB2 protein]; Varenicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]
Varenicline results in increased phosphorylation of MAPK1 protein methyllycaconitine inhibits the reaction [Varenicline results in increased phosphorylation of MAPK1 protein] Varenicline results in decreased activity of MAPK1 protein
Varenicline results in increased phosphorylation of MAPK3 protein methyllycaconitine inhibits the reaction [Varenicline results in increased phosphorylation of MAPK3 protein] Varenicline results in decreased activity of MAPK3 protein
Varenicline results in increased expression of OLR1 mRNA; Varenicline results in increased expression of OLR1 protein methyllycaconitine inhibits the reaction [Varenicline results in increased expression of OLR1 mRNA]; methyllycaconitine inhibits the reaction [Varenicline results in increased expression of OLR1 protein]
Varenicline results in increased phosphorylation of RELA protein methyllycaconitine inhibits the reaction [Varenicline results in increased phosphorylation of RELA protein]
browse the term
